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SUMMARY
The aim of the work presented in this thesis was to assess the 
protective properties of the bioflavanoid drug, (+)-catechin, and its 
palmityl ester, 3-palmitoyl-(+)-catechin, against ethanol hepato- 
toxicity (ie: fatty liver) in the rat. In initial experiments, both
(+)-catechin compounds were found to protect against the hepatic lipid 
accumulation (mainly triglyceride) after acute ethanol dosing, and 
after long-term feeding of ethanol in a liquid diet. In the latter 
situation, 3-palmitoyl-(+)-catechin was significantly more effective 
than (+)-catechin itself at preventing fatty liver, probably as a 
result of its greater lipid solubility and longer half-life in the 
liver tissue.
Published work suggested two possible mechanisms of action for 
the (+)-catechin compounds against ethanol hepatotoxicity. Firstly, 
the ability of the drugs to correct the elevated hepatic NADH:NAD 
ratio (redox-state) after ethanol dosing may limit steatosis. 
Secondly, free radical scavenging properties may prevent liver injury 
occurring as a result of ethanol-induced lipid peroxidation. Acute 
experiments were performed which confirmed that the (+)-catechin 
compounds corrected the redox-state change after acute ethanol 
administration, but subsequent studies in which correction of the 
redox-state by Naloxone or Methylene Blue was found to have little 
influence on ethanol-induced steatosis, suggested that this was not 
the mechanism of action of the drugs. Synthetic antioxidants (free 
radical scavengers) were found to prevent both acute and chronic 
ethanol-induced fatty liver, under the same experimental conditions as
those under which the (+)-catechin compounds afforded protection, 
without reversing the redox-state change after ethanol dosing.
3-Palmitoyl-(+)-catechin was then shown to prevent ethanol-induced 
hepatic lipid peroxidation (measured as mitochondrial diene conjugates 
and liver malonaldehyde levels) after acute ethanol dosing, at the 
same time as preventing triglyceride accumulation. As other effects 
of the compounds which might influence fat accumulation after ethanol 
were excluded (eg: inhibition of ethanol metabolism or lowering of
liver acetaldehyde concentrations), it was concluded that the 
(+)-catechin compounds protect against alcoholic fatty liver in rats 
by inhibiting ethanol-induced lipid peroxidation, and the possible 
consequence of the latter (ie: mitochondrial damage and impaired
fatty acid oxidation), rather than acting through modulation of the 
redox-state. The findings here cast doubts on the commonly-quoted
'redox-state' mechanism for fatty liver production by ethanol, and 
support the lipid peroxidation hypothesis for alcoholic liver injury.
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Chapter 1 
INTRODUCTION
Many substances have the ability to cause liver injury. These 
include such widely differing chemicals as carbon tetrachloride, 
acetoaminophen (paracetamol), retinol (vitamin A), bromobenzene, 
vinylidene chloride or halothane in combination with hypoxia. In 
both social and economic terms, probably the most important hepatic 
toxin of all is ethanol. Although the biochemical effects of this 
substance on the body are widespread, the consequences of excessive 
alcohol consumption for the liver nearly always overshadow effects on 
other sites, although some of its interactions with the functioning of 
other organs, for example the brain or the pancreas, may prove just as 
damaging in the long-term. In view of this, the effects of ethanol 
on the liver have been probably the most studied aspect of this 
substance’s toxicology. Yet, in spite of this, the precise
mechanisms, their relative importance, and sequence of occurrence that 
contribute to the clinical entity referred to as ’alcoholic liver 
disease' (ALD) are still not completely clear, and often poorly 
understood. Such difficulties make the task of predicting which
substances might be effective hepatoprotective agents a rather 
haphazard affair, yet over the last few years, development work has } 
yielded some drugs which look promising in terms of limiting tissue 
damage during ethanol consumption. The aim of this current thesis
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was to evaluate the prospective hepatoprotective drug, (+)-catechin, 
and it's palmityl ester, 3-palmitoyl-(+)-catechin, in terms, firstly 
of establishing these compounds' ability to limit tissue changes 
following acute or chronic ethanol administration (i.e. chiefly 
through reducing fatty infiltration or steatosis) and, secondly, to 
attempt to pinpoint precise biochemical mechanisms by which the 
substances may be acting to limit steatosis.
1.1 THE PATHOGENESIS OF ALCOHOLIC LIVER DISEASE (ALP) :
Clinically, ALD is broken down into three main stages; fatty 
liver, alcoholic hepatitis and cirrhosis, on the basis of the 
histological appearance of tissue taken by needle biopsy of the liver. 
A clearly defined hepatitis stage may not be seen in all patients, 
such subjects appearing to progress directly from fatty infiltration 
to the characteristic fibrotic state of cirrhosis. It is often 
thought that fatty liver is of little consequence as this abnormality 
disappears after a few weeks of abstinence in the alcoholic. 
However, it is now becoming evident that whilst fat accumulation is 
taking place, early fibrotic changes are occurring in the liver 
lobules which are the precursor lesions of cirrhosis (Lieber, 1983). 
When considering potential hepatoprotective drugs, substances which 
prevent steatosis have not traditionally been considered very useful 
in clinical terms, as this early stage in ALD is thought to be fully 
reversible. However, in view of the early fibrotic changes now being
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seen in association with fatty liver in primates and humans, a drug 
which can prevent this stage occurring, may also be considerably 
reducing the risk of the patient developing alcoholic cirrhosis.
1.1.1. Animal Models of Alcoholic Liver Disease
Until the early 1960's it was widely believed that alcohol was 
not hepatotoxic in its own right, and that alcoholic liver disease was 
the consequence of the poor nutritional status of alcoholics, who 
tended to derive nearly all of their calorie intake from ethanol. In 
the mid-1960's, however, Dr Charles Lieber and his co-workers in New 
York devised methods of feeding alcohol to experimental animals in
so-called 'nutritionally adequate' liquid diets. It was found that
administering 36?o of the total calorie intake as ethanol to rats in a 
diet that contained adequate amounts of protein, carbohydrate, 
vitamins, minerals and lipotropic factors, induced fatty liver after 
as little as ten days of administration, the severity of the fatty 
infiltration reaching a peak after about 24 days of alcohol feeding 
(Lieber et al, 1965; DeCarli and Lieber, 1967). In another study, 
administration of 36^ of the total calories as ethanol to healthy 
human volunteers, along with an adequate diet, under metabolic ward 
conditions was also found to induce hepatic steatosis, as confirmed 
by liver biopsy, suggesting that the rat liquid diet model was 
relevant to the human situation (Lieber et al, 1965).
The origin of the accumulated fat in the animal studies depended 
on the experimental design. When the diet contains more than about 
20% of the calories as fat, the severity of fatty liver produced is
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related to the fat content of the diet, indicating dietary fat as a 
major source (Lieber and DeCarli, 1970a). In experiments where a 
fat-free diet is employed, hepatic steatosis is still induced, but 
here the accumulated fat is presumably derived from endogenous 
synthesis, with possibly some contribution from adipose tissue fatty 
acids (Lieber and Spritz, 1966; Mendenhall, 1972).
One of the problems of the rat liquid diet feeding method for 
alcohol administration is that, although considerable amounts of 
ethanol are consumed by the animals using this regime (12-15 g/kg/day 
compared with less than 5 g/kg/day consumed by primates or human
alcoholics), steatosis is the most severe lesion that can be produced
/
in this species, even after prolonged ethanol feeding (Lieber and 
DeCarli, 1982). In order to reproduce lesions comparable to human 
alcoholic hepatitis and cirrhosis, primate species have to be 
employed, who will readily consume diets in which 50% of the total 
calories are derived from ethanol. Methods for feeding alcohol in 
liquid diets to baboons have been described, a proportion of the 
animals proceeding, after 1-2 years of feeding, to a full-blown 
cirrhotic condition (Lieber and DeCarli, 1974; Lieber et al, 1975).
These liquid diet methods of alcohol feeding have clearly 
demonstrated that ethanol is directly hepatotoxic. However, the 
possible role of nutrition in human alcoholic liver disease should not 
be overlooked, as alcoholic subjects are frequently malnourished, and 
animal work does show that dietary deficiencies alone (eg: of amino 
acids and choline) can cause liver injury which is further potentiated
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by ethanol (World et al, 1985; Lieber et al, 1969).
One important question to consider in relation to the mechanisms 
by which ethanol is hepatotoxic, is the relevance of findings made in 
the rat model to the development of the more advanced lesions seen in 
primates. Fatty liver has been considered a benign lesion that is
fully reversible on abstinence in both experimental animals and 
humans, so it might be concluded that the mechanisms that produce 
steatosis are not important in causing hepatitis or cirrhosis. 
However, there are one or two indications that this may not be the 
case. Recent studies by Lieber's group (Lieber, 1983) have shown
that liver biopsies from alcoholic baboons or patients, that only show 
steatosis when viewed by light microscopy, do often show some evidence 
of perivenular fibrosis around the centrilobular hepatic vein when 
viewed by electron microscopy. It is possible that common mechanisms 
may be operating to cause both steatosis and this early fibrotic 
lesion. There is some support for this from the study of Lieber et^  
al (1975), who found higher hepatic triglyceride levels in those 
experimental baboons at the fatty liver stage, who eventually 
proceeded to develop cirrhosis. Thus, it may not be inappropriate to 
consider biochemical mechanisms that cause alcoholic fatty liver in 
rats as being relevant in the production of alcoholic liver disease in 
man, and also to consider using agents that protect against fatty 
liver in rats as treatments for human alcoholic patients.
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1.2 BIOCHEMICAL MECHANISMS OF ALCOHOLIC LIVER INJURY
1.2.1. Relationship Between Acute and Chronic Fatty Liver
Many early studies on ethanol hepatotoxicity simply employed 
large, intoxicating doses of ethanol given to fasted rats (about 6-7 
g/kg orally), which caused a transient accumulation of hepatic 
triglyceride measured 8-24 hours later, returning to control values by 
48-72 hours after ethanol dosing (Mallov, 1955; DiLuzio, 1958; Elko 
et al, 1961). Some workers have considered that the mechanisms
underlying this acute alcoholic fatty liver are fundamentally
different from those that cause the chronic fatty liver produced in 
liquid diet feeding studies (Badawy, 1978). Certainly, the origin of 
the accumulated fat may differ, that after acute ethanol originating 
from the adipose tissue, whereas after chronic alcohol feeding, the 
increased hepatic lipid seems to be of dietary origin (Lieber et al,
1966). After chronic ethanol intake, the peripheral fat stores do,
in fact, appear to be increased in size (World et al, 1984). 
However, as will be discussed later, many agents that protect against 
acute alcoholic fatty liver in rats also prevent chronic 
ethanol-induced steatosis, suggesting that common mechanisms may be 
operating to produce both lesions.
1.2.2. The Metabolism of Ethanol; Its Role in Fatty Liver 
Production
Greater than 90% of the ethanol that is absorbed from the 
gastrointestinal tract is oxidised in the body, very little being
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eliminated unchanged via the kidneys and lungs (Forsander and
Raiha-Neils, 1960). Nearly all of this oxidation takes place in the 
liver, only a small contribution coming from extrahepatic tissues 
(Larsen, 1959).
The major pathway of ethanol metabolism in the liver involves the 
cytosolic enzyme alcohol dehydrogenase (ADH), an NAD+-dependent
dehydrogenase that oxidises ethanol to acetaldehyde. Acetaldehyde is
4.
then oxidised to acetate by another NAD -dependent enzyme, aldehyde 
dehydrogenase (ALDH). The subcellular localisation of the
physiologically-important form of the latter has been the subject of 
much debate. In most species, ALDH activity can be detected in the 
microsomal, mitochondrial and cytosolic fractions of the cell,
although in the rat, it is thought that the mitochondrial ALDH
isoenzyme makes the major contribution to in vivo acetaldehyde
oxidation. In man, one of the cytosolic ALDH isoenzymes is thought 
to make the greatest contribution to acetaldehyde removal (Parilla et 
al, 1974; Jenkins and Peters, 1983). Both ADH and ALDH are subject 
to genetic variation and it has been suggested that lack of a 
particular ALDH isoenzyme (ALDH^), may predispose individuals to both 
an exaggerated response to acute alcohol intake, including facial 
flushing arising from high circulating levels of acetaldehyde, and 
possibly also enhance the susceptibility to alcoholic liver disease, 
again as a result of impaired acetaldehyde removal (Saunders and 
Williams, 1983; Tipton et al, 1983). Alcoholic patients have been 
observed to have reduced hepatic aldehyde dehydrogenase activity,
- 8 -
including reduced cytosolic activity of the enzyme, although there has 
been some argument as to whether this is a primary genetic defect or 
simply a consequence of alcohol-induced liver damage (Jenkins and 
Peters, 1980). This defect presumably accounts for the impaired
acetaldehyde oxidation that has been reported in alcoholics (Korsten 
et al, 1975; Schukit and Rayses, 1979; Palmer and Jenkins, 1982), 
although results from these studies should be viewed with caution as a 
result of the methodological shortcomings of many acetaldehyde assay 
methods (Eriksson, 1983). Some workers maintain that this decreased 
ALDH activity in alcoholics persists with abstinence (Thomas et al,
1982), whereas others have apparently shown that the activity falls 
during alcohol consumption and reverts to control values on abstinence 
(Saunders and Williams, 1983; Jenkins et al, 1984).
The end product of ethanol oxidation by these enzymes is acetate. 
Most of this acetate is utilised extrahepatically, the skeletal 
muscles extracting the largest part, although acetate is also oxidised 
in the heart (Williamson et al, 1969; Suokas et al, 1984). Very 
little ethanol-derived acetate is incorporated into hepatic lipids or 
oxidised to carbon dioxide in the liver.
The other very important 'by-product' of hepatic ethanol 
oxidation is hydrogen, manifested in the form of a greatly increased 
hepatic NADH:NAD ratio (Slater et al, 1964). This hepatic
redox-state change resulting from ethanol oxidation may be important 
in explaining many of the hepatotoxic effects of ethanol, as will be 
discussed later. The altered redox-state is reflected in the liver
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cell as altered metabolite ratios in various redox-pair reactions, 
such as lactate/pyruvate and 3-hydroxybutyrate/acetoacetate. These 
ratios can thus be used as indicators of the cytoplasmic and 
mitochondrial NADH:NAD ratios during ethanol metabolism, both values 
showing significant increases after acute ethanol dosing (Forsander et 
al, 1965; Veech et al, 1972). These redox-state changes, apart from 
being implicated in fatty liver production by a number of reviewers
(Sherlock, 1983; Lieber, 1984), may also be responsible for other
metabolic derangements induced by ethanol, such as impaired 
gluconeogenesis and galactose intolerance (Saluspuro and Saluspuro, 
1968; Krebs et al, 1969).
Two other pathways by which ethanol can be oxidised as far as
acetaldehyde have been described. One involves peroxisomal catalase 
activity, but is probably of no physiological significance (Hawkins
and Kalant, 1972). The other pathway that has received a lot of
attention is the microsomal ethanol oxidising system (MEOS). MEOS
may contribute something between five and twenty per cent to the
overall ethanol elimination rate in vivo in naive animals, and may be
of particular importance at high blood ethanol concentrations and 
after chronic ingestion of ethanol or other enzyme-inducing drugs,
when the activity of the system is enhanced. The induction of this 
MEOS pathway, which 'involves a specific ethanol-^induced form of 
cytochrome P450 with a high affinity for alcohols and aniline as 
substrates, may account, in part, for the metabolic tolerance and 
enhanced ethanol elimination rate observed after chronic ethanol
- 10 -
intake (Lieber and DeCarli, 1968; Lieber and DeCarli, 1970b; Ugarte 
et alt 1972; Coon et al, 1983). The inducibility of the MEOS 
pathway and its role in producing metabolic tolerance to ethanol has
been neatly demonstrated in a recent study, in which strains of deer
mice lacking ADH could be weaned to consume as much ethanol per unit
body weight daily as comparable animals with hepatic ADH activity, as
a result of MEOS induction (Shigeta et al, 1984). A diagrammatic 
representation of the various pathways of ethanol metabolism is shown 
in Fig. 1.1.
A number of studies have indicated that ethanol metabolism is 
necessary for hepatic lipid accumulation to occur after acute dosing. 
Morgan and DiLuzio (1970) showed that the fatty liver produced by a 
single large dose of ethanol (6 g/kg) in rats could be prevented by 
the ADH inhibitor, pyrazole, arguing against a direct toxic effect of 
ethanol per se being responsible for the hepatic steatosis. Studies 
on rat liver slices showed that most of the effects that ethanol 
exerts on lipid metabolism in this in vitro situation, namely 
decreased fatty acid oxidation and increased esterification of fatty 
acids into triglycerides, could be prevented by the addition of
4-methylpyrazole to the system (Blomstrand et al, 1973). Further in 
vivo studies have shown that ADH inhibitors, including nicotinic acid 
and sodium diethylbarbiturate, prevent the acute ethanol-induced 
alterations in hepatic lipid disposal, at the same time as reversing 
the ethanol-mediated redox-state changes (Rawat and Kuriyama, 1972; 
Baker et al, 1973).
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F IG .1.1. Principal pathways of ethanol and acetal­
dehyde m etabolism in the hepatocyte
Ethanol
NAD
Alcohol 
dehydrogenase
NADH
h2o
Catalase 
H20
Acetaldehyde
MEOS
NAD PH
NAD
NADH
Acetaldehyde
dehydrogenase
Acetate
MEOS: microsomal ethanol-oxidizing system
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The situation during chronic ethanol treatment is not as clear 
cut. Administration of pyrazole to rats during a chronic liquid diet 
feeding study in fact enhanced the ethanol-induced steatosis whilst 
lowering hepatic triglyceride in control animals (Kalant et al, 1972). 
However, ethanol alone in this study did not cause appreciable hepatic 
triglyceride accumulation, and pyrazole administration caused marked 
decreases in dietary intake, body weight and caused some deaths, so 
that dietary-related effects cannot be ruled out to account for this 
apparent aggravation of ethanol hepatotoxicity by pyrazole. A more 
recent study, in which moderate amounts of 4-methylpyrazole were added 
to alcohol-containing liquid diets, so as to maintain blood ethanol 
levels at an approximately constant level throughout the day and 
night, without affecting dietary intake or weight gain, suggested that 
continuous oxidation of ethanol was an important pathogenetic factor 
in chronic fatty liver development in the rat, as 4-methylpyrazole 
enhanced the severity of the ethanol-induced steatosis (Lindros et al,
1983). Thus, it appears that during chronic alcohol intake, as after 
acute dosing, some consequence of ethanol oxidation is responsible for 
causing fat accumulation. One possibility is, of course, the
increase in the hepatic NADH:NAD ratio and its metabolic consequences. 
Alternatively, some toxic event mediated by the ethanol metabolite, 
acetaldehyde, may cause the triglyceride deposition.
1.2.3. Possible Metabolic Consequences of the Hepatic Redox-State 
Change After Ethanol: Relationship to Fatty Liver Production
The increased NADHjNAD ratio could influence lipid metabolism in 
a number of ways to favour triglyceride deposition in the liver after
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ethanol intake, as follows:
(i) The excess NADH will displace the dihydroxyacetone phosphate:
-glycerophosphate redox-pair towards its reduced side, so that
hepatic -glycerophosphate levels are increased, thereby favouring
esterification of fatty acids into triglycerides (Nikkila and Ojala, 
1963).
(ii) Transhydrogenation of reducing equivalents may occur from 
NADH to NADPH, resulting in an increased NADPH/NADP ratio. There is 
conflicting data on this matter. Some studies have shown no effect 
of ethanol on the hepatic NADPH:NADP ratio (Slater, 1964) whereas 
others have shown a slight increase after ethanol application either 
in vitro or in vivo (Bucher, 1970; Badawy and Evans, 1981). These 
discrepancies may be the result of methodological differences between 
the various studies. However, if ethanol does increase the hepatic 
NADPH level, this may stimulate fatty acid synthesis through substrate 
concentration effects on fatty acid synthetase. In vitro work has 
shown increased incorporation of "^C-acetate into fatty acids by liver 
slices in the presence of ethanol (Lieber and Schmid, 1961). This 
effect was associated with decreased oxidation of either labelled 
palmitate or acetate to carbon dioxide, suggesting that there was a 
block in fatty acid oxidation at the tricarboxylic acid cycle stage as 
a result of ethanol addition. These ethanol-induced abnormalities in 
lipid metabolism could be reversed by the hydrogen acceptor methylene 
blue, and were mimicked by sorbitol, another substrate that can induce 
a redox-state change. This led the authors to propose that it was
- 14 -
the hepatic redox-state changes induced by ethanol that caused the 
altered hepatic lipid disposal. Reboucas and Isselbacher (1961) 
however, found that, although ethanol administration to rats did 
increase incorporation of "^C-acetate into liver lipids, glucose and 
sorbitol also achieved this without inducing a fatty liver after acute 
dosing, and sorbitol caused a similar increase in the hepatic NADH:NAD 
ratio as that observed after ethanol. Thus, these authors proposed 
that ethanol did not increase fatty acid synthesis or esterification 
through a redox-state mediated mechanism. In vitro studies have 
shown that low concentrations of ethanol (5 mM) do in fact inhibit
fatty acid synthesis in isolated hepatocytes (Selmer and Grunnet,
1976). Results from in vivo studies on the effect of ethanol on
fatty acid synthesis are also conflicting. In fasted rats, ethanol
does not appear to stimulate fatty acid synthesis, whereas in fed rats 
accelerated lipogenesis has been reported. Chronic ethanol
treatment, using a drinking water method of alcohol feeding in rats, 
which did not induce fatty liver, induced a slight increase in de novo 
fatty acid synthesis determined using titrated water, although ethanol 
significantly lowered body weight gain in this study compared with 
controls, so that dietary factors may account for the differences in 
this experiment (Cascales et al, 1983). Thus, the possible role of 
enhanced fatty acid synthesis, secondary to the hepatic redox-state 
changes in ethanol-induced fatty liver is largely unresolved.
(iii) A third effect effect of ethanol on lipid metabolism has
been widely reported, that may be related to the hepatic redox-state
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change, and in turn, could be an important factor in the development 
of fatty liver, this being inhibition of fatty acid oxidation. This 
has been reported in liver slices (Lieber and Schmid, 1961; 
Blomstrand et alt 1973; Beauge et al, 1979), isolated hepatocytes 
(Ontko, 1973) human liver biopsies (Fischel and Oette, 1974) and in
vivo. One study in isolated hepatocytes found little effect of
ethanol on fatty acid oxidation, although increased fatty acid 
esterification was found in the same experiments (Wiebe and Belfrage, 
1980). Any ethanol-induced decrease in fatty acid oxidation could be 
the consequence of reduced NAD availability for the various 
dehydrogenases in the tricarboxylic acid cycle. As mentioned above, 
Lieber and Schmid (1961) showed that, in vitro, ethanol inhibited 
oxidation of acetate to carbon dioxide by about the same degree to
which it inhibited palmitate oxidation, suggesting the block was at
the TCA cycle stage, instead of y^-oxidation itself being affected. 
Another redox-state related effect that could influence fatty acid 
oxidation is that the NADH generated from ethanol oxidation displaces 
the NADH normally generated from TCA cycle activity, so that ethanol 
replaces fatty acids as the source of reducing equivalents for NADH 
oxidation and oxidative phosphorylation. However, other mechanisms 
could account for impaired mitochondrial fatty acid oxidation in 
ethanol intoxication, including a direct toxic effect of acetaldehyde 
(Cederbaum et al, 1973a). Alternatively, structural alterations that 
occur as a consequence of long-term ethanol intake seem to impair many 
mitochondrial functions in their own right, independently of any acute
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metabolic effects of ethanol (Cederbaum et al, 1974; Cederbaum and 
Rubin, 1975).
The inhibition of fatty acid oxidation by ethanol has been 
proposed as a central effect that could account for ethanol-induced 
fatty liver, irrespective of the mechanism of this inhibition (Baraona 
and Lieber, 1979). There is some evidence to support this view.
The antihistamine compound chlorcyclizine protects against acute 
alcoholic fatty liver in rats, apparently reversing the inhibition of 
palmitate oxidation by ethanol in vivo in the same experiment (Wooles 
and Weymouth, 1968). Similarly, administration of ^{-p-chloro - 
phenoxy-isobutyrate (Clofibrate) protects against acute 
ethanol-induced hepatic steatosis in rats, and this hypolipodemic drug 
is known to cause peroxisome proliferation, and induce peroxisomal 
fatty acid oxidation which may compensate for the ethanol-induced
block in mitochondrial fatty acid oxidation (Brown, 1966). However,
the results of this study should be viewed with caution, as clofibrate 
may also affect peripheral lipolysis. Recent studies using the 
P -oxidation inhibitor, 4-pentenoic acid have shown that 
administration of this compound in various dosage regimes causes
accumulation of triglyceride in the rat liver, suggesting a link
between hepatic fatty acid oxidation rate and triglyceride formation 
(Thayer, 1984). On the other hand, Reboucas and Isselbacher (1961) 
concluded in their experiments that depressed fatty acid oxidation was 
not important in the pathogenesis of ethanol-induced fatty liver, as 
treatment of ethanol-fed rats with nicotinamide reversed the
- 17 -
inhibition of palmitate oxidation by ethanol but did not prevent the 
fatty liver. Wooles (1966) also suggested that ethanol-induced fatty 
liver was not caused by depressed fatty acid oxidation, since, using 
blood ketone body levels as an index of hepatic fatty acid 
utilisation, there was no decrease after acute ethanol dosing until 
near the peak of the triglyceride accumulation. Glucose dosing 
suppressed blood ketone levels without inducing hepatic lipid 
accumulation. Wooles (1966) further suggested that ethanol-induced 
depression of fatty acid oxidation was unrelated to the fatty liver
production since Lossow and Chaikoff (1957) had shown glucose dosing
14 14depressed CC^ production from 1- C palmitate, as had Reboucas and
Isselbacher (1961), yet this was not associated with hepatic
triglyceride accumulation.
1.2.4. Assessment of Possible Role of Redox-State Related Effects 
in Hepatic Steatosis.
Firstly, a few comments can be made about the studies quoted 
above on fatty acid oxidation. The Wooles (1966) study used no 
direct measure of fatty acid oxidation and failed to take into account 
any specific effects that ethanol may have on ketogenesis. It has 
now been demonstrated that acetaldehyde inhibits mitochondrial 
ketogenesis (Cederbaum et al, 1975). Secondly, effects of ethanol or 
glucose dosing on peripheral lipolysis have not always been accurately 
assessed. Many of these early studies used plasma free fatty acid
(FFA) levels as indicative of peripheral lipolysis, but this does not 
take into account flux of fatty acid transport from the periphery to
- 18 -
the liver, the latter organ being very effective at removing 
unesterified fatty acids from the plasma. Most of the acute ethanol
dosing experiments have been carried out in fasted rats, a condition
in which peripheral lipolysis and plasma free fatty acid 
concentrations will be increased. Under these conditions, ethanol 
appears to have little influence on the rate of peripheral lipolysis 
or the plasma FFA levels, although some studies demonstrated an 
increase in the latter after acute ethanol dosing (Brodie et al, 1961; 
Mallov, 1955). However, glucose dosing depresses peripheral
lipolysis under these conditions so that delivery of fatty acids to 
the liver is decreased, thus any decrease in hepatic fatty acid 
oxidation under these conditions will not be of any consequence in 
terms of hepatic triglyceride disposal. Studies in man have in fact
shown either no change or a decrease in plasma FFA's during ethanol
feeding, and a fall in circulating glycerol (Lieber et al, 1962; 
Jones et al, 1963; Feinman and Lieber, 1967). Thus, whilst some 
reviewers have considered increased peripheral lipolysis as an 
important component of the ethanol-induced fatty liver, it might be 
more accurate to consider that the inappropriate response of 
peripheral lipolysis after ethanol ingestion, compared with that after 
glucose ingestion for example, is a factor necessary for the 
production of fatty liver after acute ethanol ingestion, rather than 
this being a mechanism by which the fatty liver arises. Certainly, 
if peripheral lipolysis is blocked by adrenalectomy or ^j-adrenergic 
blocking agents (Mallov, 1957; Brodie et al, 1963), the severity of
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the acute ethanol-induced fatty liver is reduced, but this is probably 
simply due to lack of fatty acids being supplied to the liver for
triglyceride synthesis. Where weights of epidymal fat pads have been 
used as an index of lipolysis, two studies have found no effect of 
acute ethanol dosing (Elko et al, 1961; Poggi and DiLuzio, 1965), 
although at very high doses, alcohol was found to enhance the 
mobilisation of ^C-palmitate from prelabelled epididymal fat pads in 
vivo (Kessler and Yalovsky-Mishkin, 1966) without, however, changing 
the specific activity of labelling in the hepatic triglycerides.
The role of enhanced peripheral lipolysis in chronic
ethanol-induced fatty liver in rats is difficult to assess. One 
early study showed that chronic ethanol feeding lowered the weights of 
epididymal and perirenal fat pads, yet no evidence of hepatic
steatosis was found in the ethanol-fed animals (Scheig et al, 1966). 
More recently, the alcoholic fatty liver produced by chronic alcohol 
feeding has been found to be associated with increased epididymal fat 
pad weights, suggesting enhanced peripheral lipolysis has little part 
to play in the hepatic triglyceride accumulation (World et al, 1984), 
which of course agrees with studies showing that most of the
accumulated lipid under these circumstances is of dietary origin 
(Lieber and DeCarli, 1970a; Mendenhall, 1972).
It will be evident from the above discussion that the effects of 
acute ethanol ingestion on peripheral lipolysis may be variable and 
possibly dependent upon experimental conditions. In experiments 
where oxidation of ^C-palmitate to in vivo has been used as an
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index of fatty acid oxidation, the effect of ethanol on lipolysis
could be important, as this will affect the degree of isotope dilution
of labelled palmitate that may take place in the hepatic free fatty
acid pool. None of the quoted studies makes any attempt to assess
pool sizes after ethanol dosing. Another factor worth bearing in
mind is the possible difference in isotope dilution of "^C-acetate
units derived from palmitate in these experiments between
ethanol-dosed and glucose-dosed animals. It is possible that acetate
units derived from glucose are more effective at diluting the
^C-acetate pool derived from "^C-palmitate than are acetate units
derived from ethanol metabolism. This may account for the apparent
ability of glucose dosing in fasted rats to suppress production
14from 1- C-palmitate by about the same extent as ethanol. In vitro
studies show that ethanol at high concentrations suppresses total
carbon dioxide production when baboon liver slices are incubated in
14the presence of palmitate, by about the same extent as CC^
production from l-^C-palmitate falls under the same experimental
conditions (Saluspuro et al, 1981). Thus, the specific activity for 
14the evolved CC^ remains approximately constant, suggesting that the
acetate derived from ethanol metabolism does not dilute the
■^C-acetyl-CoA pool derived from ^C-palmitate, but these
considerations may not hold true for glucose. Thus, it appears many
of the observations of impaired fatty acid oxidation caused by ethanol 
14where CO^ production has been employed, are probably valid, and 
reflect true inhibition of this mitochondrial function.
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One other possible experimental artefact that has to be 
14considered in CO2 production studies is the degree of 
reincorporation of the labelled product into oxaloacetate in the 
phosphoenolpyruvate carboxylase catalysed reaction. Some studies 
suggest that as much as one-third of the CO^ generated from Kreb's 
cycle activity is reincorporated in this fashion, and no information 
is available on how this may vary in the presence of various 
substrates, including ethanol and glucose (Tomera et al, 1983). 
However, taking all the above considerations into account, and also 
assessing the results of studies where mitochondrial isolated from 
ethanol-fed animals show decreased ability to oxidise fatty acids in 
the absence of added ethanol (Cederbaum et al, 1973b; Saluspuro eit 
al, 1981), there does appear to be a role for this mechanism in the 
pathogenesis of fatty liver. It is still not clear, however, whether 
this decrease in fatty acid oxidation is due to the change in the 
NADH:NAD ratio caused by ethanol metabolism.
Thus, to conclude this section, an effect of ethanol on fatty 
acid synthesis is somewhat doubtful, although it almost certainly 
depresses fatty acid oxidation and increases ^-glycerophosphate 
levels. Only the last of these effects definitely seems to be a
consequence of the hepatic redox-state change after ethanol, and yet 
this factor may not be important in the pathogenesis of alcoholic 
fatty liver. Some agents, such as antioxidants, will prevent acute 
fatty liver without correcting the altered NADH:NAD ratio (Rossiter 
and Slater, 1973). Antioxidants also prevent the chronic alcoholic
- 22 -
fatty liver (Hartman and DiLuzio, 1968). Correction of the hepatic 
redox-state after acute ethanol administration by tocopheronolactone, 
did not prevent the development of fatty liver (Hirayama and
Hiroshige, 1970). Thus, in spite of the neatness of the redox-state 
explanation for the production of fatty liver by ethanol, there is 
evidence to suggest that other factors, that will be discussed below, 
could be more important in its pathogenesis. A diagrammatic
representation of how the ethanol-induced redox-state change may 
affect lipid metabolism to cause fatty liver is shown in Fig. 1.2.
1.2.5. Role of Acetaldehyde in the Pathogenesis of Alcoholic 
Fatty Liver
Acetaldehyde can be considered as the 'reactive metabolite' of 
ethanol metabolism, which would be compared to the quinone-type 
reactive intermediate derived from paracetamol, which is responsible
for the drug's hepatotoxicity. Acetaldehyde reacts readily with 
amino and sulphydryl groups, forming Schiff base's with lysine
residues and reacting covalently with glutathione and glutathione 
precursors such as cysteine to form hemiacetals. In vitro work has 
shown acetaldehyde can bind covalently with a number of proteins, 
including albumin, erythrocyte membrane proteins, hepatic microsomal 
proteins and hemoglobin (Donohue et al, 1983a; Lumeng et al, 1982; 
Gaines et al, 1977; Nomura and Lieber, 1981; Stevens et al, 1981; 
Donohue et al, 1983b). The relevance of this binding to the toxic
effects attributed to acetaldehyde is not completely clear, but as 
will be seen in the ensuing discussion, it may certainly have a role
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to play in the block in hepatic protein secretion and possibly also 
the impairment of mitochondrial functions induced by this ethanol 
metabolite. Principally, there seem to be three mechanisms by which 
acetaldehyde could contribute to the development of fatty liver. 
These are:
(i) Direct inhibition of mitochondrial function 
(ii) Inhibition of hepatic protein secretion
(iii) Initiation of lipid peroxidation following ethanol
intake
These will now be considered in turn.
(i) Inhibition of mitochondrial functions by acetaldehyde: In
isolated mitochondria, acetaldehyde inhibits fatty acid oxidation as 
assayed by oxygen consumption and CC^ production. This inhibition is 
not mediated by metabolism of acetaldehyde to acetate in the 
mitochondria, nor due to impaired translocation of fatty acids into 
the orgenelle. These observations led Cederbaum et al (1975a) and 
Cederbaum and Rubin (1975) to suggest that acetaldehyde inhibits
.J-
NAD -dependent state 3 oxygen uptake, inhibits oxidative 
phosphorylation at site 1, and decreases calcium uptake. These 
effects were achieved at added acetaldehyde concentrations of between 
0.6 and 12.0 mM in vitro, whereas high concentrations of ethanol, 
greater than those that might be achieved in vivo (80 mM) were without 
effect. It is pertinent to ask whether these acetaldehyde
concentrations are relevant to possible in vivo effects of the
compound. The hepatic concentration of acetaldehyde during ethanol
- 25 -
oxidation has been reported to be in the range 20-100 pM (Eriksson, 
1983; Eriksson et al, 1983), rather lower than the concentrations 
used in the in vitro studies above. These acetaldehyde
concentrations were, however, those added to the incubations, and were 
not corrected for evaporative losses. These may have been
considerable since acetaldehyde boils at 21°C. Acetaldehyde has been 
shown to be responsible for the in vivo ethanol-induced decrease in 
phosphorylation potential, caused by increases in ADP and inorganic 
phosphate levels (Lindros and Stowell, 1982).
These acute effects of acetaldehyde are similar to the functional 
changes that are observed when mitochondria isolated from rats fed 
ethanol chronically were compared with those from pair-fed controls. 
Mitochondria from ethanol-fed rats were much more sensitive to the 
acute in vitro effects of acetaldehyde than mitochondria from naive 
rats (Matsuzaki and Lieber, 1977). This suggests that continued 
exposure to acetaldehyde during chronic alcohol intake causes
structural alterations that leads to impaired function, possibly
through covalent binding at critical sites on mitochondrial enzyme 
protein complexes. Ethanol consumption does in fact affect
biogenesis of mitochondrial proteins, again an effect that could be 
mediated by acetaldehyde. For example, the cytochrome a and b
contents of mitochondria from ethanol-fed rats is reduced (Rubin et_ 
al, 1970). Electron microscopic studies have shown that chronic
ethanol feeding profoundly alters mitochondrial morphology, with
swelling and abnormal christae being seen (Rubin and Lieber, 1967;
- 26 -
Rubin and Lieber, 1968). Mitochondria from ethanol-fed rats show 
altered in vitro calcium transport. Acetaldehyde added in vitro to 
these preparations at a physiological concentration (100 pM), enhances 
calcium retention but this effect is abolished by cyanamide (an ALDH 
inhibitor) pretreatment, indicating that it is acetaldehyde 
metabolism, rather than acetaldehyde itself that causes this defect 
(Korsten et al, 1983).
Further studies on mitochondria from ethanol-fed rats showed 
impaired respiratory control with succinate as the substrate, and loss 
of control of phospholipase activity in ageing experiments (Spach 
et al, 1979). These altered mitochondrial functions were not the 
result of altered acyl-chain composition of bulk-phase mitochondrial 
phospholipids, suggesting once again that a direct interaction of 
acetaldehyde may be responsible. Other studies, however, have shown 
alterations in the fatty acid composition of mitochondrial 
phospholipids after chronic ethanol intake (Cunningham et al, 1982).
A number of studies have indicated that the above effects could 
be mediated through interaction of acetaldehyde with thiol groups. 
For example, other compounds which are known to interact with thiol 
groups, such as copper (Cederbaum and Wainio, 1972), and 
5,3'-dithionitrobenzoic acid (Hangaard et al, 1969), exert similar 
inhibitory actions on isolated mitochondria in vitro. Thiol groups 
participate in many key mitochondrial sites and functions, such as 
oxidative phosphorylation (Fluharty and Sanadi, 1963; Sabadie-Pialoux
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and Gautheron, 1971), and NADH and succinate dehydrogenases (Tyler et 
al, 1965; Gutman et al, 1972; Slater, 1948). Aldehydes react very 
readily with mercaptans, and in the case of cysteine, this results in 
ring closure to form a thiazolidine residue. Indeed, cysteine, at 
equimolor concentrations to that of acetaldehyde, will protect
isolated mitochondria against the inhibition of fatty acid and 
NAD+-dependent substrate oxidation exerted by this ethanol metabolite. 
Cysteine also reversed the inhibition of oxygen uptake by 
acetaldehyde, although only a small effect on the depressed oxidative 
phosphorylation was observed (Cederbaum and Rubin, 1976).
(ii) Role of acetaldehyde in ethanol-induced effects on hepatic 
protein synthesis and secretion: Two of the earliest and most
conspicuous features of ethanol-induced liver damage are fatty 
infiltration and enlargement of the liver (hepatomegaly). In rats
fed ethanol chronically, lipid accumulation only accounts for about 
half the increase in liver dry weight, the other half being almost 
totally due to protein retention (Lieber et al, 1965; Baraona et al,
1975). This apparent block in hepatic protein secretion by ethanol
was studied further in rat liver slices by Sorrell and Tuma (1978). 
They found that ethanol alone (10 mM) inhibited both the glycosylation 
and secretion of prelabelled proteins from liver slice preparations. 
Low concentrations of acetaldehyde gave similar results. Pulse-chase 
labelling, or the use of the protein synthesis inhibitors 
cyclohexamide and puromycin, were employed to differentiate between
effects of ethanol and acetaldehyde on protein synthesis and secretion
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in turn. Further studies showed that ethanol impaired both the
synthesis and secretion of secretory glycoproteins and albumin from
rat liver slices (Tuma et al, 1981). Acute studies in isolated
hepatocytes showed that ethanol inhibited protein synthesis and 
secretion (JeeJeeboy et al, 1975; Rothschild et al, 1971), and that
this inhibition could be overcome by the addition of agents that 
corrected the increased NADHrNAD ratios arising in the incubations
from ethanol metabolism. Addition of these agents (methylene blue or 
a combination of asparate and cC-ketoglutarate) did in fact increase 
acetaldehyde concentrations in the incubations, yet still relieved 
inhibition of protein synthesis by ethanol (Baraona et al, 1980c). 
However, the relevance of these findings to acute ethanol 
hepatotoxicity is difficult to assess as there are conflicting reports 
on the effects of acute ethanol intake on hepatic protein synthesis 
and secretion in vivo. The study of Baraona et al (1980a) showed no 
effect of ethanol (3 g/kg p.o.) on hepatic protein synthesis, although 
reduced secretion of liver protein was reported. Wallin et al (1984) 
have, however, reported no effect of a similar dose of ethanol (2.88 
g/kg p.o.) on either hepatic protein synthesis or secretion. These 
doses of ethanol do not, however, cause very profound triglyceride 
accumulation in the liver. Administration of 6 g/kg ethanol orally, 
a dose that is commonly used to induce acute fatty liver in rats, 
inhibited glycoprotein and albumin secretion from the liver, this 
effect being blocked by pretreatment with 4-methylpyrazole, indicating 
that ethanol metabolism was necessary for the secretory block to occur 
(Volentine et al, 1984).
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More consistent findings have been made in rats after chronic 
ethanol feeding. Both decreased hepatic protein synthesis and
secretion have been reported after chronic ethanol administration to 
rats (Smith-Kielland et al, 1983; Sorrell et al, 1983). Studies on
isolated hepatocytes from ethanol-fed rats apparently showed no 
decrease in protein synthesis rates when measurements were compared 
with those in cells from pair-fed control animals. Furthermore, 
addition of ethanol to these preparations only inhibited protein 
synthesis in control cells, hepatocytes from ethanol-fed animals being 
unaffected. This was attributed to the attenuation of
ethanol-induced redox-state change in cells from ethanol-fed rats, and 
these authors proposed that the block in protein synthesis was due to 
the NADH:NAD ratio increase diverting amino acids away from synthesis 
to transamination reactions (eg: alanine to pyruvate), to make up for
substrate losses resulting from the redox shift (Baraona et al, 
1980a). However, these findings do not agree with effects after
chronic ethanol in vivo, suggesting that isolated hepatocytes may be 
an inadequate system for studying the effects of ethanol on protein 
synthesis and secretion. One study has shown, that unlike in liver 
slices and in vivo, ethanol does not impair protein secretion in 
isolated hepatocytes (Norland et al, 1981).
Studies on the mechanism of impaired hepatic protein secretion 
certainly indicate that acetaldehyde is implicated. In liver slices, 
pyrazole prevented the ethanol-induced secretory block, yet correction 
of the redox-state by methylene blue and pyruvate did not achieve
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this. Although sorbitol, which causes redox-state changes, did cause 
a decrease in secretion in this model, equimolor concentrations of 
fructose also achieved this, indicating this effect was not related to 
the redox-state change. Infusion of acetaldehyde alone caused a
block in secretion similar to that seen in the presence of ethanol 
(Sorrell et al, 1977a). This effect of acetaldehyde was
irreversible, as washing of the slices after incubation with the 
substance, and reincubation in fresh, acetaldehyde-free medium, did 
not reverse the secretory block (Sorrell et al, 1977b). This finding 
is consistent with a possible role of covalent binding of acetaldehyde 
to microtubular protein, that could account for the protein 
accumulation in the liver after chronic ethanol feeding (Baraona et 
al, 1977; Jennett et al, 1980). Acute ethanol administration has 
been found to decrease the volume density of microtubules and inhibit 
tubulin polymerisation in vivo, this effect being exaggerated after 
long-term ethanol feeding. These effects are further exaggerated if 
animals have been pretreated with the aldehyde dehydrogenase 
inhibitor, disulfiram, allowing acetaldehyde to accumulate (Baraona E?t 
al, 1979; Baraona et al, 1980b).
Thus, overall, the effects of ethanol on protein synthesis are 
not completely clear, but there does seem to be a lot of evidence that 
ethanol consumption impairs hepatic protein secretion, possibly 
through a covalent interaction of acetaldehyde with microtubules, that 
in turn may contribute to fatty liver production through hepatic 
retention of triglyceride in the form of very low density lipoproteins
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(VLDL). Although experimental studies show that an increase in
plasma triglycerides (TG) is associated with the development of fatty 
liver in man (Lieber et al, 1965; Allen and Adena, 1985) there is 
evidence that this may be a transient phenomenon, and that after 
continued long-term intake, plasma TG levels do in fact fall, 
supporting the hypothesis that hepatic retention of VLDL could 
contribute to fatty liver formation (Belfrage et al, 1977).
(iii) Acetaldehyde: its role in ethanol-induced lipid peroxidation:
There is experimental evidence to indicate that acetaldehyde is 
responsible for initiating lipid peroxidation after acute ethanol
exposure. In view of the controversial nature of lipid peroxidation 
in ethanol-induced liver injury, and its relevance to the work
described in this thesis, this aspect is fully discussed in the 
forthcoming section.
1.2.6. Ethanol-Induced Hepatic Lipid Peroxidation
(i) The role of lipid peroxidation in ethanol-induced liver injury: 
The role of lipid peroxidation in ethanol-induced liver injury has 
been the subject of much debate over the years. For certain 
hepatotoxic compounds, notably carbon tetrachloride, it is widely 
accepted that the initial event involved in its hepatotoxicity is
metabolism to a free radical intermediate, which can then interact 
with a number of neighbouring macromolecules in the cell, including 
covalent binding and peroxidation of unsaturated fatty acid residues 
of membrane phospholipids. The precise link between these early free 
radical-mediated reactions, and the ultimate breakdown of hepatocyte
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function and viability in carbon tetrachloride poisoning is not 
understood, but lipid peroxidation is thought to play a part in this 
process (Brattin et al, 1985). The initial hepatic change after 
carbon tetrachloride administration in experimental animals is similar 
to that after ethanol, namely an increase in hepatic triglycerides.
The concept that lipid peroxidation might be responsible for the 
ethanol-induced fatty liver in rats was first proposed by DiLuzio 
(1964). He showed that the acute ethanol-induced fatty liver could
be prevented by the co-administration of an antioxidant cocktail 
(G-50, which contains butylated hydroxytoluene, butylated 
hydroxyanisole, and propyl gallate). Further studies showed that the 
synthetic antioxidant N,N'-diphenyl-p-phenylenediamine (DPPD) and 
alpha-tocopherol acetate (vitamin E) also protect against acute 
ethanol-induced steatosis in rats (DiLuzio, 1966). Some support for 
a role of lipid peroxidation in the ethanol-induced fatty liver came 
from a study in which DPPD, in an identical dosage regime to that 
which protected against ethanol-induced liver injury, also prevented 
acute carbon tetrachloride hepatotoxicity (DiLuzio and Costales, 
1965). About this time, there was also much speculation as to the
possible role of the altered NADH:NAD ratio after ethanol dosing in 
the production of fatty liver, so that some workers, including DiLuzio 
(DiLuzio, 1965; DiLuzio and Costales, 1965), proposed that
antioxidants might protect against steatosis through modulation of 
ethanol-induced redox-state change. This question was not fully
resolved until Rossiter and Slater (1973) clearly showed that a
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variety of antioxidants (DPPD, BHT, and propyl gallate) prevented the 
acute alcoholic fatty liver without reversing the increased NADH:NAD 
ratio. This suggested that antioxidants may indeed be acting through 
inhibition of lipid peroxidation after ethanol dosing.
Much of the controversy over the role of lipid peroxidation in 
alcoholic liver damage centres on the evidence that has been produced 
in an attempt to demonstrate that ethanol intake causes increased 
peroxidation of hepatic lipids. Using an iodometric technique,
Kalish and DiLuzio (1966) demonstrated increased liver lipid peroxide 
levels after acute ethanol dosing, which were prevented by antioxidant 
administration (co-enzyme Q4), and at the same time the latter 
substance prevented fatty liver. DiLuzio and Hartman (1967) also 
reported increased liver malondialdehyde content after acute ethanol 
dosing in rats, which, again, was prevented by antioxidant 
pre-treatments, in the same experiments in which antioxidants 
inhibited steatosis. Furthermore, treatment of animals with DPPD
during chronic feeding of ethanol as 36?o of the calories intake in a 
liquid diet, also prevented the chronic ethanol-induced fatty liver 
(Hartman and DiLuzio, 1968). These findings led DiLuzio to propose 
lipid peroxidation as an important mechanism of ethanol-induced liver 
injury (DiLuzio, 1973).
The controversy relating to these views arose in the latter part 
of the 1960's. Firstly, Lieber and DeCarli (1966) found that
addition of either DPPD or ^-tocopherol acetate to their 
alcohol-containing liquid diets did not prevent fatty liver after
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chronic ethanol administration. This may, however, be due to poor 
intestinal absorption of lipid soluble antioxidants such as DPPD. It 
is now recognised that to be effective, an antioxidant has to be in 
the right place, at the right time, and at a suitable concentration 
(Slater, 1984) and this may not have been achieved in this study. 
There was also some dispute as to whether acute ethanol dosing induced 
hepatic lipid peroxidation in the rat. Hashimoto and Recknagel 
(1968), using the sensitive and specific diene conjugate assay for
detecting lipid peroxidation, found no evidence of peroxidation in any
of the subcellular liver fractions studied (microsomes, mitochondria 
or nuclei) after a large, acute oral dose of ethanol (7.9 g/kg body 
weight), whereas low doses of carbon tetrachloride produced clear 
evidence of diene absorption in the microsomal lipids using identical 
methodology. These authors also failed to find any evidence of
increased liver lipid peroxides, measured iodometrically, after the 
same ethanol dose. DiLuzio replied to these studies (DiLuzio, 1968), 
producing data that did in fact show some evidence of diene 
conjugation in the mitochondrial lipids only, one hour after a 
slightly lower dose of ethanol (6 g/kg). DiLuzio criticised
Hashimoto and Recknagel's iodometric technique for determining liver
lipid peroxides, and reported a 100% increase in liver lipid peroxides 
measured six hours after ethanol dosing, although there was no 
significant increase at earlier time points (DiLuzio, 1968). Thus, 
it appears that the discrepancies between the Hashimoto and Recknagel 
and DiLuzio's data may arise from differences in methodology, the
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ethanol doses employed, and the time points studied. The very large 
dose used by the former authors is close to the LD^p dose for ethanol 
in rats, and this dose might be expected to cause inhibition of 
ethanol metabolism due to the high liver ethanol concentrations that 
could be achieved. Alcohol dehydrogenase activity is decreased at 
high ethanol concentrations, and more recent studies have shown that 
ethanol metabolism is necessary for ethanol-induced lipid peroxidation 
to occur in vivo (Bosron et al, 1983; Sippel, 1983). In addition, 
ethanol itself is an effective radical scavenger, so that at these 
high ethanol levels, any peroxidative processes may in fact be 
counteracted (Videla and Valenzuela, 1982).
However, some other workers questioned the role of lipid
peroxidation in ethanol hepatotoxicity. Bunyan et al (1969) failed 
to find any increase in liver lipid peroxides, measured 
iodometrically, after acute ethanol dosing in rats (5-8 g/kg orally), 
although they did find that ethanol added to liver homogenates in 
vitro increased malondialdehyde production. These authors also
confirmed DiLuzio's finding that the DPPD prevented the 
ethanol-induced fatty liver, although vitamin E was not effective in 
this respect.
Since the controversy arose over ethanol-induced lipid 
peroxidation and its role in hepatotoxicity, a number of studies have 
been published that do show that ethanol induces lipid peroxidation, 
although it is clear that it is a much weaker pro-oxidant than carbon 
tetrachloride. Comporti et al (1973) showed production of
- 36 -
malondialdehyde is increased in liver homogenates taken from rats 
after acute ethanol administration, and that the reduced glutathione 
content of liver was decreased, possibly as a result of increased 
peroxidation. Macdonald (1973), using a diene conjugation method for 
detecting lipid peroxidation, found increases . in the liver 
mitochondrial lipids after acute ethanol administration (5 g/kg 
orally), and also found that susceptibility to peroxidation in both 
the mitochondrial and microsomal lipids was enhanced by repeated doses 
of ethanol over a two week period. This author also found increases 
in liver glutathione peroxidase and glutathione reductase activities 
after long-term dosing with ethanol. No liver lipid measurements 
were made in this study however. Sippel (1983) found increased diene 
conjugates in liver microsomal lipids at an early time point (2 hours) 
after a moderate intraperitoneal dose of ethanol (1.5 g/kg), this 
increase occurring in the absence of any fall in hepatic reduced 
glutathione levels. Using a newly-developed second derivative
spectroscopic method for detecting diene conjugation, Corongiu et al 
(1983) reported microsomal lipid peroxidation 24 hours after acute 
ethanol administration (7.9 g/kg orally). Valenzuela et al (1980) 
found increased diene conjugation in total liver lipids and increased 
superoxide dismutase and NADPH oxidase activities in liver homogenates 
taken from rats 6 hours after acute ethanol administration (5 g/kg 
orally).
In the isolated perfused rat liver, Muller and Sies (1982) found 
low levels of ethanol (0.5 mM) in the perfusate increased ethane and
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pentane production by the organ, this increase being blocked if 
pyrazole or 4-methylpyrazole was added to the system. Increased 
alkane production could also be initiated by adding acetaldehyde to 
the perfusate in the presence of pyrazole, indicating that ethanol 
itself, or possibly the presence of ethanol at a cytochrome P450 
binding site, is not the initiating factor for peroxidation to occur. 
The data suggests that it is some acetaldehyde-mediated action that is 
critical in this respect.
Rouach et al (1983) have also reported hepatic lipid peroxidation 
(measurement of thiobarbituric acid reactive material, thought 
principally to be malondialdehyde, MDA) during ethanol administration 
using an inhalation method, mitochondria being mainly affected. In 
accord with the study of Macdonald (1973), they found that 
susceptibility to peroxidation was enhanced after four days of ethanol 
inhalation.
Observations on the occurrence of, and the role of, lipid 
peroxidation during chronic ethanol feeding in experimental animals is 
rather limited. As already mentioned, repeated ethanol dosing
appears to enhance the susceptibility of liver lipids to the 
peroxidation induced by an acute dose of ethanol (Macdonald, 1973). 
A study by Torrelli et al (1978) failed to demonstrate any evidence of 
microsomal lipid peroxidation measured as diene conjugation after 
acute ethanol administration (7 g/kg orally) or after up to three 
weeks administration of a daily ethanol dose of 3 g/kg orally. 
However, production of TBA-reactive substances by liver homogenates
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from animals in this study was increased by the ethanol treatments. 
This ethanol dosage regime would not normally be considered a suitable 
method for the chronic administration of ethanol, and the study of 
Shaw et al (1981) is probably the most comprehensive in terms of the 
effect of a chronic ethanol feeding regime (using the Lieber-DeCarli 
liquid diet) on hepatic lipid peroxidation. This study could find no 
significant difference in microsomal or mitochondrial diene conjugates 
in rats after six weeks of ethanol feeding, but administration of a 
moderate dose of ethanol (3 g/kg) to ethanol-fed animals caused marked 
increases in diene conjugates in both subcellular fractions, but had 
little effect in pair-fed control animals. There was no hepatic 
glutathione depletion associated with this ethanol dose in either 
control or ethanol-fed animals. One of the most interesting aspects 
of this study, was however, the data obtained from baboons which had 
been fed ethanol in liquid diets for up to four years. There was a 
significant increase in diene conjugates in total liver lipids, and 
depressed liver glutathione levels in ethanol-fed animals when 
compared with controls, without having to give an acute ethanol 
challenge as in rats. Furthermore, administration of a moderate dose 
of ethanol (1.6 g/kg) caused marked hepatic glutathione depletion and 
increases in hepatic diene conjugates, these changes being greatest in 
the ethanol-fed animals, again highlighting the increased 
susceptibility to lipid peroxidation after chronic alcohol intake. 
Thus, it appears that primates are much more susceptible to 
ethanol-induced lipid peroxidation than rats, which is of interest,
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as, of course, primates develop the whole spectrum of hepatic lesions 
seen in man during long-term alcohol intake, whereas rats only proceed 
to the fatty liver stage. This suggests a possible causal link 
between hepatic lipid peroxidation and ethanol hepatotoxicity.
Studies in human alcoholics have shown increased liver lipid 
diene conjugates and depressed reduced glutathione levels in patients 
with alcoholic liver disease, when compared with patients with liver 
disease of non-alcoholic origin (Shaw et al, 1983).
(ii) Possible mechanisms of ethanol-induced lipid peroxidation: The
perfused liver study of Muller and Sies (1982) and the in vivo study 
of Sippel (1983), as mentioned above, indicate that in the rat, 
ethanol metabolism is a requirement for lipid peroxidation to occur 
after acute exposure. This, once again, incriminates the ethanol 
metabolite, acetaldehyde, in the process. There are a number of ways 
in which acetaldehyde could cause lipid peroxidation. Firstly, it's 
ability to interact with thiol groups, could cause depletion of 
reduced glutathione or glutathione precursors such as cysteine, thus 
increasing endogenous peroxidation. Both acute and chronic ethanol 
treatments cause hepatic glutathione depletion in rats and baboons 
(Comporti et al, 1983; Macdonald et al, 1977; Shaw et al, 1981;
Videla et al, 1980; Fernandez and Videla, 1981). In vitro studies 
show that pyrazole abolishes the decrease in hepatic GSH induced by 
20mM ethanol, whereas the ALDH inhibitor, disulfiram, potentiates it, 
suggesting a role for acetaldehyde (Vina et al, 1980). After chronic 
ethanol, increased glutathione breakdown may be an important
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mechanism, as the activity of hepatic ()- glutamyl transpeptidase is 
increased after long-term ethanol intake (Teschke et al, 1977; Ishii 
et al, 1978). However, some studies show that ethanol will cause 
lipid peroxidation in the absence of glutathione depletion (eg: 
Sippel, 1983), so mechanisms other than simply loss of reduced 
glutathione may be involved.i
A number of enzymatic mechanisms have been proposed by which
acetaldehyde and/or ethanol could cause lipid peroxidation. 
Acetaldehyde can act as a substrate for both aldehyde oxidase and
xanthine oxidase, both enzymes yielding superoxide anions when they 
oxidise substrates. Xanthine oxidase normally exists in vivo as an 
NAD-dependent dehydrogenase that catalyses the formation of uric acid 
from xanthine. Under certain adverse conditions, (eg: hypoxia), the 
enzyme can lose a critical thiol group, and become converted to the 
superoxide-producing form (Type 0) of the enzyme, referred to as
xanthine oxidase (Stirpe and Della Corte, 1969; Della Corte and
Stirpe, 1972). This interconversion, yielding copious amounts of
superoxide on reperfusion of a tissue with oxygenated blood after an
ischaemic episode, has been proposed as the mechanism by which tissue 
damage may occur in ischaemic heart disease (McCord, 1985). During 
ethanol metabolism, the increased oxygen consumption and centrilobular 
hypoxia that can occur in the liver might favour conversion of
xanthine dehydrogenase into the oxidase form (Baraona et al, 1983;
Thurman et al, 1984). It has been proposed that such an
interconversion, and the subsequent oxidation of ethanol-derived
acetaldehyde to yield superoxide anions, could underly ethanol 
hepatotoxicity (Lewis and Paton, 1982).
Chronic ethanol treatment does cause an increase in the liver
xanthine oxidase:xanthine dehydrogenase ratio (Oei et al, 1982), 
although comprehensive studies on the effect of a xanthine oxidase 
inhibitor (eg: allopurinol) on ethanol hepatotoxicity are required to 
assess the role of this mechanism. However, it does seem likely that 
some enzymatic process is involved in ethanol-induced lipid 
peroxidation, the latter then being exacerbated by the glutathione 
depletion. As already mentioned, loss of glutathione is probably not 
the sole explanation for ethanol-induced peroxidation, as the lowering 
of glutathione levels with diethyl maleate is not associated with 
increased lipid peroxidation in the liver (Wendel et al, 1979; 
Lindstrom and Anders, 1978).
Enzymatic processes are probably also important in the enhanced 
susceptibility to peroxidation after long-term ethanol intake. 
Proliferation of the smooth endoplasmic reticulum and increases in 
associated enzyme activities, such as NADPH oxidase, ethanol-induced
forms of cytochrome P450 and cytochrome-c reductase, could enhance
superoxide production (Reitz, 1975; Boveris et al, 1983). This 
increased capacity of the microsomal fraction to produce superoxide 
anions after chronic ethanol treatment, in the absence of a parallel 
increase in cytosolic superoxide dismutase activity, could underly the 
enhanced susceptibility to peroxidation (Boveris et al, 1983). 
Superoxide anions in their own right are not very reactive or'
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damaging, conversion to the highly-reactive hydroxyl radical, by means 
of iron-catalysed Fenton-type reactions, often being necessary before 
significant, potentially cell-damaging, events occur (Freeman and 
Crapo, 1982; Slater, 1984). Microsomal generation of hydroxyl 
radicals is enhanced after chronic ethanol treatment, but this 
increase does not correlate precisely with endogenous microsomal lipid 
peroxidation measured in vitro (Shaw et al, 1984).
In conclusion, it will be clear that the role of lipid 
peroxidation in ethanol-induced liver injury, and the underlying 
mechanisms are still the subject of much debate. It does appear, 
however, that some enzymatic metabolism of acetaldehyde in combination 
with glutathione depletion, initiated by this ethanol metabolite, may 
increase lipid peroxidation in the liver, and that after chronic 
treatment, microsomal free radical production may be increased, so as 
to enhance susceptibility to lipid peroxidation. The protective 
effects of antioxidants on fatty liver in rats, the greater 
susceptibility of primates to peroxidation, and the increased severity 
of hepatic lesions seen after ethanol intake in the latter species, 
all suggest a role for lipid peroxidation in ethanol-induced liver 
injury. The link between ethanol-induced lipid peroxidation and some 
of the other impaired hepatic functions that have been implicated in 
ethanol hepatotoxicity (eg: mitochondrial damage/dysfunction,
microtubule damage and impaired glycoprotein secretion), remains to be 
established, but investigations of such possible inter-relationships 
could prove fruitful in clarifying the biochemical mechanisms of 
ethanol-induced liver damage.
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1.3. OTHER POSSIBLE MECHANISMS OF FATTY LIVER PRODUCTION BY ETHANOL
1.3.1. Role of ethanol-derived acetate
The copious amounts of acetate produced by hepatic ethanol
oxidation could act as a precursor of the accumulated hepatic lipids 
under such conditions. However, most of this acetate is oxidised 
extrahepatically, chiefly in the heart and skeletal muscle (Fellenious 
et al, 1973; Damgaard et al, 1973). One study did find that
administration of acetate to rats caused a similar degree of
triglyceride accumulation, and a redox-state shift almost identical to
that when an equivalent dose of ethanol was given (Morgan and
Mendenhall, 1977). These authors proposed that ethanol-derived
acetate displaced fatty-acyl-CoA derivatives as substrates for
mitochondrial oxidation, thereby causing triglyceride accumulation. 
They also proposed that acetate oxidation contributed to the 
redox-state change after ethanol rather than the excess NADH being 
derived solely from oxidation of ethanol to acetate. The
possibility, however, that the steatotic effect of acetate was 
mediated by acetaldehyde formed from acetate, through reduction by 
aldehyde dehydrogenase was not investigated. Acetate has also been 
shown to inhibit peripheral lipolysis and cause a fall in circulating 
free fatty acids, effects which might in fact be thought to counteract 
the production of a fatty liver (Nilson and Belfrage, 1978; Crouse et_ 
al, 1968). Thus, a role for ethanol-derived acetate in the
pathogenesis of hepatic steatosis seems doubtful.
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1.3.2. Increased peripheral lipolysis
Early studies in rats (Brodie et al, 1961; Elko et al, 1961) 
suggested that increased mobilisation of fatty acids from peripheral 
depots could account for alcoholic fatty liver. Studies in man did 
not agree with this concept however (Crouse et al, 1968). In view of 
the more detailed discussion earlier in this chapter (Section 1.2.4), 
and the finding in rats that epididymal fat pads weights are increased 
after chronic ethanol feeding (World et al, 1984), it is doubtful 
whether increased peripheral lipolysis is an important primary 
mechanism by which ethanol causes fatty liver.
1.3.3. Induction of Specific Enzyme Activities
Acute ethanol ingestion increases the activity of hepatic 
phosphatidate phosphohydrolase, the rate-limiting enzyme in 
triglyceride synthesis .(Savoleinen, 1977; Pritchard et al, 1977), 
increases also being seen after chronic ethanol treatment (Lamb et al, 
1979). The increase in this activity precedes the ethanol-induced
triglyceride accumulation. The cause of induction appears to be
increased serum corticosterone concentrations arising in response to a 
large intoxicating dose of ethanol, adrenalectomy largely preventing 
the ethanol-induced increase in phosphohydrolase activity (Brindley et^  
al, 1979). However, ethanol-induced stimulation of phosphatidate
phosphohydrolase activity in the soluble fraction of liver is probably 
due to activation of an existing phosphohydrolase, partly by 
glucocorticoids and partly by ^C-glycerophosphate (Savoleinen and 
Hassinen, 1978), rather than true induction taking place (Sturton et^  
al, 1981).
- 45 -
More recent work indicates that phosphatidate phosphohydrolase 
normally exists in latent form in the soluble fraction of the liver, 
but undergoes activation and translocation to the microsomal fraction 
(Cascales et al, 1984). This process is promoted by unesterified 
fatty acids. It is therefore possible that the enhanced activity
seen after ethanol, prior to triglyceride accumulation in the liver, 
is, in part, a response to increased free fatty acid availability in 
the liver secondary to some other ethanol and/or acetaldehyde-mediated 
event (eg: inhibiton of fatty acid oxidation). The hepatic
concentration of free fatty acids is increased in patients with 
alcoholic liver disease (Mavrelis et al, 1983).
The first enzyme in the pathway of hepatic glycerolipid 
synthesis, sn-glycerol-3-phosphate acyltransferase, is induced by 
chronic ethanol feeding, a 73% increase being observed after six weeks 
in rats (Joly et al, 1973). . Diacylglycerol acyl transferase, the 
last enzyme in the pathway of triglyceride synthesis, and the only 
enzyme specific for triglyceride formation in the pathway (the others 
are common to phospholipid synthesis), is another enzyme that could be 
affected by ethanol treatment, since most of the accumulated lipid is 
triglyceride. One study showed no effect of acute ethanol treatment 
on the activity of this enzyme (Pritchard et al, 1977). However, the 
activity of this enzyme is controlled by a 
phosphorylation-dephosphorylation mechanism (Haaqsman et al, 1982), so 
that when the cytosolic fraction is included in the assay for activity 
in microsomes, a two-fold increase can be observed after ethanol
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dosing (Vaananen et al, 1981). Increases in other microsomal enzymes 
that may be important in ethanol-induced lipid peroxidation have 
already been discussed. The enzyme induction that has been described 
here could certainly explain the distribution of accumulated fat 
between the lipid classes that occurs after ethanol intake, although 
it seems likely that these changes, in particular the effects on 
phosphatidate phosphohydrolase, occur in response to other effects of 
ethanol on fatty acid metabolism, rather than enzyme induction being a 
primary mechanism by which triglyceride deposition occurs.
1.3.4. Increased Hepatic Blood Flow
Abrams and Cooper (1976a) carried out a quantitative analysis of 
the hepatic triglyceride accumulation following two moderate acute 
doses of ethanol (2.1 g/kg and 0.7 g/kg i.p.). At the higher dose, 
half the accumulated hepatic triglyceride could be accounted for by 
increased hepatic uptake of unesterified fatty acids from the serum. 
At the lower dose, this source could account for all of the 
accumulated triglyceride. They went on to show that this increased 
uptake of fatty acids correlated with the increase in the serum volume 
of the liver, and the increase in hepatic blood flow (measured using a 
radiolabelled colloid) after the same ethanol dose (Abrams and Cooper, 
1976b). These authors proposed that increased hepatic blood flow,
with a concomittent increase in hepatic uptake of fatty acids is 
responsible for the fatty liver after this low ethanol dose, since the 
rate of triglyceride formation is related to fatty acid availability 
in the liver, and there was no increase in lipoprotein secretion after
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ethanol to counteract the increased triglyceride synthesis.
A number of points can be made about these studies. Firstly, 
this mechanism only accounts for the mild degree of fat accumulation 
after the 0.7 g/kg ethanol dose, the high dose (2.1 g/kg) causing a 
more pronounced rise in hepatic triglycerides that could not be 
accounted for solely by increased serum uptake of fatty acids. The 
low dose of ethanol does not produce the classic, histologically 
observable, centrilobular fatty infiltration caused by larger oral 
doses of ethanol (5 g/kg) or chronic ethanol feeding in liquid diets, 
when 12-15 g/kg/day ethanol may be consumed. Furthermore, chronic 
ethanol treatment causes an increase in liver size, due to hepatocyte 
enlargement, that in fact reduces hepatic blood flow, yet, fatty liver 
persists in this condition (Israel and Orrego, 1983). Thus, 
increased hepatic blood flow is probably only important in causing fat 
accomulation after low doses of ethanol, and makes very little 
contribution to the more severe, and pathologically important, 
steatosis that occurs after large acute doses of ethanol or long-term 
alcohol intake.
1.3.5. Hypoxia and Disturbances in Thyroid Hormone Metabolism
The clearance of ethanol from the blood of animals and humans is 
enhanced after chronic ethanol intake, due to increased hepatic 
metabolism of ethanol (Lieber, 1973; Kater et al, 1969; Pieper and 
Skeen, 1973; Tobon and Mezey, 1971). This increase coexists with a 
generalised 'hypermetabolic state1 after chronic ethanol ingestion, 
which is demonstrated by enhanced oxygen requirements. Increased
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oxygen consumption occurs in rats fed alcohol chronically and human 
chronic alcoholics (Pirola and Lieber, 1975; Pirola and Lieber,
1976). The mechanism underlying this increased consumption is
disputed. Since it can be inhibited by oubain, Bernstein et al
(1973) suggested it was a consequence of enhanced Na+-K+-ATPase 
activity causing ATP consumption, thereby increasing mitochondrial 
oxygen demands for electron transport and oxidative phosphorylation. 
By this mechanism, NADH reoxidation would be enhanced, thus possibly 
accounting for the attenuation of ethanol-induced hepatic redox-state 
changes after chronic ethanol intake (Teschke et al, 1973), and also 
explaining the increased ethanol metabolism, as NADH reoxidation has 
been considered a rate-limiting step in ethanol oxidation (Badawy, 
1978). However, pyrazole treatment does not completely prevent the 
enhanced ethanol elimination rate after chronic intake, so alternative 
mechanisms may be important. Indeed, the microsomal ethanol
oxidising system, described earlier, may account for this phenomenon 
(Cederbaum et al, 1978). In one study, an enhanced ethanol
elimination rate was observed in isolated, perfused rat livers and 
cultured hepatocytes taken from ethanol-fed rats without a 
concomittant increase in oxygen consumption (Schaffer et al, 1980). 
Vuki et al (1980) reported that the influence of oubain on ethanol 
metabolism was non-specific and need not implicate Na+-K+ ATPase 
activity. Gordon (1977) reported lowered hepatic ATP levels in rats 
after long-term ethanol intake, suggesting that the injured
mitochondria were unable to adapt to produce more ATP under these
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circumstances.
Whatever the underlying mechanisms, it is apparent that ethanol 
metabolism accentuates the oxygen gradient across the liver lobule
from the arterial to the venous side, a centrilobular hypoxia
occurring. This has been demonstrated in some elegant experiments
with miniature oxygen electrodes performed by the group of Thurman (Ji 
et al, 1982; Matsumara and Thurman, 1983). Experiments with 
perfused livers have shown that anoxic stress led rapidly to
centrilobular injury with sparing of periportal areas. This could 
indicate that centrilobular hypoxia might be important in the 
pathogenesis of alcoholic liver disease.
The reason for implicating thyroid hormones in the above 
hypotheses is that treatment of animals with thyroid hormones produces
“f*similar changes in oxygen consumption and Na -K -ATPase activity in 
the liver as those caused by ethanol (Israel et al, 1973). Thus, it 
appears that a hypermetabolic state, akin to that in hyperthyroidism, 
may exist in the livers of alcohol-fed animals and humans. However, 
there is little evidence to suggest that alcohol consumption brings 
this situation about through interference in thyroid hormone 
metabolism. Although many of the changes that occur in the liver of 
hyperthyroid animals (eg: megamitochondria, proliferation of the
smooth endoplasmic reticulum) axe similar to those seen after ethanol 
(Israel et al, 1973), serum thyroid hormone levels seem to indicate
that patients with alcoholic hepatitis, are euthyroid, or if anything, 
slightly hypothyroid (Chopra et al, 1974; Israel et al, 1979).
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Nevertheless, the 'intracellular hyperthyroidism' or 'hypermetabolic 
state' theory of alcoholic liver disease and it's possible role in 
causing centrilobular hypoxia and necrosis, has remained an attractive 
one for many workers. This led to clinical trials of the antithyroid 
drug, propylthiouracil, in the treatment of alcoholic hepatitis. 
Animal studies showed that propylthiouracil protects rats which had 
been fed ethanol chronically from hypoxia-induced centrilobular 
necrosis (Israel et al, 1975). Clinical trials of the drug in
patients with alcoholic hepatitis have shown either no benefit (Halle 
et al, 1982) or only marginal improvements in outcome, mortality being 
unaffected in both of these studies (Orrego et al, 1979). A number 
of criticisms have been levelled at these trials, including the small 
numbers of patients employed and inadequate statistical methods 
(Maddrey, 1979; Kaplowitz, 1982).
With regard to the mechanism of these effects, propylthiouracil 
will also protect animals against carbon tetrachloride and 
acetoaminophen (paracetamol) hepatotoxicity (Linscheer et al, 1980; 
Orrego et al, 1976). These effects appear to be independent of any 
antithyroid action of the drug. In the case of paracetamol, it has 
been shown that the drug increases hepatic reduced glutathiuone levels 
(Linscheer et al, 1980), and can act as a substitute for glutathione 
to form a stable adduct with the active metabolite of acetoaminophen, 
thereby preventing its toxicity (Yamada et al, 1981). Thus, for 
ethanol, propylthiouracil may act non-specifically through inhibiting 
lipid peroxidation, as a result of increased hepatic glutathione
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levels, or it may form an adduct with acetaldehyde in a manner similar 
to that reported for the thiol compound, cysteine, thus protecting 
against the toxic effects of this ethanol metabolite (Hirayama et al,
1983).
Therefore, there is still some dispute about whether the 
'hypermetabolic state' or hypoxia exists in alcoholic liver disease 
(Thurman et al, 1984), and whether it is important in the pathogenesis 
of this condition. If centrilobular hypoxia does occur in human
alcoholics, as is suggested by animal studies, it may trigger another 
mechanism of damage that has already been discussed, that is free 
radical generation and lipid peroxidation, tissue damage occurring in 
a manner similar to that of ischaemic heart disease (McCord, 1985). 
As to the role of thyroid hormones in the hypermetabolic state theory 
of alcoholic liver disease, their implication seems unlikely in view 
of the effects of propylthiouracil observed in relation to 
acetoaminophen hepatoxicity (Yamada and Kaplowitz, 1983; Yamada et 
al, 1981). Further studies on the mechanisms involved are need to 
clarify this point (Szilagyi et al, 1982).
1.3.6. Disturbances in Essential Fatty Acid and Prostaglandin 
Metabolism
Chronic ethanol intake in experimental animals changes the fatty 
acid composition of the hepatic phospholipids. In particular, 
increased linoleic acid (18:2) and decreased arachidonic acid (20:4) 
contents are found, so that the 20:4/18:2 ratio is decreased, 
particularly in the mitochondrial fraction of the liver, although the
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microsomes are also affected (Reitz, 1975; Thompson and Reitz, 1978; 
Schilling and Reitz, 1980; Cunningham et al, 1982; French et al,
1971). Other polyenoic fatty acids have also been observed to
decrease. These changes could be important in determining membrane 
fluidity and membrane-associated functions after chronic ethanol, 
that, in turn could affect functioning of hepatocyte organelles (eg: 
mitochondria), so that changes in lipid disposal occur that could 
produce fatty liver.
One explanation for the changed fatty acid profiles might be
ethanol-induced lipid peroxidation (Reitz, 1975). The reactivity of 
free radical species with unsaturated fatty acids increases with the 
number of double bonds present, and in view of the high proportion of 
phospholipid acyl groups present as arachidonic acid in liver, this 
fatty acid might be a particularly susceptible target for free radical 
attack (Slater, 1981). This mechanism could account for the loss of 
arachidonic acid and the decreased double bond index/saturated fatty
acid ratio seen in animals and humans after ethanol intake (Reitz,
1975; Cairns and Peters, 1983). However, this mechanism has not 
been proven and awaits experiments in which the influence of 
antioxidant treatment on ethanol-induced changes of fatty acid 
composition is determined, in order to achieve acceptance.
More recently, there has been much interest in the role of 
altered microsomal fatty acid desaturase activities after ethanol 
treatment in causing fatty acid composition changes. The essential 
fatty acids of the n-6 series are probably the most important in
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animal tissues, although the n-3 series (derived from alpha-linolenic 
acid) may be important in the brain and cardiovascular system. 
Linoleic acid (18:2) is the most abundant dietary essential fatty acid 
and is important as the precursor for the n-6 series of fatty acids, 
including arachidonic acid. Conversion of linoleic acid to
arachidonic acid involves two desaturation steps, catalysed by 
microsomal A-6-desaturase and A-5-desaturase enzymes, and also a 
microsomal elongase. The activities of cytochrome b^-dependent A-5, 
A-6 and the A-9 desaturases are all decreased in rat liver microsomes 
after chronic ethanol feeding (Wang and Reitz, 1983; Umeki et al,
1984). This mechanism may therefore explain the changes in fatty
acid composition. In addition, ethanol has been shown to increase 
the conversion of dihomogamma-linolenic acid (20:3w6) to prostaglandin 
El, thereby depleting this acid as a source of arachidonate in 
membrane phospholipids (Manku et al, 1979; Rotrosen et al, 1980).
These effects of ethanol on essential fatty acids and 
prostaglandins have been proposed as a mechanism by which tissue 
damage, and some of the behavioural consequences of chronic ethanol 
consumption arise (Horrobin, 1980). There is some experimental
evidence to support this. Supplementation of alcohol-containing 
liquid diets with arachidonic acid prevents the formation of fatty 
liver (Goheen et al, 1980; Goheen et al, 1983; Karpe et al, 1984), 
as well as preventing the fatty liver arising from a high -fat diet. 
However, in some studies, arachidonic acid has a profound effect on 
weight gain in ethanol-fed animals, lowering it in one study (Goheen 
et al, 1983), whilst increasing it in another (Goheen et al, 1980).
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These inconsistencies, and the lack of data on blood ethanol levels or 
precise ethanol intakes (in g/kg/day) in these studies sheds some 
doubt on the findings. In addition, it should be asked whether
arachidonic acid might protect against fatty liver by inhibiting 
ethanol-induced lipid peroxidation, as arachidonate is an effective 
antioxidant in its own right (Slater, 1981). There is one study to 
show that prostaglandin El protects against alcoholic fatty liver in 
rats, although no mechanism to explain this effect has been described 
(Wilson et al, 1973).
Thus, although there is some evidence that ethanol consumption 
changes the fatty acid composition of hepatic membrane phospholipids, 
the mechanisms underlying this effect are not clearly defined, and the 
possible importance of these changes in fatty liver production is not 
clear. More studies on the mechanisms by which arachidonic acid and 
prostaglandin El protect against fatty liver are needed. It is 
evident that prostaglandins may have a non-specific cytoprotective 
effect, as prostalgandin E^ protects against carbon tetrachloride 
hepatotoxicity, as well as protecting the stomach against a variety of 
noxious agents (Stachurcha et al, 1981; Burke, 1981).
1.3.7. Carbohydrate Deprivation and Alcoholic Fatty Liver
Rao and Larkin (1984) have suggested that alcoholic fatty liver 
is the consequence of a synergistic effect between ethanol toxicity 
and the depleted carbohydrate content of the alcohol-containing liquid 
diets used to induce fatty liver in experimental animals. Some 
support for this hypothesis comes from studies in which
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supplementation of the diets with dihydroxyacetone phosphate, 
riboflavin and pyruvate prevented fatty liver (Stanko et al, 1978; 
Goheen et al, 1981). It was originally thought that these natural 
metabolites might prevent fatty liver through acting as hydrogen 
acceptors, thereby correcting the ethanol-induced hepatic redox-state 
change. However, it was recently reported that only pyruvate was
necessary out of the ’cocktail' described above to prevent fatty liver 
formation (Rao et al, 1984). Pyruvate or glycerol, at a
concentration of 22 g/1 added to the Lieber-DeCarli liquid diet,
significantly decreased ethanol-induced steatosis in rats. This 
supplementation does, however, reduce the proportion of 
ethanol-derived calories in the diet from 36% to 33.5%, so this could 
account for the decreased fat accumulation in view of the earlier 
discussion on animal models of alcoholic liver injury. Isocaloric 
substitution of carbohydrate (normally 47% of the total calories in 
the control Lieber-DeCarli diet) with ethanol will leave ethanol-fed 
animals with only 11% of their calorie intake as carbohydrate, so Rao 
et al (1984) proposed that the fatty liver was a consequence of 
long-term carbohydrate deprivation, although no detailed mechanisms by 
which this might cause steatosis were described. Furthermore, the 
liquid diet employed in this current thesis still contained 29% of its 
total calorie content as carbohydrate after ethanol had replaced 36% 
of the calories, yet fatty liver was still produced after long-term 
ethanol feeding. Thus, there is some doubt surrounding the validity 
of this recently-proposed mechanism for the pathogenesis of alcoholic 
fatty liver.
1.4. MECHANISMS OF ALCOHOL-INDUCED FATTY LIVER: CONCLUDING REMARKS
It will be clear from the above discussion that there are nearly 
as many hypotheses concerning the pathogenesis of alcoholic 
steatosis, and alcoholic liver disease in general, as there are 
workers in this field. The redox-state theory (increased NADH:NAD
ratio) is probably the most widely-quoted mechanism for the production 
of fatty liver, and is a very neat explanation for this lesion, but is 
not convincingly proven experimentally. It is still not clear
whether alterations in lipid metabolism that have been attributed to 
the redox-state changes, chiefly impaired fatty acid oxidation, are 
important in the pathogenesis of fatty liver. In the case of 
decreased fatty acid oxidation after ethanol intake, it is not clear 
whether this arises through some other mechanism, such as direct 
acetaldehyde toxicity or lipid peroxidation. Ethanol-induced lipid 
peroxidation seems a feasible mechanism, in view of the protective 
effects of antioxidants that have been reported, and the fact that 
other hepatotoxins, such as halogenated hydrocarbons, are thought to 
act through a free radical-mediated mechanism. However, no precise 
mechanism by which ethanol ingestion leads to increased free radical 
generation in the liver has been described, as has been for carbon 
tetrachloride. The possible relationship between ethanol-induced
centrilobular hypoxia and lipid peroxidation remains to be
investigated. Another criticism of the lipid peroxidation theory
might be that measurement of increased peroxidation after ethanol
- 57 -
administration may not be a primary effect of the toxin or its 
metabolism. Compromised tissues tend to show increased evidence of 
peroxidation secondary to other damaging events having occurred 
previously, and this may be the case for ethanol (lialliwell and
Gutteridge, 1984). However, the effects of antioxidants on alcoholic 
fatty liver in rats suggest that it may be an important stage
nevertheless. The possible central role of acetaldehyde in these
mechanisms should not be understated, and this substance's direct 
toxic actions may certainly have a role to play. What is needed in 
future studies is an evaluation of the inter-relationship between some 
of these proposed mechanisms. For example, is mitochondrial injury 
due to continued exposure to ethanol-derived acetaldehyde, or due to 
peroxidative damage, or both? Similarly, is impaired hepatic protein 
secretion attributable to one or both of these factors?
Many of the other mechanisms described (eg: enzyme induction) may 
be responses to other effects of ethanol on metabolic or hormonal 
balance rather than being primary mechanisms by which liver damage or 
steatosis occurs. Taking all the evidence into account, it seems
likely that ethanol-induced fatty liver, and possibly some of the
latter stages of alcoholic liver disease seen in man, are due to toxic 
effects mediated by acetaldehyde, including lipid peroxidation,
impaired protein secretion, and possibly altered mitochondrial
function, being the most important. It seems that acetaldehyde may 
exert these effects both directly, through covalent interaction with 
specific cellular proteins, and also by enzymatic mechanisms that
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could cause increased free radical production. As a result, the 
'redox-state' explanation for fatty liver may not be the most 
important underlying mechanism.
1.5. STUDIES ON HEPATQPRQTECTIVE AGENTS IN ALCOHOLIC FATTY LIVER
There have been numerous reports on the ability of a wide range 
of substances to inhibit the formation of fatty liver after acute or 
chronic ethanol administration. As a result of these studies,
various hypotheses concerning the mechanisms of fatty liver production 
have been proposed. In this section, these protective agents will be 
briefly presented along with possible mechanisms by which they act. 
A few general points on the interpretation of studies with protective 
agents should be made here though. Many agents have only been 
described to protect against acute ethanol hepatotoxicity. As 
described earlier, ethanol metabolism is a requirement for fatty liver 
to occur after acute ethanol dosing. Not all the studies described 
have presented data on the effect of the protective substances on 
ethanol metabolism, so that interpretation of the results is 
difficult. In the case of pyrazole (see Section 1.2.2.), inhibition 
of ethanol metabolism can lead to conflicting results between acute 
and chronic experiments of fatty liver production, even though it 
seems similar mechanisms may account for both types of fatty liver. 
Effects of protective agents on factors that may affect the extent of 
fatty infiltration of the liver, independent of the proposed mechanism
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of action of the compound, are not always assessed, eg: effects on 
peripheral fatty acid release. In chronic studies, effects of
compounds on dietary (and hence ethanol) intake are not always
reported, any large reduction in the daily ethanol intake (expressed 
in g/kg/day) obviously affecting the degree of fatty infiltration
observed. Any effects of the compounds on ethanol metabolism or
absorption should be determined from blood ethanol measurements, 
although these are not always carried out. The various substances 
that have been reported to prevent alcoholic fatty liver in rats are 
briefly described below.
1.5.1. Substances Other Than (+)-Catechin Compounds
(i) Lipotrophic cocktail: Addition of pyruvate, dihydroxyacetone
phosphate and riboflavin to high-fat ethanol-containing liquid diets 
of rats was found to prevent the chronic fatty liver (Stanko et al,
1978). These authors proposed that these substrates acted as
hydrogen acceptors, correcting the elevated NADH:NAD ratio in the 
liver. However, no redox-slate measurements were made in this study, 
and it has subsequently been discovered that only pyruvate is 
necessary for fatty liver prevention (Rao and Larkin, 1984). The 
possible implications of this latter finding have been discussed in 
detail above (Section 1.3.7.)
(ii) Barbiturates: Phenobarbital has a partial protective effect
against the acute ethanol-induced fatty liver (Vincenzi et al, 1967), 
when given in a dosage regime known to induce cytochrome P450. 
However, no blood ethanol levels were determined in this study, and it
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has subsequently been shown that sodium diethylbarbiturate prevents 
the acute ethanol-induced effects on lipid metabolism in mouse liver 
through inhibition of alcohol dehydrogenase (Rawat and Kuriyama,
1972).
(iii) Nicotinic acid: Early studies showed that pre-treatment of
rats with nicotinamide corrected the disturbed NADH:NAD ratio after 
acute ethanol administration, but did not affect the triglyceride 
accumulation under the same conditions (Reboucas and Isselbacher, 
1961). Nicotinic acid also corrects the redox-state after acute
ethanol dosing, but does prevent the hepatic lipid accumulation
occurring. This effect is probably due to the vitamin inhibiting
alcohol dehydrogenase activity and peripheral lipolysis in 
ethanol-treated rats (Greenberqer et al, 1965; Baker et al, 1973).
(iv) Antihistamines and SKF-525A: The antihistamine drugs
chlorcyclizine and promethazine, as well as the 'hepatic microsomal 
enzyme stimulant' SKF-525A prevented the hepatic triglyceride 
accumulation after a large dose of ethanol (6 g/kg orally) (Wooles, 
1968). SKF-525A can also act as a cytochrome P450 inhibitor, and no 
mechanism of action for the protective effect of this substance was
proposed in this study. However, promethazine protects against
carbon tetrachloride toxicity, partly due to its antioxidant action,
although physiological effects of the drug (lowering of body 
temperature) also influence carbon tetrachloride metabolism (Reddrop 
et al, 1983). No determination of the effects of promethazine on 
blood ethanol levels was made in the Wooles (1968) study, although
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more detailed study of the action of chlorcyclizine showed that this 
drug did not affect ethanol metabolism after the large ethanol dose 
used to produce fatty liver, and furthermore, chlorcyclizine prevented 
the ethanol-induced decrease in fatty acid oxidation in vivo (Wooles 
and Weymouth, 1968). It was suggested that promethazine and
chlorcyclizine might act through a free radical-scavenging action, 
although in view of the data on SKA-525A it was proposed by the 
authors that stimulation of microsomal enzyme activity was the more 
likely mechanism of protection for these drugs, since SKF-525A does 
not possess a benzyl carbon atom, thought to confer antioxidant 
activity (Wooles, 1968). However, more detailed studies on the free 
radical scavenging action of these compounds, their interaction with 
ethanol metabolism and hepatic microsomal enzyme activity are lacking.
(v) Antioxidants; A detailed discussion of the protective action
of a number of antioxidants against ethanol-induced fatty liver, and 
the possible role of lipid peroxidation in this process, is given in 
Section 1.2.6. However, more detailed studies on the in vitro
antioxidant activity of some of these compounds, their ability to 
inhibit ethanol-induced lipid peroxidation in vivo, and their 
interaction with ethanol metabolism are required, in order to 
establish that these compounds do exert their protective action 
through inhibition of lipid peroxidation.
(vi) Clofibrate: The hypolipademic drug ethyl £)(.-p-chloro-
phenoxyisobutyrate (Clofibrate) has been shown to inhibit both the 
acute (Brown, 1966) and chronic (Spritz and Lieber, 1966) forms of
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alcoholic fatty liver. The mechanisms of protection may be different 
for the two experimental situations. After acute ethanol dosing, the 
drug prevents the increased o6-glycerophosphate:dihydroxyacetone 
phosphate ratio, and may also inhibit peripheral lipolysis (Kahonen jst 
al, 1971; Kahonen et_al, 1972; Rifkind, 1966). The former action 
could be achieved simply by inhibition of ethanol metabolism, yet no 
data on the effect of the drug on ethanol elimination was given in 
these studies.
In the chronic study (Spritz and Lieber, 1966), the drug may act 
through one or both of its two more recently described properties. 
Firstly, clofibrate is a potent inducer of peroxisome proliferation 
and greatly enhances peroxisomal ^J-oxidation of fatty acids, so that 
this may overcome any ethanol-induced block in mitochondrial fatty 
acid oxidation, thus preventing esterification of excess fatty acyl 
moieties into triglycerides (Eliassen and Osmundsen, 1984). 
Secondly, clofibrate feeding enhances hepatic aldehyde dehydrogenase 
activity in rats, thus possibly protecting against toxic effects of 
acetaldehyde (Kramar et al, 1984).
(vii) Propylthiouracili The concept of the ethanol-induced 
hypermetabolic state, its possible relationship to centrilobular 
hypoxia, and the possible role of antithyroid drugs in counteracting 
these effects has already been described in detail (Section 1.3.5). 
This theory was supported by the protective effect exerted by 
propylthiouracil against experimental alcoholic hepatitis in rats 
(Israel et al, 1975), and one clinical trial showed some benefit of
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the drug in patients with alcoholic hepatitis (Orrego et al, 1979). 
However, hypothyroidism does not protect against the development of 
alcoholic liver injury (Soff and Resnick, 1981), and propylthiouracil 
also protects against the hepatotoxicity of acetoaminophen and carbon 
tetrachloride, independently of any antithyroid action, as discussed 
previously (Linscheer et al, 1980; Orrego et al, 1976). These 
propylthiouracil studies have not been followed up as yet with studies 
on the action of other antithyroid drugs in the same experimental 
models.
(viii) Penicillamine and other thiol compounds: There has been much
interest in the use of penicillamine in the treatment of hepatic 
cirrhosis due to its ability to inhibit lysyl oxidase, so limiting the 
ongoing fibrotic process (Orbison, 1975). Its properties as a
copper-chelating agent have led to its use for the treatment of 
Wilson’s disease (Walshe, 1960). There is also evidence to suggest 
that this compound may be effective in preventing fatty liver, due to 
its ability to interact with acetaldehyde, and prevent 
acetaldehyde-induced mitochondrial injury in vitro (Cederbaum and 
Rubin, 1976b), in a manner similar to that reported for cysteine 
(Cederbaum and Rubin, 1976a). These thiol compounds appear to
interact with acetaldehyde through their free sulphydryl and amino 
groups to form hemi-acetals, cysteine derivatives in which the amino 
or sulphydryl groups are blocked (eg: 5-methylcysteine or
N-acetylcysteine) not being effective in these in vitro studies. 
The potent ability of thiol compounds to prevent these acetaldehyde
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induced mitochondrial impairments has only been partially followed up 
by in vivo studies on their influence on ethanol-induced liver injury. 
Penicillamine has been shown to lower blood acetaldehyde levels after 
ethanol dosing in vivo (Nagasawa et al, 1977), although the 
acetaldehyde concentrations reported were very high and may reflect 
artefactual formation problems in the assay procedure (Eriksson, 
1980). Macdonald et al (1977) showed that cysteine, methionine and 
j] -merceptoethylamine improved survival time in mice given lethal 
doses of ethanol, although no objective measures of liver injury were 
carried out. Cysteine protects against LD^g doses of acetaldehyde 
given to rats (Sprince et al, 1975), but again this was not related to 
measures of hepatotoxicity. 2-mercaptopropionpylglycine and reduced 
glutathione afforded partial protection against the increase in 
hepatic triglyceride resulting from repeated daily ethanol dosing (3 
g/kg orally) (Torrelli et al, 1978). Cysteine and
2-mercaptopropionylglycine protect against the acute ethanol-induced 
fatty liver in rats, this effect being associated with lowering of 
hepatic acetaldehyde concentrations (Hirayama et al, 1983).
There have been no studies reported on the ability of the thiol 
compounds mentioned above to inhibit the fatty liver induced by 
feeding of ethanol in a liquid diet. Lieber and DeCarli (1966),
' however, found that addition of methionine to the liquid diet regime 
prevented the chronic alcoholic fatty liver in rats. The mechanism 
of protection of methionine is not clear, but it may involve 
conversion to cysteine, as methionine itself cannot interact with
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acetaldehyde, as it does not possess a free sulphydryl group. 
Methionine has also been shown to protect against ethanol-induced 
lipid peroxidation (Shaw et al, 1981), but again, this may be through 
a direct interaction with free radicals, or through conversion to 
cysteine and lowering of liver acetaldehyde levels as a result. Many 
of these thiol compounds (cysteine, penicillamine,
2-mercaptopropionylglycine, methionine) have free radical scavenging 
(antioxidant) properties in their own right, so this may account, in 
part, for some of the reported protective effects (Slater, 1981). 
Cysteine and methionine may influence hepatotoxicity through their 
role as glutathione precursors. Thus, more detailed and
comprehensive studies on the effect of thiol compounds on ethanol 
hepatotoxicity are required before their mechanism of action is 
completely understood.
(ix) Arachidonic acid and prostaglandins: Dietary arachidonic acid
protects against chronic alcohol-induced fatty liver in mice and rats 
(Goheen et al, 1980; Goheen et al, 1981; Goheen et al, 1983; Karpe 
et al, 1984). Prostaglandin El will also prevent the chronic
alcoholic fatty liver (Wilson et al, 1973). The possible
relationship between these observations and altered essential fatty 
acid and prostaglandin metabolism during ethanol consumption has 
already been discussed (Section 1.3.6). As with many of the other 
hepatoprotective agents described, the effect of these agents on 
ethanol intake, absorption and elimination has not always been 
completely investigated. In the case of arachidonic acid, the daily
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dose consumed in some experiments is quite considerable (up to 1 
g/kg/day), and it has to be asked whether at this dose, a possible 
antioxidant effect of the acid is responsible for its protective 
action.
(x) ^-Adrenergic agents: The protective actions of ^-adrenergic
blockers (dibenamine and ergotamine) against acute alcoholic fatty 
liver (Brodie et al, 1961) have already been mentioned (Section
1.3.2), and the possible relevance of these effects to the role of 
peripheral lipolysis in fatty liver production discussed in detail.
(xi) Lipotropic factors; Methionine and choline protect against the 
chronic ethanol-induced fatty liver in rats (Lieber and DeCarli, 
1966). This may be considered a pharmacological action of these
substances, since the levels added to the alcohol-containing liquid
diets was greatly in excess of that required to prevent hepatic
steatosis arising from choline or methionine-deficient diets alone. 
Carnitine supplementation of alcoholic liquid diets also reduces the 
triglyceride accumulation after long-term ethanol intake in rats 
(Sachan and Rhew, 1983). The daily carnitine intake of animals in 
the latter study was of the order of 1.5 g/kg/day, so once again, a 
pharmacological action of the substance is probably responsible for
its anti-steatotic effect. Studies on the mechanism of action of 
these substances are lacking, although a possible mechanism for 
methionine has already been discussed above. Both carnitine and 
choline have the ability to react with acyl groups, so may possibly 
act as acetaldehyde traps, but there is no experimental evidence to
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support this. It is unlikely that carnitine prevents fatty liver by 
overcoming an ethanol-induced block in mitochondrial fatty acid uptake 
as a result of carnitine deficiency, as the livers of alcohol-fed rats 
in fact show an increased carnitine content (Sachan and Rhew, 1983).
1.5.2. (+)-Catechin (cyanidanol-3) and 3-Palmitoyl-(+)-Catechin
The subject of this thesis is the investigation of the effect of 
(+)-catechin (3',4',5,7-tetrahydroxyflavan-3-ol), and its more lipid 
soluble ester, 3-palmitoyl-(+)-catechin, on ethanol hepatotoxicity in 
the rat. Many of the studies on the mechanism of action of the drugs 
have employed the latter substance, due to its greater potency at 
preventing fatty liver.
(i) Chemical and physical properties: The chemical structures of
(+)-catechin and 3-palmitoyl-(+)-catechin are shown in Fig. 1.3. 
(+)-Catechin is a naturally-occurring benzopyran bioflavanoid 
substance. 3-Palmitoyl-(+)-catechin is a chemically synthesised
derivative of (+)-catechin. Both compounds are poorly soluble in 
water, but show good solubility in alcohols (eg: 50% solubility in
methanol) and most organic solvents. Both substances are stable at 
room temperature for several years and are not affected by exposure to 
light.
(ii) Absorption, distribution, metabolism and excretion studies:
The findings of various studies which have investigated the metabolism 
of (+)-catechin and 3-palmitoyl-(+)-catechin can be summarised as 
follows. Both substances are well absorbed after oral dosing, up to 
80% of the administered dose being taken up. Absorption is rapid,
3 - Paimitoyl ~[+] ~ Catechin
\ OH
OH 
\+] - Catechin
o - c o - [ c h 2] 14- c h 3
M.W. = 528
OH
Fig. 1.3. CHEMICAL STRUCTURES OF 3-PALHIT0YL-(+)-CATECHIN
AND (+)-CATECHIN
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particularly in the case of 3-palmitoyl-(+)-catechin. Both compounds 
undergo extensive first pass metabolism in the liver, and there is a 
rapid disposition of both substances in the whole organism. About 
75% of the 3-palmitoyl-(+)-catechin in plasma is protein-bound, as 
opposed to 50?d in the case of (+)-catechin itself. After oral 
administration of radiolabelled [U-^C]-3-palmitoyl-(+)-catechin and 
[U-^C]-(+)-catechin, the highest concentrations of radioactivity are 
found in the liver (about four times the concentration found in the 
blood). In the case of [U-^C]-(+)-catechin there is a rapid
increase in liver radioactivity with a peak at one hour after dosing, 
followed by a rapid decrease. This peak level of radioactivity after
3-palmitoyl-(+)-catechin dosing in rat liver is not achieved until
4-12 hours after oral dosing, and there is considerable persistence of 
radioactivity in liver tissue, possibly as a result of protein binding 
of the drug. Significant levels of radioactivity are recovered in 
the kidney after administration of both compounds. Levels of 
radioactivity in the lungs, heart, muscles and testes are lower than 
blood radioactivity levels for both substances, and no radioactivity 
is detectable in the brain of rats after administration of either 
drug.
In the rat, the metabolism of (+)-catechin seems to involve a 
methylation step at the 3‘ position on the catechol ring, conjugation 
of this metabolite to glucuronic acid and sulphate taking place before 
excretion in the bile. 5-Adenosylmethionine is thought to be the 
source of the donated methyl group, the transfer being catalysed by
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catechol-O-methyl transferase. Reabsorption and enterohepatic
circulation of these metabolites is thought to take place, most of the 
drug being excreted in the urine as 3'-0-methyl-(+)-catechin 
glucuronide or 3'-0-methyl-(+)-catechin sulphate (Shaw and Griffiths, 
1980; Hackett et al, 1982). Earlier studies have shown that the 
intestinal microflora can act on the biliary metabolites of 
(+)~catechin to produce the ring scission products 
m-hydroxyphenylpropionic acid, p-hydroxyphenylpropionic acid, 
8-(3-hydroxyphenyl)- Jf -valerolactone and 8-(3,4-dihydroxyphenyl)- 
valerolactone. These metabolites are reabsorbed and excreted in the 
urine (Das and Sothy, 1971). There is some species variation in the 
reabsorption and elimination route of (+)-catechin metabolites. In 
the rat, 66% of an oral dose of [U-^^C]-(+)-catechin is eliminated in 
the urine, 24% being recovered in the faeces, whereas in the marmoset, 
22% of the dose is excreted in the urine, and 70% in the faeces 
(Hackett et al, 1982)
The metabolism of 3-palmitoyl-(+)-catechin is very similar to 
that of (+)-catechin, once the drug has been hydrolysed to form the 
parent compound. This initial de-esterification appears to be the 
rate-limiting step in the overall metabolism of the compound and could 
account for the delayed elimination of the drug when compared with 
(+)-catechin (Hackett and Griffiths, 1982). (+)-Catechin is rapidly 
eliminated, serum levels falling rapidly after oral dosing. After 
dosing with [U-^C]-(+)-catechin, 90% of the radioactivity is excreted 
in the first 24 hours after dosing. After oral administration of
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3-palmitoyl-(+)-[U-^C]-catechin, steady levels of radioactivity are 
achieved in the serum in the first 24 hours after dosing, and it takes 
17 days for greater than 90% of the administered dose to be recovered 
in the urine, faeces and expired carbon dioxide. persists in
certain tissues, and 28 days after dosing, 3-7% of the dose was still 
present in the animal body (Hackett and Griffiths, 1982). Unlike 
(+)-catechin, some retention of radioactivity after 
3-palmitoyl-(+)-[U-^C]-catechin dosing occurs in the adipose tissue. 
Studies in human volunteers have confirmed the animal findings that 
glucuronides of (+)-catechin and 31-0-methyl-(+)-catechin are the 
major urinary metabolites of (+)-catechin. After
[U-^C]-(+)-catechin dosing in man, 53% of the dose was recovered in 
the urine in the first 24 hours. Ring scisson product metabolites 
accounted for less than 10% of the urinary metabolites of (+)-catechin 
in this study (Hackett et al, 1983). No human data on the metabolism 
and excretion of 3-palmitoyl-(+)-catechin has been reported.
(iii) Toxicity studies: Both compounds are non-toxic in animals at
the normal doses employed in pharmacodynamic studies. Acute studies 
in rats show that greater than 5 g/kg orally of the drugs have to be 
given before any deaths occur. (-f)-Catechin is also safe given by 
the intraperitoneal route, but 3-palmitoyl-(+)-catechin has an LD^p of 
about 80 mg/kg in rats when given by this route. Chronic toxicity
tests in rats with 3-palmitoyl-(+)-catechin showed that daily oral 
dosing with up to 900 mg/kg of the drug for two weeks was without 
effect, but repeated dosing with 2700 mg/kg led to deaths within one
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week. Studies in dogs showed that daily oral doses of
3-palmitoyl-(+)-catechin (400 mg/kg) reduced food intake and caused 
weight loss.
(iv) Animal pharmacodynamic studies; The first study outlining the 
potential hepatoprotective properties of (+)-catechin was that of 
Gajdos et al (1972). This showed that the drug prevented hepatic ATP 
depletion induced by ethionine or malonic acid administration. The 
drug also protected against hepatic steatosis induced by a low-protein 
diet, orotic acid or ethanol. In the case of the latter two toxins, 
correction of the reduced NADrNADH ratio and lowered ATP levels by 
(+)-catechin was reported. The ethanol experiment involved twice 
daily intraperitoneal injection of a 20% (w/v) solution for one week, 
each dose being 1.4 g/kg body weight. This regime apparently caused 
hepatic steatosis, although no saline-dosed controls were employed. 
Daily subcutaneous injection of (+)-catechin (50 mg/kg) or daily oral 
dosing of the drug (200 mg/kg) caused approximately 25-30% lowering of 
the total hepatic lipid concentration in ethanol-treated animals. No 
controls were employed. Increases in the NADrNADH ratio and hepatic 
ATP level due to (+)-catechin were reported, but these were measured 
in tissue samples which had simply been removed into ice-cold buffer, 
no freeze-clamping being performed as would normally be expected for 
measurement of these labile metabolites. Thus, this early study 
suggested a possible hepatoprotective action for (+)-catechin against 
ethanol hepatotoxicity, although the model employed would not be 
considered a valid one for chronic ethanol-induced fatty liver, and
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other methodological shortcomings indicated further work was required. 
Correction of the altered hepatic redox-state by (+)-catechin appeared 
to be the mechanism of action in this study.
Danni et al (1977) reported in vitro studies indicating that 
(+)-catechin was a potent free radical scavenger (antioxidant). In 
vitro, low concentrations of the drug (10-100 pM) protected microsomes 
against stimulation of lipid peroxidation by carbon tetrachloride, 
although high doses (1.5 g/kg i.p.) were required to protect against 
carbon tetrachloride hepatotoxicity in vivo (Slater and Scott, 1981). 
The reactive radical formed from carbon tetrachloride is thought to be 
CC1^0*2> (+)-catechin having an EC^g (50% inhibitory concentration) 
against in vitro peroxidation induced by this radical of 26.9 pM. 
(+)-Catechin reacts even more readily with hydroxyl radicals generated
2 j
by NADPH-ADP/Fe , its EC^g for in vitro peroxidation induced in 
microsomes by this system being 9.6 pM (Slater, 1968; Slater and 
Scott, 1981). (+)-Catechin also shows reactivity with superoxide
anions generated by NADH and phenazine methosulphate (Ponti et al, 
1978), the EC^g for nitroblue tetrazolium reduction by this system 
being 215 pM. All the quoted EC^g values are lower still if
3-methyl-(+)-catechin or 3-butyl-(+)-catechin are substituted for 
(+)-catechin itself, indicating that lipid solubility is important in 
protecting liver membranes against peroxidation. These observations, 
in combination with the pharmacokinetic considerations already 
discussed, were the underlying reason for development of
3-palmitoyl-(+)-catechin as a more potent derivative of (+)-catechin
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for in vivo studies.
There have been several studies on the protective action of 
(+)-catechin against hepatotoxins other than ethanol. Some studies 
on carbon tetrachloride in isolated rat liver microsomes have already 
been described, and the drug protects isolated hepatocytes against the 
’blebbing' (observed by electron microscopy) and release of 
intracellular proteins and enzymes into the incubation medium induced 
by either carbon tetrachloride or phalloidin (Perrissoud et al, 1981). 
In vivo protection against the hepatotoxicity of bromobenzene, 
thioacetamide, vinylidene chloride and halothane in combination with 
hypoxia has been reported (Siegers, 1981; Siegers et al, 1983). 
(+)-Catechin protects against galactosamine-induced inhibition of 
hepatic protein synthesis and secretion in rats (Reutter and Hassels,
1980). No precise mechanism of action of the drug against these
hepatotoxins was proposed in these studies, most ascribing protection 
to a relatively non-specific membrane stabilisation and/or free 
radical scavenging activities. Videla et al (1981), suggested that 
the latter mechanism might account for the protective action of 
(+)-catechin against ethanol hepatotoxicity. They showed that the 
drug (400 mg/kg i.p.) given at the same time as ethanol (5 g/kg p.o.) 
prevented the decrease in hepatic glutathione levels and increased 
lipid peroxidation of liver lipids (measured as diene conjugates) 
after ethanol administration. These findings were not correlated 
with any hepatic triglyceride measurements, however, and several 
criticisms can be levelled at these authors method of measuring diene
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conjugates. These were determined in whole liver homogenates rather 
than subcellular fractions, and the absorbance of the lipid extract 
was determined at 233nm in relation to the protein content of the 
homogenate, no lipid determination being carried out. If it is 
assumed that ethanol dosing caused an increase in liver triglyceride 
content, the increase reported in diene conjugates per milligram liver 
protein may simply reflect increased end absorption of hepatic lipids 
due to triglyceride accumulation, rather than true diene absorption. 
Thus, it cannot be firmly established from this study whether ethanol 
actually induced lipid peroxidation.
There are relatively few studies on the effects of (+)-catechin 
on drug metabolism. A single large dose of the drug (200 mg/kg i.p.) 
given 13 hours prior to sacrifice, decreased the cytochrome P450 
concentration by 24%, aminopyrene and p-nitroanisole metabolism being 
reduced by similar degrees, but marked inhibition (> 50%) of
ethoxycoumarin and ethoxyresorufin metabolism was found. This 
suggests a preferential inhibition of metabolism mediated by 
cytochrome P448. In vitro, (+)-catechin is a powerful inhibitor of 
epoxidatiun of carbamazepine in rat liver microsomes (Steffen et al,
1981). Acute and chronic treatment with (+)-catechin has been found 
to inhibit glutathione-S-transferase activity towards epoxide or acyl 
substrates (Younes et al, 1982). (+)-Catechin does not cause
induction of any drug-metabolising enzyme activities in the liver or 
increase hepatic cytochrome P450 concentrations after long-term 
treatment.
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Some immune-stimulating properties of (+)-catechin have been 
reported that may account for its ability to induce seroconversion 
(ie: elimination of hepatitis-B surface antigen) in patients with
various forms of chronic hepatitis. In leucocyte migration
inhibition tests, the drug amplifies the cell-mediated immune response 
with the antigen tuberculin and HBsAg (Vallotton and Frei, 1981).
(-i-)-Catechin has been shown to interact with collagen metabolism. 
In vitro, collagen that has been treated with the drug is resistant to 
the action of collagenase, and degradation of soluble collagen is thus 
decreased. Detailed studies have shown that 6-7 molecules of
(+)-catechin are bound per -chain of collagen in these studies, and 
that the drug promotes cross-linking of collagen (Rao et al, 1981; 
Kuttan et al, 1981). In view of these properties, it has been
proposed that the drug be used for the treatment of diseases where the 
formation of a normal collagen matrix is impaired, such as
osteogenesis imperfecta (Pontz et al, 1982).
An unrelated property of (+)-catechin that has been reported is 
its ability to inhibit gastric ulcer formation in rats as a result of 
its inhibition of histidine decarboxylase. This may make the drug an 
alternative to the histamine-h^ receptor antagonist drugs that are 
conventionally used to treat gastric and duodenal ulceration in man 
(Parmar and Ghosh, 1981).
Some basic in vitro studies on metabolic effects of (+)-catechin 
have yielded some interesting findings that may be relevant to the
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correction of ethanol-induced redox-state changes reported by Gajdos 
et al, (1972). In isolated rat hepatocytes, (+)-catechin inhibits 
glycogenolysis and stimulates net glycogen production. The drug was 
found to enhance the activities of glycogen synthase a and inhibit 
glycogen phosphorylase a activities, in accord with the observed 
effects on total glycogen production (Nyfeler et al, 1983). These 
findings do not correlate with the mechanism proposed by Gajdos et al 
(1972) to explain the correction of the increased NADH:NAD ratio and 
lower ATP levels in the livers of ethanol-dosed rats. These authors 
proposed that the drug stimulated glycolysis, thereby generating more 
pyruvate to reoxidase NADH by way of the lactate dehydrogenase 
reaction, ATP being synthesised in the process as a result of 
substrate level phosphorylation in the glycolytic pathway.
(v) Clinical studies on (+)-catechinr Several clinical trials of 
(+)-catechin in the treatment of hepatitis have been reported. In 
patients with acute viral hepatitis the drug accelerated the 
disappearance of hepatitis B surface antigen from the blood, lowered 
serum bilirubin and relieved various clinical symptoms of the illness 
(Blum et al, 1977). Piazza et al (1983) found greater reductions in 
plasma transaminase activites and serum bilirubin levels in patients 
with chronic persistent hepatitis when drug-treated subjects were 
compared with placebo-dosed controls. However, one of the largest 
studies of the drug in hepatitis patients found no improvement in any 
of these paramaters in drug-treated patients (Schomerus et al, 1981).
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Studies on the influence of the drug on alcoholic liver disease 
have also failed to give clear-cut findings. Again, improvements in 
serum liver function tests have been reported, although improvement 
is often observed in the placebo group as well in these studies, as a 
result of patients abstaining or reducing their alcohol intake during 
the study (Conn, 1983). One Italian study in alcoholic cirrhotics 
showed consistent improvements in liver function tests and clinical 
symptoms t,uch as anorexia and abdominal discomfort (Palmas, 1981). 
In another study carried out in pre-cirrhoric alcoholics, no 
significant effect of the drug could be found (Henning, 1981). 
Another study suggested that the drug was of benefit in the early 
stages of alcoholic liver disease, but not once established lesions 
(cirrhosis) had been induced (Ugarte et al, 1981).
Two trials of the drug in alcoholic liver disease have been 
completed in the United Kingdom. The first, undertaken at the Royal 
Free Hospital, was a three-month, randomised, double-blind, placebo- 
controlled study in 40 patients with pre-cirrhotic liver disease. 
Patients were classified as either 'abstinent1 or 'drinking' during 
the study, however in neither group did the drug have any significant 
effect on histological appearance of the liver, serum liver function 
tests or the mean corpuscular volume (Colman et al 1980). The study 
of World et al (1984) was of six months duration. Interestingly, the 
drug-treated group in this study had worse liver function tests at the 
outset, drank consistently more during the trial, yet after the fourth
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week of treatment, showed consistently lower gamma-glutamyl 
transpeptidase and aspartate aminotransferase activities, although 
these changes were not statistically significant. This suggests that 
the drug may have had a slight protective effect against ongoing liver 
damage in drinking alcoholics. Thus, there is some confusion as to 
the clinical effectiveness of the drug at the present time. It 
should be noted that the doses of the drug employed in these studies 
(1.5-2.0 g/day or about 25 mg/kg/day) are rather less than those that 
are effective at influencing liver function in animal models. 
Therefore, more promising results might be achieved if 
3-palmitoyl-(+)-catechin had been used in place of (+)-catechin in 
these studies, in view of the more favourable pharmacokinetic and 
pharmacodynamic properties of this derivative discussed earlier. No 
clinical studies on 3-palmitoyl-(+)-catechin have been reported to 
date.
1.6. PROPOSED STUDIES
It will be clear from the discussion above that (+)-catechin has 
a number of properties that may be of benefit in the treatment of 
alcoholic liver disease. Modulation of the redox-state, free radical 
scavenging and immunological effects are probably the most important 
of these. In terms of preventing experimental alcoholic liver injury 
in rats (ie: fatty liver), the study of Gajdos et al (1972) suggests
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redox-state correction may be a possible mechanism, whereas Videla et 
al (1981) indicate that inhibition of ethanol-induced lipid
peroxidation could be the mode of action. . These mechanisms are 
somewhat presumptuous since neither study employed a satisfactory 
model of chronic ethanol-induced steatosis to determine whether the 
drug was effective. Thus, the aim of the experimental work was,
firstly, to establish the protective properties of (-f)-catechin and 
3-palmitoyl-(+)-catechin in valid models of acute and chronic (using a 
liquid diet method of ethanol administration) fatty liver in rats. 
Having established the effect of the drugs in these experimental 
models, the mechanism by which they may afford any protection will be 
investigated by comparing the actions of (+)-catechin or
3-palmitoyl-(+)-catechin with those of certain reference compounds 
with specific properties (eg: antioxidants or compounds which modulate
the hepatic redox-state) in the same experimental situations. This
approach should enable some distinction to be drawn between the two 
mechanisms of action proposed for the drug by Gajdos et al (1972) and 
Videla et al (1981) respectively.
The experiments presented here have concentrated on the ability 
of the (+)-catechin compounds to prevent steatosis by prophylactic 
means. In both the chronic and acute experiments, a number of
parameters have been included in the protocols in order to gain as 
much information as possible about, for example, the relationship of 
redox-state changes to alterations in hepatic lipid disposal, and the
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effects of reference compounds in this respect. This approach 
should, hopefully, lead to a clear picture of the mode of action of 
the (+)-catechin compounds emerging.
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Chapter 2 
MATERIALS AND METHODS
2.1 CHEMICALS, DIETS AND REAGENTS
(i) Liquid Diet Constituents: 'Complan* (plain flavour) was
supplied by Glaxo-Farley Foods, Plymouth, Devon, England.
'Orovite-7' was supplied by Bencard, Greenford, Middlesex. Casein 
(white, soluble, cat. no. 44016 6T) was supplied by B.D.H. Chemicals, 
Poole, Dorset. Glucose (anhydrous) was supplied by Sigma Chemical 
Co., Poole, Dorset. The ethanol used in all experiments was 100% 
absolute alcohol supplied by James Burroughs Ltd., London.
(ii) Liver lipid assays: Total lipids were measured using test
kits supplied by B.C.L. Ltd., Lewes, Sussex (cat. no. 124303). 
Triglycerides were measured using a colorimetric kit supplied by 
Sigma.
(iii) Tissue Metabolite Assays: Perchloric acid (60%, analar grade)
was from B.D.H. Chemicals. All cofactors (NAD and NADH) were
obtained in preweighed vials (cat. nos. 260-120 and 340-102 
respectively) from Sigma. Lactate dehydrogenase (Type II, cat. no.
L2500) and ^-glycerophosphate dehydrogenase (Type I, cat. no. G6751) 
were also supplied by Sigma. 3-Hydroxybutyrate dehydrogenase (Grade 
II, cat. no. 127191) was supplied by B.C.L. Ltd. Florisil (100-200 
U.S. mesh, chromatographic grade, cat. no. 15026) was from B.D.H. 
Chemicals.
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(iv) Lipid Utilisation Studies: [U-^C] palmitic acid (specific
activity 403 mCi/mmol cat. no. CFB37), [1-^C] palmitic acid (specific 
activity 49 mCi/mmol, cat. no. CFA23), and [^C]-hexadecane internal 
standard (1 x 10^ dpm/g; cat. no. CFR6) were supplied by Amersham 
International Ltd., Amersham, Bucks. Hyamine 10X was obtained as a 
10% (w/v) solution in methanol, (scintillation grade) from B.D.H.
Chemicals (cat. no. 14608 4B). Soluene-350 tissue solubiliser and
Dimilume-30 liquid scintillation cocktail were supplied by Packard 
Instrument Co. Ltd., Caversham, Bucks. All organic solvents employed 
were of analar grade from B.D.H. Chemicals. Bovine serum albumin 
(fatty acid-free, cat. no. A6003) was from Sigma. Silica Gel 60 
thin-layer chromatography plates (Merck No. 5713, 20 x 20 cm, layer 
thickness 0.25 mm) were supplied by B.D.H Chemicals. Barium 
hydroxide was obtained as a 0.3N solution (cat. no. 14-3) from Sigma, 
and was stored over Carbosorb (6-12 mesh, B.D.H. Chemicals) in a 
dessicator. Hydrogen peroxide (30% v/v) was also from B.D.H.
Chemicals.
(v) Gas chromatography: Poropak-Q (50-80 mesh) and the
Pressure-Lok A2 gas syringe were supplied by Chromatography Services 
Ltd., Hoylake, Wirral, Merseyside. Acetaldehyde and n-propanol were 
of 'Aristar* grade and supplied by B.D.H. Chemicals. In some 
experiments, blood or serum ethanol was determined enzymatically using 
kits supplied by B.C.L. Ltd., (cat. no. 123960)
(vi) Assays for in vitro Antioxidant Activity; Phenazine
methosulphate and nitroblue tetrazolium were from Sigma and were
- 84 -
stored dessicated in the dark at 0-5°C. NADPH was obtained from 
Sigma in preweighed vials (cat. no. 201-201). 2-Thiobarbituric acid 
(cat. no. T5500), ADP (Grade III, cat. no. A2754) and superoxide 
dismutase (cat. no. 57008, bovine liver, 3000 U/mg prot.) were from 
Sigma.
(vii) Serum Assays: Serum total protein and albumin were assayed
using kits supplied by B.C.L. Ltd., (cat. no. 124281 and 263869 
respectively). Rat albumin (cat. no. A6272) was from Sigma. Serum 
glutamate dehydrogenase activity was assayed using kits (cat. no. 
124320) supplied by B.C.L. Ltd.
(viii) Drugs; Authentic samples of (+)-catechin and 3-palmitoyl-(+)- 
catechin were donated by the Research Dept., Zyma, Nyon, Switzerland. 
Preservative-free Naloxone hydrochloride powder was donated by Du Pont 
Ltd., Glenolden, Pennsylvania, U.S.A. Butylated hydroxytoluene (cat. 
no. B1378), methylene blue (cat. no. MB-1) and sorbitol (cat. no. 
S1876) were all from Sigma. N,Nf-Diphenyl-p-phenylenediamine (DPPD) 
(cat. no. 66167) was supplied by B.D.H Chemicals.
(ix) Animals: All rats used in the present studies were supplied
by the Animal Unit, University of Surrey, Guildford, Surrey. They 
were Male Wistar Albino Rats (University of Surrey strain), and body 
weight details are given later in each particular experiment. When 
animals were not maintained on the liquid diet regime, a standard chow 
diet (41B cube diet, Heygates Ltd.) and water was given.
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2.2 INDUCTION OF ACUTE AND CHRONIC ETHANOL-INDUCED FATTY LIVER IN THE 
RAT
2.2.1 Acute studies:
The effects of protective agents on hepatic triglyceride 
accumulation was assessed after two different acute doses of ethanol. 
Firstly, the widely employed 6 g/kg oral ethanol dose was used. 
Ethanol was given by gastric tube as a 50% (v/v) solution in water, 
appropriate controls being dosed with isocaloric amounts of glucose 
(10.7 g/kg as an 71% (w/v) solution in water). Fasted rats were
used. This ethanol dose has been used in a large number of studies
on the acute effects of alcohol, and has the advantage that high blood 
ethanol levels are achieved (often over 400 mg/100 ml) and sustained 
for several hours after dosing. This leads to a large increase in 
the hepatic triglyceride level, the peak being observed between 10-18 
hours after dosing (Mallov and Bloch, 1956; DiLuzio, 1958; Wooles, 
1966). In the studies presented, animals were dosed at about 1800 h
and sacrificed for liver triglyceride analysis 16 hours later, at 
lOOOh the following day. This regime produced a
histologically-observable centrilobular fat accumulation, similar to 
that seen after chronic ethanol feeding, although no evidence of 
hepatocellular necrosis was seen. Some of the disadvantages of this 
ethanol dose are that, due to its size, it does induce a prolonged 
narcosis and other profound physiological effects in the animals (eg: 
lowering of body temperature). The high concentration of the alcohol
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solution used causes gastric irritation and pyloric stenosis so that 
absorption of the ethanol may be highly variable and prolonged. 
These very high blood ethanol concentrations are often greater than 
those found in animals and humans during long-term ethanol intake, so 
the mechanisms of liver injury may not be identical between the two 
situations.
As discussed previously (Section 1.2.1) the mechanisms of liver 
injury after these large acute doses may differ from those operating 
during chronic ethanol intake (Badawy, 1985). In order to overcome 
some of these objections, a more moderate dose of ethanol given 
intraperitoneally was used. Two g/kg body weight ethanol was
injected as a 20% (w/v) solution in saline, appropriate controls being 
dosed with equivalent volumes of saline or isocaloric solutions of 
glucose (ie: 3.5 g/kg as a 35% (w/v) solution in saline). This
ethanol dose and route of administration gives very reproducible blood 
ethanol levels, which are similar to those found in animals fed the 
alcohol-containing liquid diet. Ethanol is metabolised quite
rapidly, the blood levels returning to zero within 6-8 h after dosing, 
and the degree of narcosis and physiological impairment is much less 
than with the 6 g/kg oral dose. In fasted rats, this ethanol dose 
does however, cause a reproducible and significant increase in the 
hepatic triglyceride level during the intoxication period (Abrams and 
Cooper, 1976a; Abrams and Cooper, 1976b). Some typical liver 
triglyceride concentrations and blood ethanol concentrations after 
these acute ethanol doses are shown in Table 2.1. The values agree
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well with those in the literature for identical experimental
situations (Brodie et al, 1961; Wooles, 1966; Abrams and Cooper,
1976a).
2.2.2. Chronic Ethanol Intake Studies:
A number of methods have been employed in an attempt to produce 
chronic alcoholic liver injury in rats, including administration of 
alcohol in the drinking water (Fry et al, 1978), or repeated daily 
dosing with ethanol (Torrielli et al, 1977). The drinking water 
method does not produce significant fat accumulation, and with both 
methods, producing identical nutritional intake between 
alcohol-treated and control animals is difficult. Thus, a model 
based on the nutritionally-adequate liquid diet, described by DeCarli 
and Lieber (1967), was developed to produce chronic fatty liver, and a 
pair-feeding technique has been was used to ensure identical calorific 
and nutrient intake between alcohol-fed and control animals. The 
liquid diet devised was based on the liquid food supplement,
'Complan', in combination with casein, glucose and a commercial
vitamin supplement ('Orovite-7'). This formula was chosen since the 
Lieber-DeCarli diet, in its commercial form, is very expensive and 
difficult to obtain in this country, and it is quite time-consuming to 
prepare from its basic ingedients. The 'Complan' diet is cheap by 
comparison, and is easy to prepare.
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(i) Dietary Regime; A typical chronic experiment lasted for 36
days. The dietary regime was as follows:
Days 1-7: All animals receive control liquid diet,
containing no ethanol, ad libitum.
Days 8-15: Ethanol-fed animals receive liquid diet in
which 20% of the total calories are derived from ethanol, 
the ethanol calories replacing an isocaloric amount of
glucose. Control animals are pair-fed control diet in
which the ethanol calories are replaced by glucose.
Days 16-36: Ethanol-fed animals receive liquid diet in
which 36% of the total calories are derived from ethanol, 
the control animals being pair-fed as described above.
(ii) Preparation of Diets: The 'control' diet consisted of:
121g 'Complan' (plain flavour)
98g Glucose (anhydrous) 
lOg Casein 
5g (one sachet) 'Orovite-7'
- made up to one litre with cold tap water
The diet containing 20% of the total calories as ethanol 
consisted of:
121g 'Complan'
42g Glucose 
lOg Casein 
5g 'Orovite-7'
32.5 mis Absolute alcohol
- made up to one litre as above
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The diet containing 36% of the total calories as ethanol
consisted of:
121g 'Complan1 
lOg Casein 
5g 'Orovite-7'
56.5 mis Absolute alcohol 
- made up to one litre as above
The diets were prepared in a Kenwood liquidiser to ensure uniform 
dissolution of the casein. All diets were prepared fresh daily.
Diets were presented in graduated glass bottles with stainless steel 
nozzles. All bottles and nozzles were washed thoroughly daily, and 
were sterilised with a 1% (w/v) solution of sodium metabisulphite
before fresh diet was placed in them. The composition of these
alcohol-containing liquid diets, and the dietary regime are shown in 
Fig. 2.1.
Pair-Feeding: Ethanol-containing diets were placed in the
drinking bottle so that each bottle contained 250 mis of diet, the
level being marked with a waterproof pen. Next day, the volume of
diet consumed by that animal (or pair of animals) was determined by 
counting the graduations in the bottle uncovered by the consumption of 
the diet. The average dietary intake of the ethanol consuming
animals (mls/day) was calculated, and that volume of control diet was 
given to each animal (or pair of animals) in the corresponding control 
group. Thus, comparable calorie intakes between alcohol-fed rats and
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control animals was maintained throughout. In some experiments, 
animals were housed individually, and in others, they were housed in 
pairs. The latter arrangement did not affect the average volume of 
diet consumed per animal, blood ethanol levels, or the severity of 
fatty liver induced.
(iii) Comparison of the 1Complan' diet with the Lieber-DeCarli diet: 
A detailed comparison of the composition of these two diets is shown 
in Table 2.2. Some effects of the Complan diet on hepatic and serum 
parameters after chronic alcohol feeding are shown in comparison with 
reported values for the Lieber-DeCarli diet in Table 2.3. It will be 
seen that the composition of the Complan diet is not greatly different 
from the Lieber-DeCarli diet, although the former does have a lower 
proportion of calories present as fat, the percentage of calories 
arising from this source being closer to that found in normal rat 
solid diets than is the case for the Lieber-DeCarli diet. This in 
fact means that a higher proportion of calories are present as 
carbohydrate in the Complan diet, so possibly overcoming the objection 
of Rao and Larkin (1984) that carbohydrate deprivation during ethanol 
intake may produce fatty liver (see Section 1.3.7.). The
concentration of some lipotropes and vitamins is lower in the Complan 
diet, but it appears that the latter is more palatable, and that 
animals consume slightly larger volumes of it per day than has been 
reported for the Lieber-DeCarli diet. Serum ethanol concentrations 
during ingestion of the Complan diet are also slightly higher as a 
result. The ethanol intake per unit body weight, body weight gains
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TABLE 2.2
COMPARISON OF THE COMPOSITION OF THE 'COMPLAN1 AND LIEBER-DECARLI 
ALCOHOL-CONTAINING LIQUID DIETS
Lieber-DeCarli Diet*
Calorie content 0.97 Kcal/ml 1.0 Kcal/ml% total calories as:
Protein 16.0 18.0
F at 19.0 35.0
Carbohydrate (Control
diet) 65.0 47.0
Carbohydrate (36% ethanol
diet) 29.0 11.0
Choline 158 mg/1 250 mg/1
Methionine 948 mg/1 1500 mg/1
Vitamin E 16.0 mg/1 30 mg/1
Vitamin A 4000 U/l approx. 6000 U/l
Vitamin D 4.8 {ig/1 10 pg/1
Vitamin C 72 mg/1 N.S.
Vitamin B^ (thiamine) 2.9 mg/1 0.73 mg/1
" B£ (riboflavin) 2.4 mg/1 1.25 mg/1
" B^ (pyridoxine) 2.5 mg/1 0.73 mg/1
Pantothenic Acid 3.6 mg/1 5.0 mg/1
Nicotinamide 25.7 mg/1 3.75 mg/1
*According to DeCarli and Lieber (1967) N.S. = not stated
CO
MP
AR
IS
ON
 
OF 
TH
E 
EF
FE
CT
S 
OF 
TH
E 
CO
MP
LA
N 
DI
ET
 
AN
D 
LI
EB
ER
-D
eC
AR
LI
 
DI
ET
 
ON 
ET
HA
NO
L 
IN
TA
KE
 
AN
D
or
<c
C_J0QI
c r
LJ
CD
L J
X)
0
O
JZ
o
CJ
o
Ll
4J
c
o
CJ
r"
LP>
o +
• • 0 VO
m VO cn •
r— i CSI ra VO
Ll
+  11 1 0
>
o O n ro CO
• • s,./ •
CSI in vo
rH r—i m
<— i
O n
+
VO
CO
vom
+ + 
m  vo
I i +1 +1
<H CO
VO O 
<3- <-1
to
C
CL
O
CJ
cc X) r-i 00 m
LJ 0 • m • •
1— L_ o m ON o m
LJ 1 ON r—i O n CSI r— i r— I
s: rH •
+  1 +  1< o 1 1 O n 1
DC n «H
<C o m CO CO r- 1— 1
o_ o VO * VO • •
r— 1 CSI r—i o VO
CJ < r—i ON
ou
4-3
c
o
CJ
r^• mo
<h  m
+ 1 +1
O  csi
• •
CO o  
< t rH
E
/-V n. O
>s O .— v
0 rH cn
X \ cn
\ .— cn \ cn
r-i E cn E
E 0 v-z- E v_-
v_/ X /-N '— y
N/ 1—1 0
* cn 0 o 0 0
0 0 c X X
-X \ 2 0 •H •H
0 cn \ JC C l Li
4-3 v_/ cn 4-> •H 0
C •-— -> 0 rH O
•H 0
c E o rH
4-3 0 •H D •H cn
0 4-3 0 Li 4-3 •H
•H c cn 0 0 M
X •H 0 CL 4-3
• 0
0 r—I 4-3 r—1 r~ Ocn O 2 0 •H
0 c CJ i—1 4-3
Li 0 •H 0 0
0 JC X Q- 4-3 C l
> 4-3 o O 0
LJ CD (— t— X
4-3
0
X
4-3 c
c 0
0
0 •H
0 rH
(4 (4
Q. 0
0 CJ
U 0
o
X
c E
0 O
(4
Ll.
4-3
0 +
•r-i
X
0 •
JZ rH
4-> o
c
JZ 0
4-3 JZ
•H 4-3
S 0
4-3 0
ZJ 0
O
0
X
0 0
•r-i 4-3
Ll c
t-4 •H
0
o 0
•H
0 Li
4-3 O
c iH
0 0
E O
•H
U s?
0 vo
CL m
X
0 U—
o
0
4-3 X
0 o
i-H •H
CL Li
E 0
O Q-
O
cn
(4 c
ZJ •r-i
o t4
(4- D
X
L—
O X
0
0 0
0 0
cn 0
c 00
0 0
Li 0
U II
O
*
0
C
0
0 •
E CL
ZJ
0 o
Ll Li
0 cn
4-3 Li
0 0
•H Q.
X
0
C rH
0 0
rH E
Q . •H
E C •
O 0 Z'--V
CJ r"
>N vo
Ll 4-> O n
o Li ■H
L - O S_z
0_
0 Li
0 4-3 0
ZJ 0 -O
iH 0 0
0 0 •H
> rH
- 95 -
and hepatic lipid changes after three weeks of ethanol intake with the 
Complan diet are almost identical to those that have been reported for 
a similar duration of alcohol intake with the Lieber-DeCarli diet 
(Table 2.3).
2.3 ASSAYS FDR LIVER LIPID CONTENT
Hepatic total lipid and triglycerides were assayed by the 
application of colorimetric serum methods to 12.3 % (w/v) of liver 
homogenate. Dilution of liver homogenates was carried out using the 
same medium as was utilised for the original homogenisation step (ie: 
either isotonic saline or 0.25M sucrose).
2.3.1. Total lipid assay:
This was carried out using kits supplied by B.C.L. Ltd. The 
method is based upon the reaction of sulphovanillin with charred 
lipids in an acid medium to give a red colour (Woodman and Price, 
1972). Aliquots (0.03 ml) of diluted homogenate or lipid standard
(10 mg/ml in ethanol, as supplied with the B.C.L. kit) was placed in a 
clean test tube and 2.0 ml concentrated sulphuric acid added. The 
tubes were mixed and then plugged with cotton wool stops. They were 
heated in a boiling water bath for ten minutes, cooled in tap water, 
and 0.1ml aliquots of charred extract removed into clean test tubes. 
A blank was set up at this stage, consisting of 0.1 ml concentrated 
sulphuric acid. The colour reagent (2.5 ml of 13 mM vanillin in 14M 
phosphoric acid) was then added to all tubes, mixed, and the
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absorbance at 530 nm read vs. the blank after 20-30 minutes.
Accuracy of the method was checked using B.C.L. 1 Preclip' quality 
control serum, and values were found to be within the quoted range for 
all analyses performed. Five replicate analyses of a liver
homogenate prepared from a normal, solid-diet fed male Wistar rat gave 
a mean value of 35.3 mg/g liver, standard deviation being 1.75 mg/g, 
giving a coefficient of variation for the method of 4.9?o.
Coefficient of variation between duplicate analyses of rat liver
homogenates was found to be 3.3?o.
2.3.2. Liver Triglyceride Assay:
This assay was based on the colorimetric procedure described for 
serum by Fletcher (1968), and was carried out using kits supplied by 
Sigma Chemical Co.. Lipids were extracted from the homogenate into 
isopropanol and all polar lipids absorbed onto activated alumina to 
leave the triglycerides in the solvent phase. After saponification, 
oxidation of released glycerol was carried out to yield formaldehyde, 
which was reacted with acetylacetone to give a yellow colour that 
absorbs at 405 nm.
Portions (0.2 ml) of diluted liver homogenate were placed in 
screw-cap test tubes containing 800 mg (+ 200 mg) activated alumina 
and 5.0 mis isopropanol. Blank tubes contained 0.2 ml saline in 
place of homogenate, and standards (0.75, 1.5, 2.25 and 3.0 mg
triolein/ml in isopropanol) were set up at the same time. The 
standard solutions were added to tubes containing 4.8 ml isopropanol 
and 0.2 ml saline. All tubes were then capped, extracted for twenty
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minutes on a rotary mixer, and then centrifuged at 1500 g for 10
minutes. An aliquot (2.0 ml) of the isopropanol phase was removed
into a clean test tube and 0.5 ml IN potassium hydroxide added. The
tubes were mixed and heated in a 60°C water bath for five minutes,
before cooling in tap water. Sodium-m-periodate (0.5 ml of a 2.5 
mg/ml solution in 2N acetic acid) was then added to all tubes, a stop 
clock being started at the first addition, and the approximate time 
between additions noted. Exactly ten minutes after the addition of 
periodate, 3.0 ml colour reagent was added to all tubes at about the
same rate as the periodate, so that all the tubes received colour
reagent exactly ten minutes after the periodate addition. The colour 
reagent consisted of 20 ml 2M ammonium acetate added to 40 ml
isopropanol and 0.15 ml acetylacetone. Best results are achieved if 
the reagent is allowed to ’age1 overnight before use. The reagent is
stable at 4°C in a dark bottle for seven days. After addition of
colour reagent, the tubes were stopped with glass marbles and heated 
in a 60°C water bath for exactly thirty minutes. After cooling in 
tubes in tap water, absorbances were read against the blank at 405 nm 
within 20 minutes.
The calibration curve for the assay is shown in Fig. 2.1, and 
shows that the method obeys Beer’s law. Accuracy assessment, using 
Preclip control serum, gave good results and five replicate analyses 
of a liver homogenate from a normal, solid diet-fed, male Wistar rat 
gave a mean liver triglyceride concentration of 7.0 mg/g with a 
standard deviation of 0.57 mg/g, so that the coefficient of variation
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was 8.1%. Recovery studies using liver homogenate spiked with
[1-14C] triolein showed extraction efficiency in this method to be 
between 92 and 98%, overall recovery of unlabelled triolein added to 
homogenates being in the range of 88-92%.
2.4 LIVER METABOLITE ASSAYS
2.4.1. Sample collection:
Samples of tissue for metabolite analysis were collected by 
freeze-clamping. Animals were sacrificed by cervical dislocation,
the abdomen rapidly opened, and a portion of the liver quickly frozen 
in situ using aluminium tongs which had been pre-cooled in liquid 
nitrogen. The frozen piece of tissue was excised, any portions
protruding from the edges of the tongs broken off, and the frozen 
portion between the tongs stored in liquid nitrogen until extraction 
and analysis.
2.4.2. Sample extraction:
The frozen sample was ground to a powder under liquid nitrogen in 
a pestle and mortar. Approximately 800-1000 mg powdered tissue was 
placed in a pre-weighed homogeniser tube containing 5.0 mis ice-cold 
0.6N perchloric acid, the mixture homogenised in the cold with a 
teflon pestle driven by an electric drill motor, and the homogeniser 
tube and contents then re-weighed to determine the exact amount of 
tissue added. The ’homogenate’ was then centrifuged in the cold at 
2000 g for ten minutes, the supernatent removed into a clean test tube
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kept on ice, the residue in the centrifuge tube re-extracted with 2.0 
mis 0.3N perchloric acid and centrifuged as above. The combined 
supernatents were then neutralised to pH 5-6 using 5M potassium
carbonate with a pH meter. The clear extract, obtained after
centrifuging away the potassium perchlorate precipitate was then
treated with Florisil as described by Williamson et al (1967). 
Florisil (100-200 mesh) was then added (100 mg/ml extract), mixed, the 
extract centrifuged at 3000 g for 15-20 mins. The clear supernatent, 
free from interfering flavines as a result of the Florisil treatment, 
was then used for the metabolite assays as described below. The 
volume of this final extract was determined, and the mg liver 
tissue/ml extract calculated. ATP and pyruvate assays were carried
out rapidly after preparation of the extract, as these substrates are 
the least stable in the neutralised preparation.
2.4.3. ATP assay;
ATP was measured by the enzymatic method originally described by 
Bucher (1947), using kits supplied by B.C.L. Ltd. All reagents were 
prepared as directed in the instructions of the kit. 
Triethanolamine buffer/glycerate-3-phosphate solution (2.0 ml), NADH 
(0.2 ml of a 2.5 mPl solution), and 0.1 ml sample extract were placed 
in a spectrophotometer cuvette. After mixing, the absorbance at 340 
nm was read against air at room temperature (reading A^). Enzyme 
suspension (0.2 ml; glycerate 1,3-diphosphate
dehydrogenase/phosphoglycerate kinase/triosephosphate
isomerase/glycerol phosphate dehydrogenase) was then added, and the
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absorbance determined again after ten minutes, once the reaction had 
come to completion (= reading • The absorbance change (AA) was 
then calculated:
AA = Ax - A2
For each kit, the absorbance change due to addition of the enzyme 
suspension was determined by running the assay using water in place of 
the sample. AA values were then corrected to allow for this.
2.A.4. Pyruvate Assay:
Pyruvate was measured by the method of Czok and Lamprecht (1974). 
Sample extract (2.0 ml) was placed in a cuvette containing 1.0 ml 
phosphate buffer (0.1M, pH = 6.8; prepared as described by Mellanby 
and Williamson (1974)) and 0.1 ml NADH solution (5 mg/ml in water). 
After mixing, and equilibration at room temperature, the absorbance at 
340 nm was read against a cuvette containing 1.0 ml buffer and 2.1 ml 
distilled water (= reading A^). Lactate dehydrogenase (0.3 mg
protein/ml; > 360 U/mg protein) suspension (0.01 ml) was then added,
mixed, and the absorbance read again after five minutes. If the
absorbance continued to decrease, further readings were taken at 10 
and 13 minutes and the final absorbance determined by extrapolation to 
time zero to give reading A^•
AA ~ Aj, — .
2.4.5. Acetoacetate Assay:
Acetoacetate was assayed as described by Mellanby and Williamson 
(1974), in the same cuvette as that used for the pyruvate assay (see
above). After completion of the pyruvate assay, an absorbance
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reading was taken (= A^), and 0.01 ml 3-hydroxybutyrate dehydrogenase 
suspension added (3 mg protein/ml: BCL product was used undiluted).
After 15-30 minutes, when the reaction had come to completion, a 
further reading was taken (A^ ).
AA for the acetoacetate assay = A^ - A^ .
2.4.6. Lactate Assay?
Lactate was measured by the method of Gutmann and Wahlefeld 
(1974). Blank and sample cuvettes were set up as follows:
Blank Sample
Buffer (0.4M Hydrazine,
0.5M glycine, pH = 9.0) 2.5 ml 2.5 ml
NAD (30 mg/ml in water) 0.2 ml 0.2 ml
Sample extract - 0.2 ml
Perchloric acid (0.6N) 0.2 ml
The buffer was prepared by dissolving 11.4 g glycine and 25 ml 
hydrazine hydrate (24%) in 200 ml wate®, checking the pH (should be 
9.0), and making up to 300 ml with distilled water. The absorbance 
of the blank and sample cuvettes were read against air at 37°C at 340 
nm. Lactate dehydrogenase suspension (0.01 ml of Sigma L-2500
undiluted) was then added to both cuvettes, mixed, and the cuvettes 
incubated at 37°C for 30 minutes. The absorbances were redetermined 
and the AA values for the blank and sample cuvettes calculated. AA for 
the calculation of results = AA sample - AA blank.
2.4.7. 3-Hydroxybutyrate Assay:
This substrate was assayed as described by Williamson and 
Mellanby (1974). Sample extract (1.0 ml) was placed in a cuvette
containing 1.0 ml distilled water, 1.0 ml buffer and 0.1 ml NAD 
solution (10 mg/ml in distilled water) at room temperature. The 
buffer was prepared fresh daily by mixing 1 ml hydrazine hydrate 
(99%), 20 mg EDTA (disodium salt) and 5 ml IN HCI, and diluting to 20
ml with Tris-HCI buffer (0.1M, pH = 8.5). Measurements were made at 
340 nm against a blank cuvette containing 1.0 ml buffer and 2.0 ml 
distilled water. An initial absorbance reading was taken (A^) and 
0.01 ml 3-hydroxybutyrate dehydrogenase suspension (as for 
acetoacetate assay) added to both cuvettes. After one hour, the 
absorbance was read again (A2) and the absorbance change calculated.
AA = A2 - Ar
2.4.8. ril -Glycerophosphate Assay:
The method of Michal and Lang (1974) was employed for this 
metabolite. Sample extract (1.0 ml) was placed in a cuvette
containing 1.0 ml buffer and 0.1 ml NAD solution (40 mg/ml in water). 
The buffer was prepared by suspending 5.2 g hydrazine sulphate, 7.5 g 
glycine and 0.2 g EDTA (disodium salt) in a little water, adding 51 ml 
2N sodium hydroxide, and making up to a final volume of 100 ml with 
water. The pH was then checked (should be 9.5) and the buffer was
discarded after one week. Measurements were made at room temperature 
against a water blank. Once a stable initial absorbance at 340 nm 
was achieved, reading A^ was taken, and 0.01 ml ^(-glycerophosphate 
dehydrogenase suspension (Sigma No. G6751 undiluted) added to the 
cuvettes. After mixing and waiting for the reaction to come to
completion (about 10 minutes), reading was taken. AA = - A^ .
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2.4.9. Calculation of Results from Metabolite Assays:
The concentration of metabolites per millilitre of tissue extract 
was calculated in the above assays using the following formula:
pmol metabolite/ml extract = AA x Total assay volume (ml)
6.22 Sample volume (ml)
(6.22 = Molor extinction coefficient for NADH at 340 nm)
The above equation holds true providing that spectrophotometer 
cuvettes of 1 cm light path are used. The concentration of
metabolite per g wet weight liver is then calculated by dividing the 
p.mol/ml extract value by the mg tissue/ml extract value calculated 
earlier.
Some values obtained for various metabolites using the above 
methodology in fasted male Wistar rats are shown in Table 2.4, in 
comparison with published values obtained using identical methods. 
In experiments in which duplicate analyses of metabolite concentration 
were performed, the following coefficients of variation were obtained: 
ATP: Coefficient of variation = 3.4%
Pyruvate:
Lactate:
3-Hydroxybutyrate: 
Acetoacetate:
-Glycerophosphate
= 12.1% 
= 5.6%
= 4.1%
= 2.9%
7.2%
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TABLE 2.4
LIVER METABOLITE ASSAYS: VALUES OBTAINED USING METHODOLOGY DESCRIBED IN
COMPARISON WITH REPORTED VALUES 
Metabolite Values Obtained* Reported Values
ATP 3726 + 383 3250 + 300+
Pyruvate 42.4 + 91. 47.0 + 24.0*^
Lactate 633 + 195 780 + 400++
3-Hydroxybutyrate 1173 + 69 1790 + 830++
Acetoacetate 458 + 33 500 + 240++
Lactate:Pyruvate 16.5 + 8.0 17.0 + 5.6^
3-Hydroxybutyrate:Acetoacetate 2.58 + 0.30 3.60 + 1.4++
-glycerophosphate 142 + 14 140 + 20+++
*Values given were obtained in liver tissue from fasted male 1/Jistar rats (mean 
of five animals)
+ From Lindros and Stowell (1982)
++ From Williamson et al (1967)
111 From Michal and Lang (1974)
All values are given in nmol/g.liver (except ratios), and are shown as means + 
S.D.
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2.5 METHODS FOR INVESTIGATING HEPATIC LIPID UTILISATION AFTER ACUTE 
ETHANOL ADMINISTRATION
From the discussion in Chapter 1, it will be evident that ethanol
metabolism causes disturbances in the normal lipid disposal of rat
liver, that in turn could account for the production of fatty liver.
Depressed fatty acid oxidation and increased esterification of fatty
acids into triglycerides are the major features of this altered
hepatic lipid metabolism. Thus, methods were set up to investigate
the influence of the (+)-catechin compounds on these parameters after
a moderate acute dose of ethanol (2.0 g/kg i.p).
The first experiment determined the hepatic uptake and
14
incorporation of injected [U- C] palmitic acid into hepatic lipids 
after acute ethanol dosing, and assessing the effect of (+)-catechin 
in these respects. Secondly, the influence of the (+)-catechin
compounds on ethanol-induced changes in the ability of liver tissue to 
oxidise [1-^C] palmitate was investigated using liver slices taken 
from animals after acute in vivo ethanol administration.
14
2.5.1. Hepatic Uptake and Incorporation of [U- CJ Palmitic Acid: 
This method is based on that described by Abrams and Cooper 
(1976a), but incorporating some of the modifications outlined by 
Beauge et al (1979).
The label solution was prepared as follows. An appropriate
14
aliquot of LU- CJ palmitic acid in toluene was placed in a glass tube 
which had been pretreated with trichloromethylsilane (5% (w/v) in
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chloroform), and evaporated to dryness under a stream of nitrogen gas 
at 37°C. Freshly-prepared rat serum from a fasted rat was then added 
to the tube so that the final concentration of radioactivity would be 
10 pCi/ml serum. The tube was then vigourously vortex mixed and
incubated at 37°C for 30 mins, and revortexed. The incubation and 
mixing was continued until a clear solution was obtained. This
procedure resulted in 70-80% of the added radioactivity being bound to 
the rat serum. This value was found to be lower if serum from fed 
rats, or if non-silylated glassware was used. An aliquot of this 
preparation was solubolised in 0.5 ml Soluene-350 for 3-4 hours at
room temperature, 10 mis Dimilume-30 liquid scintillant added, and the 
sample counted to determine the radioactivity concentration of this 
label solution.
Label solution (200 jil) was injected intraperitoneally at 90 mins 
after etiianol administration (2 g/kg i.p.). Label solution was 
prepared fresh and maintained at 37°C prior to injection. Exactly 
ten minutes after injection of label, the animal was sacrificed by 
cervical dislocation, and the liver rapidly excised into ice-cold
0.25M sucrose. After weighing, a 50% (w/v) homogenate was prepared 
in 0.25M sucrose using a Potter tube driven by an electric drill 
motor. Total radioactivity taken up by the liver was determined by 
solubilising 0.2 ml aliquots of homogenate in 1.0 ml soluene-350 at 
55°C for three hours. The samples were then bleached by adding 0.2 
ml hydrogen peroxide (30% v/v), and reheating at 55°C for one hour. 
Dimilume-30 (10 ml) was then added and the samples counted. The
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1 4
percentage of the injected dose of LU- C] palmitate taken up by the 
liver was then calculated.
Lipids were extracted from the homogenate by the method of Folch 
et al (1957). Homogenate (0.25 ml) was placed in a screw-cap sovriel 
tube (vol = 10 ml) and 4.25 ml chloroform:methanol (2:1) added.
After capping, the tube was vortex mixed and shaken on a rotary mixer 
for 15 minutes. The mixture was then filtered through a Whatman No.l 
filter paper which had been pre-moistened with chloroform:methanol 
(2:1) into a graduated, glass-stoppered pyirex tube (vol = 10 ml). 
The remaining residue in the Sovriel tube was re-extracted briefly 
with 3.0 mis chloroform:methanol (2:1), using a vortex mixer, and then 
filtered through the same filter .paper into the pyrex tube. The 
volume of the extract was adjusted to 7.5 ml in the pyrex tube with 
chloroform:methanol, 1.5 ml 0.88 (w/v) KC1 added, and the tubes
stoppered, and shaken on a rotary mixer for 5 mins before centrifuging 
at 2000 g for 10 mins to separate the phases. The upper phase was 
then aspirated as completely as possible without disturbing the lower 
phase. The lower phase was then washed three times by the careful
addition of 1.0 ml aliquots of pure solvents upper phase 
(chloroform:methanol:water: 3:48:47). This was aspirated using a
vacuum pump, and any remaining upper phase combined with the lower 
phase by the addition of methanol.
This extract was then taken to dryness under nitrogen gas at 
37°C. The residue was redissolved in 0.5 ml chloroform:methanol
(2:1), and 50 pi aliquots spotted out as 1 cm lanes on a silica gel 60
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thin-layer chromatography plate. Appropriate markers were placed 
alongside the sample spots (triolein; 3 mg/ml in isopropanol;
cholesteryl stearate; 1 mg/ml in isopropanol; lecithin; 1 mg/ml in 
methanol). The plates were developed in hexane:diethyl ether: acetic 
acid (80:20:1), and placed in a tank containing iodine vapour to
visualise the spots. The areas of silica gel containing
triglycerides, cholesterol esters and phospholipids were scraped from 
the plate into screw-cap test tubes, extracted with 
chloroform-methanol (1.0 ml), and aliquots counted in Dimilume-30 to 
determine radioactivity incorporated into individual lipid classes. 
An aliquot of the redissolved residue from the Folch extraction was 
also counted to give radioactivity incorporated into total liver
lipids. Recovery studies using [1-^C] triolein showed that 91% of 
the radioactivity added to liver homogenates was recovered after the 
Folch extraction and thin-layer chromatography, and that the 
coefficient of variation for recovered radioactivity between duplicate 
extractions and chromatographic separation was 9,1%,
2*5.2. Oxidation of [1-^C] Palmitic Acid by Rat Liver 
Slices:
Animals were sacrificed 90 minutes after ethanol dosing, and 
livers rapidly excised into ice-cold Krebs-Hanseleit bicarbonate 
buffer (pH = 7.4). After thorough rinsing, a section of liver lobe 
was removed and sliced with a tissue grafting blade on a clean glass 
plate, moistened with buffer, and located on an ice bed. Slices were 
cut so that they were of the order of 0.3-0.3 mm thick.
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Approximately 100-150 mg of slices (wet weight after blotting on 
Whatman No.l filter paper) were placed in the outer well of a
pre-weighed Ehrlenmeyer flask with a centre well, which contained 3.0 
mi Krebs-Hanseleit buffer. The flasks were then reweighed to
determine the exact amount of tissue added. Label solution (0.4 ml) 
containing [l-^C] palmitic acid (2.5 pCi/ml; 5 mM) was then added,
septum caps placed in the flasks, the flasks sealed, and the
preparations incubated for 90 minutes at 37°C in a shaking water bath 
(60 oscillations per minute). The reaction was stopped by injecting
0.5 ml 1M citric acid through the septum cap into the outer well.
0.6 ml Hyamine 10X solution was then injected into the centre well and 
the flasks further reincubated for 40 mins. After placing the flasks 
on ice for about 15 mins, the septum cap was then removed, and the
contents of the well placed in 10 mis Dimilume-30 liquid scintillation
cocktail. The centre well was washed twice with 1.0 ml portions of 
scintillant, and the washings added to the counting vial. The slices 
and incubation medium were then homogenised using a Potter tube, and 
stored at -20°C until analysis for protein content and radioactivity 
incorporated into triglycerides. After counting, the radioactivity 
evolved as carbon dioxide, was corrected for quenching with an
internal standard. The CO2 production was expressed in either dpm/g 
liver or dpm/100 mg liver protein.
In experiments where total carbon dioxide production was
measured, 0.5 ml barium hydroxide (0.3N) was placed in the centre 
well, after the incubation had been stopped with citric acid, and the
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flasks left overnight at room temperature. The next day, 10 pi 
thymolphathlein indicator (0.1% (w/v) in ethanol) was placed in the 
centre-well and the contents titrated using 0.179N HC1 dispensed 
through a. Hamilton syringe (100 pi volume). The total CO2 produced 
was calculated from the volume of acid required to neutralise the well 
contents, as described by Conway (1962). The specific activity of
r 14-i
the carbon dioxide evolved from Ll- CJ palmitic acid was then 
determined.
2.5.3. Krebs-Hanseleit Bicarbonate Buffer (pH = 7.4, calcium 
free):
This was prepared by mixing the following:
760 mis 0.9% (w/v) Sodium chloride
30.4 mis 1.15% (w/v) Potassium chloride
7.5 mis 2.11% (w.v) Potassium dihydrogen
phosphate
7.5 mis 3.82% (w/v) MgS04. 7H20
160 mis 1.3% (w/v) Sodium hydrogen
carbonate
The pH was checked (should be 7.4) and adjusted if necessary with 
either IN HCI or IN NaOH. The volume was then made up to 1 litre 
with distilled water. The solution was bubbled with 100% O2 for 10 
mins, and the pH checked before use on each occasion.
2.5.4. Label Solution ([1-~^C] Palmitic Acid; 2.5 pCi/ml; 5 mM):
An aliquot of [1-^C] palmitic acid label solution (in toluene)
was placed in a silylated Sovriel tube and 100 pi of 18 mM unlabelied
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palmitic acid solution (as sodium palmitate in methanol) added per 1 
pCi of label dispensed. The contents of the tube were then dried 
down under a stream of nitrogen gas at 37°C. Freshly-prepared fatty 
acid-free bovine serum albumin solution (2% (w/v) in Krebs-Hanseleit 
buffer; 0.4 ml) was then added per 1 pCi of label, the tube 
vortex-mixed, and incubated at 37°C for one hour with occasional 
mixing, until a clear solution was obtained. This procedure resulted 
in greater than 90% of added radioactivity being bound to the serum 
albumin solution, providing fatty acid-free BSA and silylated Sovriel 
tubes were employed.
2.3.3. Other determinations:
Radioactivity incorporated into liver slice triglycerides during
the incubations was determined as described above, for the
incorporation of radioactivity into liver triglycerides after
-14intraperitoneal injection of [U C] palmitic acid, but using 1.0 ml 
of homogenised incubation medium in place of 0.25 ml liver homogenate 
as the starting point for the Folch extraction procedure.
Liver slice protein content was determined by the method of Lowry 
et al (1951). Standard solutions of bovine serum albumin were
prepared in distilled water (0.25, 0.50, 1.0 and 2.0 mg/ml).
Aliquots of homogenised liver slice medium (30 pi) were placed in 
clean test tubes and made up to 0.5 ml with distilled water. 
Aliquots (0.5 ml) of standard solutions were likewise pipetted into 
test tubes, alongside a blank consisting of 0.5 ml of distilled water. 
Sodium hydroxide (1.0 ml of a 1.0N solution) was then added to all
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tubes, mixed, and the tubes incubated at 37°C for 15 minutes. A 5.0
ml aliquot of freshly-prepared copper tartrate reagent (10 ml 1% (w/v)
CuSO^. 51^0 and 10 ml 2% (w/v) Na-K tartrate made up to 100 ml with
distilled water) was then added to all tubes, mixed, and the tubes
left to stand for 10 minutes. Folin-Ciocalteau reagent (0.5 ml;
freshly-prepared by diluting 2N stock solution 1 in 2 just before use)
was then added whilst each tube was being mixed on a vortex mixer.
After 30 minutes the absorbances at 700 nm were read against the
blank. A calibration curve was constructed, and protein content of
the samples determined from this (see Fig. 2.3).
2.5.6. Validation of fatty acid oxidation experiments:
Initial experiments showed that recovery of radioactivity in the
hyamine was dependent upon the presence of liver tissue in the outer
wells of the flasks. Blank flasks, in which slices were omitted,
showed negligible amounts of radioactivity recovered in the centre
well at the end of the incubation. Using liver slices prepared from
14the same liver, it was found that CC^ evolved was proportional to
the amount of tissue in the incubation, up to a maximum of about 200
14mg liver slices per flask. Above this amount, the yield of CO^ per
, . 14
gram tissue decreased (Fig. 2.4). The evolution of appeared to
be linear up to 90 mins, the linearity disappearing after this time,
hence 90 mins was used as the incubation time in all subsequent
experiments (Fig. 2.5). The coefficient of variation for duplicate
incubations (90 mins) of slices taken from the same liver was found to
average 10.6% for all incubations carried out. In the first series
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of experiments in which fatty acid oxidation by liver slices from 
ethanol-dosed animals was examined, no significant differences in 
ethanol-induced effects were observed when oxidation was expressed as 
dpm/90 mins/g.liver as opposed to dpm/90 mins/100 mg liver protein. 
It is for this reason, that in later experiments, the protein 
determination was not carried out, and results expressed in relation 
to wet weight of tissue. When total CO^ production was determined,
it was found that ethanol dosing did not affect the specific activity
of the evolved C^, indicating isotope dilution was not taking place, 
hence radiolabelled CO^ evolution was a reliable indicator of CO^
production in these experiments.
2.5.7. Scintillation counting:
All liquid scintillation counting was carried out using a 
Nuclear Enterprises NE 8312 radioactivity counter. Counting
efficiency was determined by spiking samples with ^C-hexadecane 
liquid scintillation standard, and was found to be in the range 88-92% 
for all counting carried out in the above methods. All counts were
corrected for efficiency, and expressed as disintegrations per minute
(dpm).
2.6 GAS CHROMATOGRAPHIC ANALYSIS OF ACETALDEHYDE AND ETHANOL IN RAT
BLOOD, SERUM AND LIVER SAMPLES
A method for the simultaneous measurement of acetaldehyde and 
ethanol in biological samples was devised, based on those described by
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Eriksson et al (1977) and Von Wartburg and Ris (1979). Particular 
care was taken to ensure that true liver acetaldehyde levels were 
measured, and that artefactual formation of acetaldehyde from ethanol 
present in the samples was avoided, a problem encountered in many 
earlier studies (Korsten et al, 1975; Eriksson, 1980).
2.6.1. Sample Collection and Preparation:
Blood samples were obtained either from the necks of animals 
after sacrifice, or by closed cardiac puncture under ether 
anaesthesia. Liver samples were collected by freeze-clamping as
described earlier for the determination of liver metabolites. Blood 
samples were allowed to clot, and then centrifuged to obtain the 
serum. Frozen liver samples were ground to a powder under liquid
nitrogen (working in the cold room), and approximately 300 mg powdered 
tissue placed in a pre-weighed homogeniser tube containing 3.0 ml 
ice-cold 0.6N perchloric acid to which was added 25 mM thiourea to 
inhibit the artefactual formation of acetaldehyde from ethanol present 
in the sample. After brief homogenisation, the tube was reweighed to 
determine the exact amount of tissue added, and the contents 
immediately centrifuged for 5 mins at 3000 g at 4°C. A portion of 
the supernatent (2.0 ml) was immediately removed into a glass vial 
containing 1.0 ml n-propanol internal standard solution (0.5 mg/ml, 
freshly prepared) and 0.1 ml distilled water. The glass vial was 
capped with a teflon-lined rubber septum cap, and heated at 60°C in a 
water bath for exactly 30 minutes before 2.0 ml head-space was removed 
using a Pressure-Lok A2 gas syringe for gas chromatographic analysis.
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Serum samples were treated as follows. Sample (50 pi) was 
placed in a glass vial containing 1.0 ml n-propanol solution as above, 
but the vial also contained 0.1 ml 60% (v/v) perchloric acid and 1.95 
ml distilled water. The vial was sealed and heated for 30 mins at 
60°C before removal of head-space samples, as described above for 
liver samples.
2.6.2. Gas Chromatography:
Analysis of head-space samples was carried out on a 
Hewlett-Packard 5710A Gas Chromatograph fitted with a 1.8 m x 4 mm
I.D. glass column packed with Poropak-Q (50-80 mesh). Running 
conditions for the gas chromatograph were: column temperature 150°C;
flame-ionisation detector temp: 250°C; injection port temperature:
200°C; nitrogen carrier gas flow: 30 ml/min., hydrogen flow: 30
ml/min., and air flow: 200 ml/min. The retention times for
acetaldehyde, ethanol and n-propanol were 58, 98 and 260 seconds
respectively. Calibration was carried out by treating aqueous
solutions of acetaldehyde (2.0-200 nmol/ml) and ethanol (25-300 mg/100 
ml; 5.4-65.2 mmol/1) in the same manner as the samples, peak
height-ratios method being used to calculate the concentrations
present in the samples. All standard solutions and the n-propanol 
internal standard solution were prepared fresh each day.
2.6.3. Validation of Methodology:
Construction of standard curves for the acetaldehyde and ethanol 
assays showed the detector response to be linear for both compounds 
(Figs. 2.6 and 2.7). The limit of detection for acetaldehyde was
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approximately 75 pmol injected, which would allow measurement of blood 
or tissue acetaldehyde levels down to 1 pM. A chromatogram of a 
standard solution containing both acetaldehyde and ethanol is shown in 
Fig. 2.8. Extraction of frozen liver tissue into PCA-thiourea which 
had been spiked with 10 mM ethanol resulted in a low level of 
artefactual formation of acetaldehyde, this being equivalent to only
1.5 nmol/g liver at this ethanol concentration (Fig. 2.9). 
Artefactual formation of acetaldehyde was not enhanced at higher 
ethanol concentrations (up to 100 mM), but did become significant if 
heating of the extract at 60°C prior to removal of head-space samples 
was prolonged to greater than 45 minutes (results not shown). At an 
ethanol concentration of 80 mM, heating for 75 minutes instead of 30 
minutes resulted in acetaldehyde equivalent to 20.9 nmol/g liver being 
formed artefactually, as opposed to only 1.5 nmol/g formed in the 
shorter incubation period. Artefactual formation problems could also 
arise if deproteinised liver samples were not immediately centrifuged 
after extraction of the tissue powder with PCA-thiourea. After 
homogenisation of rat liver powder in PCA-thiourea that contained 10 
mM ethanol, only 1.5 nmol/g liver acetaldehyde was formed if the 
sample was immediately centrifuged and the supernatent removed (Fig. 
2.9), whereas leaving the deproteinised sample on ice for one hour 
prior to centrifugation resulted in 8.7 nmol acetaldehyde/g liver 
being formed. Thus, in order to avoid artefactual formation
problems, in assays for rat liver acetaldehyde, rapid centrifugation 
after the extraction procedure, and an incubation period at 60°C of
Ethanol 
1
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J
n-Propanol
vv
Attn.= *64
2 .8 ,
0 1 2 3 4 5
T Mins.
Injection (Attn.= x8)
GAS CHROMATOGRAM OF AN AQUEOUS SOLUTION CONTAINING 25 pmol/1 
ACETALDEHYDE AND 100 ma/100 ml ETHANOL
Fig. 2
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T
Ethanol
Ace taldehyde
I-----1--- 1----1----1----1
0 1 2 3 4 5
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Injection (Attn.=x4)
9. GAS CHROMATOGRAM OF A RAT LIVER EXTRACT SPIKED WITH 10 mmol/I
(46 uq/q) ETHANOL
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exactly 30 minutes were employed.
Recovery of 50 pM acetaldehyde added to PCA-thiourea in presence 
of rat liver powder, was found to be in the range of 94.1-104.5%. 
Duplicate extractions of portions of powdered tissue from the same rat 
liver after acute ethanol administration resulted in a coefficient of 
variation between the values obtained of 8.9%, at a mean liver 
acetaldehyde level of 24.7 nmol/g liver. This value was obtained in 
rat liver taken 90 mins after an intraperitoneal dose of ethanol (2.0 
g/kg), and agreed well with published values for a similar ethanol 
dose at the same time point (Eriksson et al, 1983). Pre-treatment of 
animals with cyanamide, an aldehyde dehydrogenase inhibitor, (1 mg/kg 
p.o.) one hour prior to ethanol dosing (2 g/kg i.p), resulted in very 
high acetaldehyde levels being detectable in the liver (145.6-225.2 
nmol/g liver).
Studies on the determination of blood and serum ethanol showed a 
mean recovery of 98.2% for human blood, 97.4% for human serum, 98.9% 
for rat blood and 97.9% for rat serum. The coefficients of variation 
for duplicate determinations were found to be below 2% for all these 
types of sample.
2.7 ENZYMATIC DETERMINATION OF ETHANOL IN BLOOD AND SERUM SAMPLES
In some experiments, ethanol was determined enzymatically using 
kits supplied by BCL Ltd (Cat. No. 123960). All reagents were 
prepared as directed in the instructions given with the kit. Samples
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(50 pi of serum or blood) were mixed with 0.4 ml 0.33N perchloric acid 
(ice-cold), centrifuged, and 100 pi of supernatent used in the assay 
as instructed by the manufacturers. Aqueous standards were employed
to calibrate the method, as for the gas chromatographic method. 
Analysis of six rat serum samples by both methods showed almost
identical values achieved by each method, the correlation coefficient
being 0.984 (P > 0.3). A calibration curve for the enzymatic method 
is shown in Fig. 2.10. One disadvantage of this method was that 
linearity of standard curve is lost above an ethanol concentration of 
300 mg/100 ml, so it was not suitable for the measurement of very high 
blood or serum ethanol levels (data not shown). Coefficient of 
variation for duplicate analyses of serum samples using this method 
was found to be 1.3%.
2.8 ASSAYS FOR IN VITRO ANTIOXIDANT ACTIVITY OF DRUGS
2.8.1. Assay for Ability to Scavenge Superoxide Anions:
This procedure was based on the method described by Ponti et al 
(1978). NADH is used to reduce phenazine methosulphate which can
then reduce molecular oxygen to produce superoxide anions. The rate
of superoxide production can be determined in this system by following 
the reduction of nitroblue tetrazolium to a diformazan which absorbs 
at 560 nm. Superoxide scavenging ability of compounds is assessed by 
determining the degree of inhibition of diformazan formation when the 
drugs are added to the reaction mixture.
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(i) Reagents:
1. 0.1M Tris-HCI buffer (pH = 8.0).
2. 31.2 mM Phenazine methosulphate. Prepared fresh and kept
protected from light.
3. 480 p.M Nitroblue Tetrazolium. Prepared fresh and
kept protected from light.
4. 1.1 mM NADH. (2mg in 2.3 mis solution 1, prepared
just before use).
3. Drug solutions were prepared either in water or
dimethylformamide (DMF) at a concentration of 10 mM, so 
that addition of 30 p.1 to the incubation mixture would
yield a final concentration of 100 p.M, 15 p.1 would give 50 
p.M, etc.
(ii) Method: Distilled water (1.5 ml), 0.3 ml solution 1, 0.5 ml
solution 3, and 0.2 ml solution 4 were placed in a spectrophotometer 
cuvette which was then positioned in a Cecil CE393 spectrophotometer 
at room temperature cX= 560 nm). Drug solutions and/or water to a 
final addition volume of 30 p.1 were then added using micropipettes or 
a Hamilton syringe. A chart recorder was started, and once a stable 
baseline had been achieved, 0.5 ml solution 2 was added and mixed.
The absorbance at 560 nm was recorded for 3-4 minutes and the mean
initial change in absorbance per minute (AA/min) calculated from the
chart trace.
(iii) Results;
Addition to Reaction Mixture AA'^/min % Inhibiton 
Water 0.320+0.005
10U Superoxide Dismutase 
(Sigma, from Bovine liver
3100 U/mg prot) 0.010+0.002 96.9
Values shown are the means + S.D. of six determinations. The 
potent inhibitory action of superoxide dismutase demonstrated Lhe 
specificity of this procedure for assessing superoxide scavenging 
ability of potential protective agents.
2.8.2. Assay for ability to scavenge hydroxyl free radicals:
This method was based on the ADP-chelated iron-NADPH system
described by Slater (1968). Rat liver microsomes are incubated in
2 +
the presence of ADP/Fe /NADPH and the formation of thiobarbituric 
acid (TBA)-reactive material determined after a 15 minute incubation, 
as an index of hydroxyl radical production and subsequent formation of 
lipid peroxidation products.
(i) Reagents
1. 0.22M Potassium chloride
2. 90 mM Tris-HCl buffer (pH = 8.0)
3. NADPH solution, 3.33 mg/ml in solution 2. (Prepared 
fresh)
4. ADP 10 mg/ml in solution 2. (Prepared fresh)
5. FeS0^.7H20 40 |ig/ml. (Prepared fresh)
6. 10?o (w/v) Trichloroacetic acid
7. 0.67% (w/v) Thiobarbituric acid (TBA)
8. Drug solutions (10 mM in water or DMF). 30 pi aliquot 
added to the incubation gave a final concentration of 100
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(ii) Method; Washed microsomes were prepared from the livers of 
female Wistar albino rats (150-200 g) after an overnight fast by 
differential ultracentrifugation. The final preparation was
suspended in 50 mM Tris-HCI (pH = 7.4) buffered saline (1.15% KCI), so 
that the microsomes from 1 g of liver were contained in 1 ml
suspension.
Solution 1 (2.0 ml), 0.5 ml solution 2 and 0.1 microsome
suspension were placed in a clean test tube. Appropriate aliquots of 
drug solutions (or water/DMF in the case of controls) were then added 
and mixed. Aliquots (0.1 ml) of solutions 3, 4, 5 were then added to 
each tube to start the incubation, and the tubes placed in a shaking 
water bath at 22°C for 15 mins. The incubation was stopped by
removing 1.0 ml reaction mixture into a 10 ml sovriel tube containing 
2.0 mis ice-cold solution 6. After mixing, the precipitated
incubation mixtures were left on ice for 10-15 mins before
centrifuging in the cold (30,000 g-min). After centrifugation, 2.0
ml clear supernatent was removed into a clean test tube and 2.0 mis 
reagent 7 added and mixed. The tubes were capped and heated in a 
boiling water bath for 10 mins, and then cooled in ice. The 
absorbance at 535 nm was then determined against a blank preparation, 
which consisted of microsomes taken through the above procedure, but 
with 0.1 ml aliquots of water being added in place of solutions 3, 4 
and 5 at the beginning of the incubation. Results obtained using 
this method of determining hydroxyl radical scavenging activity are 
given in Chapter 4.
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2.9 ASSAYS FOR HEPATIC LIPID PEROXIDATION
Two methods for measuring hepatic lipid peroxidation in vivo 
after acute ethanol administration were adopted. In view of the 
possible role of depressed glutathione concentrations in the 
development of hepatic lipid peroxidation after ethanol, an assay to 
measure the reduced form of this metabolite (GSH) was also set up.
2.9.1. Measurement of Hepatic Lipid Peroxidation by the Presence 
of Diene Conjugation in Microsomal and Mitochondrial Lipids;
Free radical attack of polyunsaturated fatty acids causes 
double bond rearrangement in these acids, so that conjugated dienes 
are formed as an intermediate in the peroxidative breakdown of the 
phospholipid fatty acids. These dienes absorb in the UV in the
region 230-250 nm, whereas the polyunsaturated fatty acids, with their 
unconjugated double bond patterns, have peak absorbance at 210 nm. 
Thus, increased absorbance of a lipid extract in the 230-250 nm 
region, expressed per unit lipid, can be an indication of peroxidation 
having occurred. The method described for measuring diene
conjugation has been adapted from that described by Hashimoto and 
Recknagel (1968).
(i) Method; Animals were sacrificed at various time intervals after 
the administration of ethanol (5 g/kg orally as a 20% (w/v) solution 
in water) or an equivalent volume of saline. The liver was rapidly
excised into the ice-cold 10 mM potassium phosphate buffered 0.25M
sucrose containing 3 mM EDTA (pH = 7.4). After rinsing, blotting and
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weighing, the liver was minced with scissors and homogenised in 
sucrose-EDTA (as above) using a Potter tube driven by an electric 
drill motor to give a 50% (w/v) homogenate. This homogenate was then 
diluted to 10% (w/v) with sucrose-EDTA. This diluted homogenate was 
centrifuged at 400 g for 10 mins to sediment the nuclear pellet, and 
the supernatent was centrifuged at 400 g for 12 mins to produce a 
mitochondrial pellet. When microsomes were examined for diene
conjugation, the 10% homogenate was spun at 7000 g for 20 mins to give 
a post-lysosomal supernatent which was then centrifuged at 100,000 g 
for one hour to produce a crude microsomal pellet. In the case of 
both mitochondria and microsomes, the quantities of original 
homogenate used were always such that the pellet obtained represented 
the subcellular fraction derived from 2.5 g of liver tissue.
(ii) Diene Conjugation Analysis: The supernatent above either the
microsomal or mitochondrial pellet was decanted out of the centrifuge 
tube, after the preparation of subcellular fractions, and discarded. 
The tubes were then gently rinsed out with sucrose-EDTA, without 
disturbing the pellet, but removing any floating lipid that adhered to 
the wall of the tube after the centrifugation. Methanol (6.0 mis; 
Analar grade) was then placed in the tubes, vortexed to disperse the 
pellet, and the contents of the tube decanted into a 35 ml pyrex tube 
(acid-washed, glass stoppered). Chloroform (12.0 mis; Analar grade) 
was then added and the tubes allowed to stand at room temperature for 
10 mins with occasional mixing. The tubes were then centrifuged for 
5 mins at 400 g to sediment the insoluble material. The resulting
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clear supernatent was carefully decanted into a clean, acid-washed, 
pyrex tube (35 ml, glass stoppered) and the volume of the extract made 
up to about 25.0 mis with chloroform:methanol (2:1). Distilled water 
(8.3 mis) was added to all tubes, and mixed in gently by inversion. 
The tubes were then recentrifuged (400 g for ten minutes) to separate 
the phases, and the upper methanol-water layer was aspirated using a 
pasteur pipette attached to a vacuum pump. All the tubes were then 
left in ice for 5 mins, recentrifuged, and any remaining 
water-methanol droplets aspirated using the vacuum pump. An aliquot 
(2.0 mis) of the clear chloroform layer was then pipetted into a clean 
sovriel tube (10 ml, acid-washed), and evaporated to dryness under a 
stream of nitrogen gas at 40-50°C. After ensuring that all the 
chloroform was removed, the residue was redissolved in 3.0 mis 
cyclohexane (spectrosol grade, B.D.H). The absorbance of the
cyclohexane extract was then read against a cyclohexane blank, in UV 
silica spectrophotometer cuvettes, at 300, 280, 260, 250, 245, 240, 
235, 233, 232, 230, 225 and 220 nm. The cyclohexane extract was then 
retained, frozen at -20°C, for determination of its total lipid 
concentration.
The total lipid concentration was determined by the 
sulphovanillin method described earlier for liver homogenates, using 
kits supplied by B.C.L. Aliquots (0.5 ml) of the cyclohexane extract 
were placed in clean test tubes and evaporated to dryness under 
nitrogen gas at 40°C. Distilled water (50 (il) was added to each 
tube, and standards set up at this stage (50 pi aliquots of 10 mg/ml
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lipid standard supplied with B.C.L. kit). Concentrated sulphuric 
acid (2.0 mis) was then added to all tubes, which were then plugged 
with cotton wool and heated in a boiling water bath for 10 mins. 
Determination of lipid concentration was then carried out exactly as 
described earlier (Section 2.3.1).
The lipid concentration in the cyclohexane extracts was 
calculated in mg.lipid/ml extract. All of the absorbances obtained 
in the diene conjugate analyses were then corrected to give 
absorbances for a 1 mg.lipid/ml extract. The corrected absorbances 
at each wavelength for each treatment group were plotted against 
wavelengths, and where appropriate, difference spectra (eg: 
ethanol-treated vs. saline controls) constructed. If lipid
peroxidation had occurred in the subcellular fraction under study, 
this was revealed as a peak in the difference spectrum in the region 
230-240 nm.
This method for determining diene conjugation was validated by 
studying liver microsomes isolated from rats 30 mins after an oral 
dose of carbon tetrachloride (2.5 mg/kg as a 1:1 solution in liquid 
paraffin). The absorbance of microsomal lipids from CCl^-treated
rats was found to be 0.525/mg. lipid at 233 nm compared to 
0.375/mg.lipid at 233 nm in microsomal lipids isolated from control 
animals. These results gave a peak of 0.150 on the difference
spectrum (CCl^-treated rats vs. controls), this being almost identical 
to the change reported by Hashimoto and Recknagel (1968) after a 
similar dose of carbon tetrachloride, a substance well known to induce 
hepatic microsomal lipid peroxidation.
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2.9.2. Measurement of Liver Malonaldehyde Levels by the 
Thiobarbituric Acid Reaction
Malonaldehyde (MDA), and its precursors, were determined using 
thiobarbituric acid as described for tissues by Uchiyama and Mihara 
(1978). Liver homogenates (10% w/v) were prepared as described for 
the diene conjugate analysis. A mixture of 0.5 ml homogenate, 1 ml 
thiobarbituric acid (0.6% (w/v) in water) and 3.0 mis of 1% (v/v)
H^PO^ was incubated at 100°C for 45 mins in a boiling water bath. 
After cooling, the mixture was extracted with 4.0 mis butan-l-ol, the 
butanol phase separated by centrifugation (400 g for 10 mins), the 
upper phase removed, and its absorbance determined at both 535 nm and 
520 nm against a butan-l-ol blank. The difference in absorbance at 
these two wavelengths was then calculated for each sample, and the 
malonaldehyde/malonaldehyde precursor concentration in the liver 
calculated assuming an absorbance coefficient of 1.56 x 10^ mM cm  ^
for MDA. Coefficients of variation for this method of measuring MDA
in liver tissue was 4.25% between duplicates. Analysis of control
liver samples gave MDA values almost identical to those reported by 
Uchiyama and Mihara (1978).
2.9.3. Measurement of Liver Reduced Glutathione (G5H) 
Concentrations
This method is based on that described by Bernt and Bergmeyer 
(1974). A portion of 50% (w/v) liver homogenate, prepared as
described in the diene conjugate method, was frozen in liquid nitrogen 
immediately after preparation and stored at -70°C until analysis.
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Thawed homogenate (0.3 ml) was mixed thoroughly with 5.0 mis ice-cold 
1.0N perchloric acid. After centrifuging away the protein
precipitate, the supernatent was decanted into a graduated pyrex tube
(10 ml), 1.0 ml 1.75M K^PO^ added and mixed. The pH of the extract
was checked with a pH meter, and if necessary, further K^PO^ ac*ded to
bring the pH to 6.5-7.0. The tube was then left on ice for a few
minutes for the potassium perchlorate to settle out, and the volume of 
the extract was then determined so as to calculate the mg.liver/ml
extract. The extract was then filtered through Whatman No.l filter 
paper into a clean test tube. The following spectrophotometer 
cuvettes were then set up (UV silica cuvettes):
Sample Blank
Filtered Extract 0.5 ml 0.5 ml
Distilled Water 2.5 ml 2.5 ml
1% Egg Albumin 0.15 ml 0.15 ml
Glyoxylase I 0.01 ml —
After mixing, the absorbance at 240 nm of the sample was read 
against the blank at room temperature (= reading A^). A 0.02 ml 
aliquot of freshly-prepared methylglyoxal (0.1M) was then added to the 
sample cuvette, and the absorbance redetermined against the blank 
after five minutes (= reading • Another 0.02 ml methylglyoxal was 
then added to the sample cuvette and the absorbance read again after 
one minute (= reading A^ )
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AA = (A2 - A1) - (A3 - A2)
pmol GSH/g.liver = AA x 1
3.37 mg.liver/ml in cuvette
2
3.37 = Absorbance coefficient/pimol/cm for S-lactoyl-GSH at 240 nm
Analysis of liver homogenates from control, fasted male rats gave 
a mean GSH concentration of 3.68 + 0.82 pmol/g.liver, a value close to 
those given in the literature. Coefficient of variation for the 
method was found to be 5.7% for duplicate analyses of the same liver.
2.10 MISCELLANEOUS ASSAYS
2.10.1. Serum Glutamate Dehydrogenase Activity (GLDH)
Serum glutamate dehydrogenase activity was determined by 
following the decrease in absorbance at 340 nm due to the oxidation of 
NADH and o£-ketoglutarate by the enzyme. All determinations were 
carried out using kits supplied by BCL Ltd. (Cat. No. 124320). The 
assay was carried out at 23°C according precisely to the instructions 
supplied with the kit. For each batch of samples run, the accuracy 
of the assay was checked using BCL 'Precinorm1 quality control serum, 
all values obtained coming within the acceptable values quoted for 
this preparation. For rat serum, the coefficient of variation for 
duplicate analyses of the same sample was found to be 4.4%.
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2.10.2. Statistical Analysis
Unless indicated otherwise, all experimental values given in the 
ensuing chapters are expressed as means + standard deviation. 
Statistical significance of the difference between means values for 
various experimental groups was assessed by using Student's t-test for 
paired data. All statistical analyses were carried out by the author 
using an Apple computer. The following mathematical definitions were 
assumed in the programming process for the computer.
Mean (5T)= S  x where x = observed values
n n = number of observed values
Standard deviation, s, was determined according to the formula:
S = I Z(x - x)2 
(n - 1)
where = 'sum of'
x = observed value
x = arithmetic mean
n = number of observations
x - x = deviation of a value from the mean, x
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The 't' value in the Student's t-test for paired data was defined 
thus:
t = I n _ d 
sd
■ F
where n = number of pairs of observations
d = mean of the differences between pairs of values
S , = standard deviation of the differences d
The level of significance, expressed as a 
P-value, was determined by reference to statistical tables (Ciba-Geigy 
Scientific Tables)
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Chapter 3
PROTECTIVE EFFECT OF (+)-CATECHIN COMPOUNDS AGAINST ACUTE 
AND CHRONIC ETHANOL-INDUCED FATTY LIVER
The aim of these initial experiments was to establish and confirm 
the hepatoprotective properties of (+)-catechin that have been
described by previous authors (Gajdos et al, 1972). In the chronic
alcohol feeding experiment, a comparison of the relative potency of 
(+)-catechin and 3-palmitoyl-(+)-catechin at preventing fatty 
infiltration was carried out, so as to select the most suitable 
compound for further studies on the mechanism of action of these 
drugs.
3.1 METHODS
(i) Animals: Male Wistar Albino Rats (University of Surrey Strain,
180-220g) were used.
(ii) Ethanol Administration: Acute fatty liver was induced by
administering ethanol as a single dose (6g/kg orally) in fasted rats
(see Section 2.1). Chronic ethanol administration was carried out
using the liquid diet formula described in Section 2.1. Ethanol 
feeding, as 36% of the total calorie intake, was carried out over a 
period of three weeks, following an introductory period to the diet, 
control animals being pair-fed diet in which the ethanol-derived 
energy was replaced by glucose.
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(iii) Drug Administration; In the acute study, (+)-catechin was 
given as a suspension in saline (500 mg/kg i.p.) at 24, 3 and 0 hrs 
before ethanol. In one experiment, a single dose of catechin (500 
mg/kg i.p.) was given 0.5h before ethanol.
In the chronic alcohol feeding study, (+)-catechin was given once 
daily (200 mg/kg orally) by gastric tube in 5% (v/v) Arabic Gum and 
3-palmitoyl-(+)-catechin was given in a similar manner, but at a lower 
dose of 100 mg/kg orally. In all experiments, appropriate controls 
were sham-dosed with vehicle substances at che same time as the 
(+)-catechin compounds were administered.
(iv) Analyses: In the acute experiments, animals were sacrificed 16
hours after ethanol administration, livers removed, rinsed, blotted, 
weighed and homogenised in 0.25M sucrose. Hepatic triglycerides were
determined as described in Section 2.2.
At the end of the chronic ethanol feeding experiment, animals
were anaesthetised with diethyl ether, blood collected by closed
cardiac puncture, and serum prepared. Animals were then sacrificed 
by cervical dislocation, and the liver removed, rinsed, blotted and 
weighed. A small piece of liver ( f\J 200 mg) was placed in
formal-saline for histological examination using hemotoxylin and eosin 
staining. The remaining liver tissue was homogenised in 0.25M
sucrose and analysed for total hepatic lipid and triglyceride
contents. Serum was analysed for ethanol and GLDH activity.
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TABLE 3.1
THE EFFECT OF (h-)-CATECHIN ON THE ACUTE ETHANOL-INDUCED FATTY LIVER IN
THE RAT
Treatment Hepatic Triglyceride 16h after ethanol
(mg/g liver)
Experiment 1
Glucose 5.0 + 1.0
Glucose + Catechin 5.1 + 1.2
Ethanol 20.9 + 4.3*
Ethanol + Catechin 14.1 + 1.8+
Experiment 2
Glucose 6.1 + 1.2
Glucose + Catechin 6.5 Hr 1.7
Ethanol 19.6 + 3.1*
Ethanol + Catechin 7.7 + 2.9**
Fasted Male Wistar rats were given ethanol (6 g/kg P-o.) or
dose of glucose (9.3 g/kg p.o.) and sacrificed 16 hours later. In 
experiment 1, a single dose of (+)-catechin (500 mg/kg i.p.) was given 0.5h 
before ethanol. In Experiment 2, three doses of (+)-catechin (500 mg/kg 
i.p. on each occasion) were given at 24, 3 and 0 hours before ethanol.
Values given are the means + S.D. of six determinations.
* = p < 0.001 vs Glucose group. + = p < 0.05 vs Ethanol only group.
** = p < 0.001 vs Ethanol only group
0 GO
•H C
XI 0
c 0
•H cn >s E
JZ C  rH
o •H *H 0
1— 0) >  0 JZ
< 4-> •H X 4-3
tr CO
Cd
0
a  0 0
Ld 1 0 a (4
ZC --V f4 c 0
h- o
CO CZ
Z 1 + * rH C 3
►h r—1 rH * O  0 O
>, o • r- o t4 > JZ
CC \ ° • Ov * rH • 4.3 -H 0
Ld Q|4-> VO rH i— 1 Ov CO LA c cn •
> *H
+  1 +  1 +  1
o 0 Cd
t— ( E +  1 + 1 +1 a  0 0
i— 1 (4 z 0
CO Ov CO o o CO A* r- 0 «H >
>- D_ • ♦ • • 4-3 S 0
h- 1 Ov VO Ov CM CO 0 r=> LA
f— rA A* CM •H C O
< X  -H •
Ll. + sz
X  o •
O
CD r—1 •H 0 vy
Id O Z  4-3 rH
Cd c cr a 0 CL
zz CO •H CJ >
Q JZ rH I •H X
2 4-> f— \ 4-3 c
►— I 
1
Id 0 *}■ 0
0
0
_J C  1 CL CD
o •H rH 0
>N 0 0
< c CO o U >
zc ■H DC 4-3
1— JZ * 0 *H >n H
Ld o * * * 0 E '— f CZ
0 NV * * 3  rH H 0
C_) 4J CO • <r VO 0 0 •
t— 1 CO • VO • A- • 0 CL f4 0
Z2C Cd o *— 1 a - A- rH 0 1 O
o •
+1 +  1 +  1
C4 fA V
CC cd| + +1 +1 + | JZ cnin 4-3 X DC a.
cd H o o lA LA VO C
o CO • • • A* • U- CO cn 1
z c o Ov CM VO o E
o CO
JZ
H Ov fA c
X  -H O
+
z: 4-3 O  JZ O
•— i Ld •H 0 <H
it: U  0 •
Cd 0  4-3 X CD
Ld * CL 0 C
H— o * * Cd 0 0
< >N vo • a » Ov 0 1 >
O rH • a ~ • Ov • *—V X
1 C CO o >—i Ov LA VO t4 + rH H
o
+1 +  1 +  1
0 W' «H O
+ +1 +  1 +  1 > 0 O• .rH o *4 •
1 CD O ON o o o fA CD O O
_l C • • • Ov • 0  •
>- CO o fA Ov CM iA DC 0 cn v
o -CZ LA lA f"H 0 0 DC
1— 4-3 «H 4-3 O \ CL
H Ld C  0 cn
21 •H Z E II
— I rH
< Ov 0 cncz *
a. o • •—4 •H O *
i CO • CO • • P4 >,CM
i a rH VO »~H CM rH O  JZ •
o
+  1 +1
rH U_ CL
O *1 u +1 +  1 1 +  1 0 X O Z  •< 4 - 3 0 0 O  <
< c VO VO o i 0 0 f4
o CO • • • • <— 1 0 0 cn 0
Cd o Ov VO LA 0 H 0 >
i— i rH KV 4-3 0- O 4-3
zz O 0 X C  rH
{_) '— > 4-3 (4 0 O
Ld CO 4-3 E O
H- 0 GO 0 4-3 •
< JZ 0 0 O
Cd
1
>>
X
4-3 3 X
O
0
f4 vy
Z -^N L- >> •H 4-3
+ 4-3 cn 0 cn C4 CL
'— r GO >— s <-V (4 0 (4
cn cn 1— 1 o? 0 CL 0  II
L_ cn E \ E VO C CL
O c
•H
cn
E O
rA 0 cn
c
*
0
1— H 0 v_ O 0  >H •H 1— 1
Cd ' Z X '— 1 0 O X 0
Ld CO X •H 0 \ c 0 E
L_ f4 CL X cn c 0 0 •H
Lt. 0 c '— ' •H •H E /-v 0  JZ U_ C
Ld 4-3 •H cn rH (4 s_/ '— 1 >  4.3 0
0 0 v_x 0 \ •H 0 0
Ld E cn a a rH ZD cn JZ 4-3
ZZ 0 4-3 •H >> O N__/ 0 4-3 JZ
1— f4 4—3 JZ 4-3 rH c CO JZ cn
0 JZ cn 0 cn 0 zz 0  4-3 4-3 •H
Q_ cn •H CL *H JZ CD 2 z 0
•H 0 0 4-3 __1 JZ 0
0 2 JZ 4-3 0 Cd rH 0 JZ Li—
O  -H cn O
U r— 1 (4 E E C  JZ z
>N 0 0 0 Z Z 0 3 0 •
X > 4-3 > U f4 JZ p4 CD
o •H o •H 0 0 4-3 C JZ «
CO -J h- uo cn Id -H 4-3 CD
3.2 RESULTS AND DISCUSSION
Data from the acute studies is shown in Table 3.1. A single 
dose of (+)-catechin (500 mg/kg i.p. 0.5h before ethanol) had only a 
partial protective effect against the acute alcoholic fatty liver, 
whereas divided doses of the drug (500 mg/kg i.p. at 24, 3 and 0 hours 
before ethanol) afforded almost complete protection against hepatic 
triglyceride accumulation. These findings parallel, to some extent, 
those of Slater and Scott (1981), who found that repeated high doses 
of (+)-catechin were necessary to prevent the acute carbon 
tetrachloride-induced fatty liver. Although not reported
specifically in this chapter, subsequent experiments reported in this 
thesis (Chapters 5 and 9) showed that 3-palmitoyl-(+)-catechin, 
protects against the heptic triglyceride accumulation after acute 
ethanol administration (either 2 g/kg i.p. or 5 g/kg p.o.).
Results from the chronic fatty liver study are shown in Table
3.2. Administration of (+)-catechin and 3-palmitoyl-(+)-catechin had 
no effect on liquid diet intake, and thus the ethanol intake expressed 
as g.consumed/kg body weight/day was almost identical between the 
ethanol-fed groups (data not shown). Neither compound influenced 
body weight gain or liver weights in the animals. Administration of 
ethanol alone caused 292%, 821% and 201% increases in the hepatic
level of total lipid, triglycerides and the serum GLDH activity 
respectively. Administration of (+)-catechin reduced the extent of 
these increases to 153%, 439% and 29% respectively in ethanol-fed
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rats, these effects of the drug being statistically significant.
3-Palmitoyl-(+)-catechin, even though it was given at only half the 
dose of the parent compound, was slightly more effective at preventing 
hepatic steatosis in ethanol-fed rats than (+)-catechin, the total 
hepatic lipid concentration in animals which received 
3-palmitoyl-(+)-catechin being significantly less than that in the 
(+)-catechin-treated groups. The biochemical findings of reduced
steatosis in the drug-treated animals were confirmed by histological 
assessment. The size of lipid vesicles was reduced, and the area of 
liver tissue affected lower in the animals treated with the
(+)-catechin compounds (Fig. 3.1). Due to the wide individual
variation in serum GLDH activities in the 3-palmitoyl-(+)-catechin 
treated animals, the decrease in this parameter in ethanol-fed rats 
caused by the drug was not statistically significant.
Serum ethanol concentrations at sacrifice were similar between 
all the ethanol-fed groups, suggesting that the drugs did not exert 
their hepatoprotective effects through interfering with ethanol
absorption or elimination.
Pilot experiments, not reported in detail here, demonstrated that 
(+)-catechin also protected against the mild degree of fat
accumulation induced by feeding 28% of the total calories as ethanol 
for 28 days. In order to compare the relative effectiveness of the 
two drugs at preventing fatty liver, it was decided to modify the 
liquid diet formula to contain a final level of 36% of the total 
calories as ethanol, as described in this thesis, in order to induce
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more severe fatty infiltration of the liver. It was not possible, 
due to the large number of animals that would have been required, to 
assess the effects of the (+)-catechin compounds alone on the liver 
lipids in control animals in the same experiment as that reported
here. However, a pilot experiment, in which (+)-catechin (200
mg/kg/day p.o.) was given to animals maintained on the control liquid 
diet for 36 days, showed the drug to have no influence on any of the 
biochemical or histological parameters used to assess the protective 
properties of the (+)-catechin compounds in the present experiment.
Thus, these studies have confirmed previous observations that 
(+)-catechin and, in addition, 3-palmitoyl-(+)-catechin, possess
protective properties against ethanol hepatotoxicity in the rat 
(Gajdos et al, 1982; Perrissoud et al, 1985). The latter compound 
appeared to be more potent than (+)-catechin itself, in spite of the 
fact that it was given at only half the dose of the parent compound. 
In molar terms, allowing for the higher molecular weight of
3-palmitoyl-(+)-catechin (H.W. = 528) compared with (+)-catechin (M.W. 
= 290), the palmitoyl derivative is thus at least 3.6 times more
effective at preventing ethanol-induced steatosis than (+)-catechin. 
Some possible reasons for this have already been indicated in the 
introductory chapter (see Section 1.5.2.), and probably include the 
greater lipid solubility and more favourable pharmacokinetic 
characteristics that result from the rate-limiting de-esterification 
step involved in the elimination of 3-palmitoyl-(+)-catechin (Hackett 
and Griffiths, 1982). Studies employing [U-^C]-labelled
Fig. 3.1. REPRESENTATIVE HISTOLOGICAL APPEARANCE OF LIVER TAKEN 
FROM RATS AT END OF CHRONIC ETHANOL-FEEDING STUDY 
Stain: Haematoxylin and Eosin ( x 200)
v t
I
Group A: Controls
Group B: Ethanol Only
contd. over
Fig. 3.1. (contd.)
l
Croup C: Ethanol and (+)-Catechin (200 mg/kg/day)
Croup D: Ethanol and 3-Palmitoyl-(n-)-Catechin (100 mg/kg/day)
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(+)-catechin and [U-^C] 3-palmitoyl-(+)-catechin have shown that the 
half-life and bioavailability of the latter compound in the liver is 
much greater than for the parent compound after oral dosing (Ryle et_ 
al, 1983). The study of Hackett and Griffiths (1982) showed that
perfusion of the isolated rat liver with 3-palmitoyl-(+)-catechin 
caused the release of (+)-catechin, and its glucuronide and sulphate 
conjugates, into the perfusate, indicating that the drug is converted 
to (+)-catechin after de-esterification in the liver. Thus, it might 
be assumed that the same molecule, namely (+)-catechin, is mediating 
the hepatoprotective effect of both compounds,
3-palmitoyl-(+)-catechin and (+)-catechin itself, after oral dosing. 
The mechanism of action of both drugs is probably similar at the 
biochemical level. Therefore, for many of the future studies on the 
mechanism of action of these drugs, 3-palmitoyl-(+)-catechin has been 
used, due to its greater potency, although it is probable that any 
findings regarding this compound's mode of action would also apply to 
the action of (+)-catechin itself.
- 150 -
Chapter 4
IN VITRO ANTIOXIDANT PROPERTIES OF (+)-CATECHIN COMPOUNDS
4.1 INTRODUCTION
The studies described in Chapter 3 have demonstrated the 
protective action of (+)-catechin and 3-palmitoyl-(+)-catechin against 
ethanol hepatotoxicity in the rat. As already discussed in the 
introductory chapter, there are probably two properties of these 
compounds that might account for these hepatoprotective effects.
Firstly, there are the redox-state modulating effects of the compounds 
described by Gajdos et al (1972), and secondly, the free
radical-scavenging (antioxidant) properties, described by Danni et al 
(1977) and Slater and Scott (1981), may afford the drugs these
protective actions. The experiments in this chapter aim to confirm 
the antioxidant properties of (-f)-catechin and
3-palmitoyl-(+)-catechin, and assess these relative to certain
reference compounds known to possess antioxidant activity.
4.2 METHODS
The ability of substances to scavenge superoxide anions was 
assessed using the phenazine methosulphate-NADH-nitroblue tetrazolium 
method describee by Ponti et al (1978), and given in detail in Section 
2 .8 .1 .
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Hydroxyl radical scavenging was determined using the
NADPH/Fe^+/ADP system in rat liver microsomes, as described in detail 
in Section 2.8.2. Candidate drugs or reference compounds were
dissolved in either water or dimethyl formamide (DMF), and added to 
the assay systems to give final concentrations in the range 1-100 |iM. 
Depending upon the degree of inhibition of the radical-mediated
effects in the assay systems, approximate FC,-g values for each assay 
substance were calculated to obtain some impression of their relative 
effectiveness as antioxidants. The FC^ -g value was defined as the 
concentration of the scavenger in the assay system which achieved 50% 
inhibition of the radical-mediated action, when compared to the 
control incubations. In the case of the superoxide-scavenging assay, 
this value represents the concentration at which 50% inhibition of NBT 
reduction is achieved. In the case of the hydroxyl
radical-scavenging assay, the value represents the concentration at 
which production of thiobarbituric acid-reactive material, produced 
after incubation of microsomes with NADPH/Fe^+, is inhibited by 50%.
Initial experiments showed that the solvent dimethylformamide had 
no effect on these parameters, when added to the incubations in 
amounts even in excess of those used to add potential scavengers to 
the assay systems.
4.3 RESULTS
Data on the ability of (+)-catechin and 3-palmitoyl-(+)-catechin 
to scavenge 0*2 in the NADH/NBT/PMS assay are given in Table 4.1. 
Both compounds exerted an inhibitory effect on NBT reduction in this 
experiment. Data from the hydroxyl radical-scavenging studies are
shown in Table 4.2. All of the compounds tested, including
(+)-catechin and 3-palmitoyl(-{-)-catechin, exerted an inhibitory effect 
on the production of TBA-reactive material during incubation of rat 
liver microsomes with the hydroxyl radical generating system, 
NADPH/Fe^+/ADP. The FC,-g values given in Table 4.3 indicate the
relative effectiveness of the compounds tested at scavenging either 
superoxide or hydroxyl radicals. In the NADH/PMS/NBT system,
(+)-catechin was twice as effective as 3-palmitoyl-(+)-catechin at 
scavenging superoxide anions. Conversely, in the NADPH/Fe^+/ADP
system, the more lipid-soluble 3-palmitoyl-(+)-catechin appeared to be 
five times more effective than (+)-catechin itself at protecting rat 
liver microsomes against lipid peroxidation caused by hydroxyl 
radicals. In this respect, 3-palmitoyl-(+)-catechin was as effective 
as the reference synthetic antioxidants, DPPD
(N,N'-diphenyI-p-phenylenediamine) and BHT (Butylated Hydroxytoluene), 
and slightly more effective than tocopherol acetate (vitamin F).
TABLE 4.1
EFFECT OF (+)-CATECHIN AND 3-PALMIT0YL-(+)-CATECHIN ON NBT REDUCTION IN 
THE PRESENCE OF PHENAZINE METHOSULPHATE-NADH
Addition to Incubation AA^^/min ?o Inhibition
- 0.320 + 0.010 -
I0U Superoxide dismutase 0.010 + 0.001 96.9
(-O-Catechin (1 pH) 0.316 + 0.007 1.0
(-;-)-Catechin (5 pH) 0.302 + 0.012 5.6
(+)-Catechin (10 pH) 0.295 + 0.006 7.8
(+)-Catechin (25 pH) 0.239 + 0.010 25.3
(+)-Catechin (50 pH) 0.172 + 0.008 46.2
(+)-Catechin (75 pH) 0.090 + 0.004 72.0
(+)-Catechin (100 pH) 0.022 + 0.002 93.1
3-Palmitoyl-(+)-catechin (1 pH) 0.323 + 0.011 —
3-Palmitoyl-(+)-catechin (10 pH) 0.310 + 0.009 3.1
3-Palmitoyl-(+)-catechin (25 pH) 0.287 + 0.006 10.3
3-Palmitoyl-(+)-catechin (50 pH) 0.252 + 0.005 21.2
3-Palmitoyl-(+)-catechin (100 pH) 0.172 + 0.018 46.3
3-Palmitoyl-(+)-catechin (200 pH) 0.008 + 0.002 97.4
Drug solutions were prepared in either water or dimethylformamide and added 
to the incubation mixture which contained Nitroblue Tetrazolium (NBT); 80 
pH; NADH; 75 pM; Phenazine Hethcsulphate; 5pH; in Tris-HCI (pH = 8.0);
10 mfi. NBT reduction was measured by following the change in absorbance 
at 560 nm. Values are shown as the means + S.D. of at least three 
determinations.
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TABLE 4.2
EFFECT OF (-f)-CATECHIN, 3-PALMITOYL-(+)-CATECHIN AND REFERENCE COMPOUNDS 
ON LIPID PEROXIDATION IN MICROSOMES INCUBATED UITH "NADPH/Fe2+/ADP
Addition to Incubation A^^/ml Incubation Medium % Inhibition
- 0.348 + 0.017 -
(+)-Catechin (0.1 pM) 0.340 0.009 2.3
(+)-Catechin (1 pM) 0.313 + 0.010 10.0
(+)-Catechin (10 pM) 0.023 + 0.002 93.4
(+)-Catechin (100 pM) 0.017 + 0.003 95.1
3-Palmitoyl-(+)-Catechin (0.1 pM) 0.330 + 0.007 5.2
3-Palmitoyl-(+)-Catechin (1 pM) 0.179 + 0.010 48.6
3-Palmitoyl-(+)-Catechin (10 pM) 0.010 + 0.003 97.1
3-Palmitoyl-(+)-Catechin (100 pM) 0.002 + 0.001 99.4
DPPD (0.1 pM) 0.331 + 0.010 4.9
DPPD (1 pH) 0.231 + 0.012 33.6
DPPD (10 pM) 0 100
DPPD (100 pM) 0 100
BHT (0.1 pM) 0.317 + 0.009 9.0
BHT (1 pM) 0.207 + 0.020 40.5
BHT (10 pM) 0.028 + 0.005 92.0
BHT (100 pM) 0.020 + 0.007 94.1
Tocopherol Acetate (1 pM) 0.282 + 0.018 19.0
Tocopherol Acetate (10 pM) 0.057 + 0.014 83.6
Tocopherol Acetate (50 pM) 0.019 + 0.002 94.5
Rat liver microsomes were incubated for^^ mins. at 22°C with a hydroxyl 
radical generating system (NADPH/ADP/Fe +) and the production of 
TBA-reactive substances determined after the incubation was stopped with 
TCA. Values shown are the means + S.D. of at least three determinations. 
DPPD = N,N'-Diphenyl-p-phenylenediamine, BUT = Butylated Hydroxytoluene
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TABLE 4.3
ECsn INHIBITORY CONSTANTS FOR VARIOUS COMPOUNDS IN THE SUPEROXIDE 
AND HYDROXYL RADICAL SCAVENGING ACTIVITY ASSAYS
Substance EC^g Value
U'2~ OH’
(NADH/PMS/NBT) (NADPH/ADP/Fe2+)
(+)-Catechin 54 pM 5.0 pM
3-Palmitoyl-(+)-catechin 108 pM 1.0 pM
DPPD - 1.5 pM
BHT - 1.2 pM
Tocopherol Acetate - 2.6 pM
Values are calculated from the data given in Tables 4.1 and 4.2, and 
represent the concentration at which the radical-mediated end point event 
(NBT reduction, or production of TBA-reactive material) was inhibited by 
50&. ^50 values for DPPD, BHT and tocopherol acetate in the 0^ system
were not determined due to turbidity problems in the assay.
DPPD = N,N'-Diphenyl-p-phenylenediamine 
BHT = Butylated Hydroxytoluene
4.4 DISCUSSION
These experiments have demonstrated that (+)-catechin and
3-palmitoyl-(+)-catechin are potent scavengers of free radicals in 
vitro. With respect to superoxide scavenging, (+)-catechin is more 
effective than its palmityl derivative, possibly due to its greater 
solubility in water, and the fact that the NADH/PMS/NBT assay is in an 
aqueous environment. In the hydroxyl radical-scavenging system,
however, 3-palmitoyl-(+)-catechin is more effective, probably as a
result of its greater lipid solubility. In terms of protecting
against free radical-mediated tissue damage in vivo, ability to
scavenge hydroxyl radicals is probably more important than superoxide 
scavenging, since the former species is much more reactive and travels 
further within the cell from its site of production than does 
superoxide (Slater, 1984). In addition, there are ready-made
mechanisms for detoxifying superoxide, through superoxide dismutase, 
in cells. Thus, in view of this, and also the pharmacokinetic
factors discussed in the previous chapter, 3-palmitoyl-(+)-catechin is 
probably the best candidate to be an effective tissue antioxidant in
vivo. Results from the hydroxyl radical-scavenging experiment
(NADPH/Fe2+/ADP system), and the values calculated for the
various scavengers, reveal that 3-palmitoyl-(+)-catechin is actually a 
slightly more effective scavenger than tocopherol (viamin E), the
substance thought to be the major lipid-soluble chain-breaking 
antioxidant in animal tissues (Slater, 1984).
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These studies cannot accurately predict, however, the relative 
effectiveness of the substances tested at preventing lipid 
peroxidation in vivo. For a scavenger to be effective in vivo, it 
has got to be present at the site of free radical production at the 
right time, and in a suitable concentration. Thus, the ability of 
these substances to scavenge radicals in vivo depends, not only on 
their avidity for various radical species, but also on their 
absorption, distribution and elimination characteristics. Endogenous 
tocopherol, for example, is thought to reside in close proximity to 
arachidonic acid residues in membrane phospholipids, thereby 
protecting the molecule from free radical attack (Diplock and Lucy, 
1973). However, in spite of its known antioxidant properties,
tocopherol administration is not effective at preventing carbon
tetrachloride hepatotoxicity in rats (Ghoshal, 1976). This has been 
attributed to inability of the administered vitamin to penetrate to
the precise locus of generation of the CCl^ radical in sufficient 
concentration to prevent this species causing membrane damage. Thus, 
in vivo antioxidant potency does not always correlate with in vitro 
findings. However, in view of the greater potency of
3-palmitoyl-(+)-catechin at scavenging hydroxyl radicals in vitro, and 
its pharmacokinetic and lipid solubility properties, the findings 
presented here suggest that this compound would be a much better
candidate for preventing free radical-mediated tissue injury in vivo 
than (+)-catechin.
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Chapter 5
EFFECTS OF (-t-)-CATECHIN COMPOUNDS ON THE ICPATIC 
REDOX-STATE AND LIPID UTILISATION AFTER ACUTE ETHANOL
ADMINISTRATION
5.1 INTRODUCTION
The data described in the previous chapter has shown that the 
(+)-catechin compounds exert potent antioxidant properties in vitro, 
that might contribute to their protective actions against ethanol 
hepatotoxicity in vivo (Chapter 3). However, Gajdos et al (1972) 
suggested that (+)-catechin exerted its hepatoprotective effects 
through modulation of the disturbed NADH:NAD ratio observed after the 
administration of a number of hepatotoxins. The possible
relationship between the increased NADH:NAD ratio arising from ethanol 
metabolism in the liver, the altered hepatic metabolism of fatty 
acids, and the development of alcoholic fatty liver has already been 
discussed in Chapter 1.
The aim of the work in this chapter was to re-examine the effect 
of (+)-catechin, in addition to 3-palmitoyl-(+)-catechin, on the 
hepatic redox-state after ethanol dosing, and to attempt to correlate 
any changes to the patterns of hepatic lipid disposal under the same 
experimental conditions.
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5.2 METHODS
5.2.1. Animals and Administration of Drugs:
Male Wistar albino rats (University of Surrey strain, 180-220g) 
were used. They were maintained on laboratory chow and water and
fasted for 24 hours prior to ethanol administration. (+)-Catechin 
and 3-palmitoyl(+)-catechin were given at doses of 200 mg/kg p.o. and 
100 mg/kg p.o. respectively in 5% (w/v) Arabic Gum, at 24 and 0 hrs 
before ethanol dosing. Ethanol was given intraperitoneally (2 g/kg) 
as a 20% (w/v) solution in 0.9% NaCl. Controls were administered
equivalent volumes of saline.
5.2.2. Redox-state and Fatty Acid Utilisation Studies:
(i) In vivo incorporation of [U-^4C]-palmitic acid: [U-^C] Palmitic
Acid was injected (i.p.) 90 mins. after ethanol in rat serum and ten 
minutes later, the animals sacrificed by cervical dislocation, and a 
portion of liver rapidly freeze-clamped in situ for metabolite 
determinations. The remainder of the liver was excised, rinsed in
ice-cold 0.25M sucrose, blotted, weighed and homogenised in 0.25M 
sucrose. Incorporation of radioactivity into various hepatic lipid 
fractions was determined after extraction and separation by thin-layer 
chromatography (see Chapter 2, Section 2.5). The freeze-clamped 
liver sample was extracted with perchloric acid, and the lactate, 
pyruvate and oL -glycerophosphate levels determined by standard
enzymatic methods (Section 2.4). Hepatic triglycerides and serum 
ethanol were determined as already described (Section 2.3 and 2.7)
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(ii) Oxidation of [1-^C] palmitate by liver slices from
ethanol-treated rats: Animals were sacrificed by cervical
dislocation 90 mins. after ethanol-dosing and a portion of liver
freeze-clamped in situ for metabolite determinations as described
above. A further portion, well away from the freeze-clamping site,
was removed into ice-cold saline, and cut into slices on an ice-bed
using a tissue-grafting knife. Approximately 100-150 mg of slices
were then incubated for 90 mins. in Krebs-Hanseleit bicarbonate buffer
14
containing lpCi albumin-bound LI- C] palmitic acid. The incubations
14
were stopped using 1M citric acid and the CO2 evolved during the 
incubation was collected into 10% (w/v) hyamine 10X and counted. At 
the end of the incubations, the medium and slices were homogenised and 
protein content determined by the method of Lowry et al (1951). Full 
details of the methodology are given in Section 2.5.
5.3 RESULTS
The effect of (+)-catechin on the hepatic redox-state and 
14
incorporation of [U- CJ palmitic acid into liver lipids after ethanol 
dosing is shown in Table 5.1. Ethanol caused a 220% increase in the 
hepatic lactate/pyruvate ratio, due to both an increase in the lactate 
and a decrease in the pyruvate concentrations. Ethanol caused a 188% 
increase in the hepatic c<.-glycerophosphate concentration, and almost 
doubled the amount of injected radioactivity taken up by the liver and 
incorporated into the total hepatic lipids. Host of the latter was
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accounted for by a 300?o increase in radioactivity incorporated into 
the triglyceride fraction, although significant increases in 
radioactivity incorporated into phospholipid and cholesterol esters 
were also seen. The hepatic triglyceride concentration was doubled 
by ethanol administration. Pre-treatment of ethanol-dosed animals 
with (4-)-catechin almost completely reversed all of these 
ethanol-induced effects. A significant reduction in the
lactate/pyruvate ratio due to drug administration was found, mainly as 
a result of increased pyruvate levels. Interestingly, 
o£ -glycerophosphate levels were not significantly reduced by 
(+)-catechin.
Nearly all of the ethanol-induced alterations in hepatic disposal 
of [U-^CJ palmitate were counteracted by (+)-catechin, significant 
decreases in the incorporation of radioactivity into all the lipid 
fractions being seen. (-t-)-Catechin also decreased the hepatic
triglyceride level in ethanol-dosed animals, although this effect was 
not statistically significant due to the wide individual variation. 
Serum ethanol levels indicated that (+)-catechin did not achieve these 
effects simply through inhibition of ethanol oxidation. (+)-Catechin 
alone did not significantly affect any of the parameters studied. A 
diagramatic representation of the hepatic fatty acid disposal patterns 
in the various treatment groups is given in Fig. 5.1.
The results of the experiments in which the effects of 
(+)-catechin and 3-palmitoyl-(-*-)-catechin on the hepatic redox-state 
and palmitate oxidation after ethanol dosing were studied are shown in 
Table 5.2. As found in the previous experiment (Table 5.1),
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ethanol caused increases in the hepatic lactate/pyruvate ratio and 
cL -glycerophosphate concentrations. Ethanol dosing caused a 62%
14
decrease in the ability of liver slices to oxidise [1- CJ palmitate
to (+)-Catechin partly, and 3-palmitoyl-(+)-catechin
completely, prevented this decrease in fatty acid oxidation, at the 
same time as preventing the ethanol-induced hepatic redox-state
changes, as already described for (+)-catechin in the previous
experiment (Table 5.1). With respect to the comparative ability of
(+)-catechin and 3-palmitoyl-catechin to reverse the ethanol-induced 
hepatic changes, the latter compound, in spite of being given at a 
lower dose than that of the parent drug, appeared to be slightly more 
effective than (+)-catechin itself at correcting both the redox-state 
change and the decreased fatty acid oxidation. As previously, 
neither (+)-catechin compound had any significant effect on any of the 
parameters studied when administered alone, and the drugs did not 
influence serum ethanol concentrations in ethanol-dosed rats.
5.4 DISCUSSION
These experiments have confirmed the findings of Gajdos et al 
(1972) that (-f)-catechin is able to correct the altered hepatic 
redox-state (NADH:NAD ratio) resulting from ethanol administration, 
and shown that 3-palmitoyl-(+)-catechin also exerts this effect.
3-Palmitoyl-(+)-catechin is, in fact slightly more effective than 
(+)-catechin in this respect, in spite of the lower dose employed.
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As was discussed in the previous chapter, this is probably due to its 
more favourable pharmacokinetic characteristics. In this experiment, 
only the lactate/pyruvate ratio was studied, being an indicator of the 
cytosolic NADH:NAD ratio, although it is possible that the drug also 
reverses disturbances in the mitochondrial redox-state as well. It 
is thought that the nicotinamide adenine dinucleotides do equilibrate 
between the two cell compartments, through the various shuttle systems 
involved in NADH transport into the mitochondria, so that a change in 
the cytosolic redox-state will be reflected in the mitochondria 
(Baroana and Lieber, 1979). Subsequent studies reported in this 
thesis show that correction of the hepatic redox-state changes after 
ethanol administration by Naloxone involves normalisation of both the 
cytosolic and mitochondrial redox-states (Chapter 6).
It is not clear from these experiments exactly how the
(+)-catechin compounds achieve their correction of the redox-state 
changes. Gajdos et al (1972) proposed that (+)-catechin may
stimulate glycolysis, generating pyruvate to reoxidise NADH by way of 
the lactate dehydrogenase reaction. Some of the present results 
support this view, since (+)-catechin did not fully restore 
&C-glycerophosphate levels to normal in ethanol-treated animals, thus 
possibly indicating that concentrations of the glycolytic intermediate 
dihydroxyacetone phosphate may be increased, this resulting in 
elevated -glycerophosphate levels, even though the redox-state had 
been corrected. Conversely, if (+)-catechin influences the
redox-state through stimulating pyruvate production, one might expect
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to see, if not increased pyruvate, then definitely increased lactate 
levels, over and above those seen in animals given ethanol alone, when 
(+)-catechin is given with ethanol. This was not found to be the 
case, however, so some doubt still surrounds this possible mechanism 
of redox-state modulation by the drug.
Alternative mechanisms for the correction of redox-state changes
by (+)-catechin include direct, non-enzymatic oxidation of NADH, as is 
carried out by hydrogen acceptors such as Methylene Blue, or increased 
NADH oxidation in the mitochondria. The latter mechanism is a
possibility, since bioflavonoids have been observed to have an
uncoupling effect on oxidative phosphorylation in isolated
mitochondria (Gajdos et al, 1972). Both of these mechanisms seem a 
little unlikely, since they might result in greatly decreased hepatic 
ATP levels, whereas (+)-catechin has in fact been reported to increase 
hepatic ATP concentrations (Gajdos et al, 1972). Serum ethanol
measurements made in these experiments indicate that (+)-catechin does 
not prevent the ethanol-induced redox-state changes and effects on
lipid disposal through inhibition of ethanol oxidation, as is the case 
for the alcohol dehydrogenase inhibitor pyrazole (Blomstrand et al,
1973).
The (+)-catechin compounds also reversed nearly all of the 
ethanol-induced alterations in hepatic fatty acid disposal in these
experiments. Ethanol caused a significant increase in hepatic
triglyceride, in association with increased palmitate esterification
in vivo, and decreased palmitate oxidation by liver slices in vitro,
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these latter changes possibly accounting for the hepatic lipid 
accumulation. It could be assumed that reversal of these
abnormalities in lipid metabolism by the (+)-catechin compounds is the 
mechanism by which the compounds lower the extent of the 
ethanol-induced hepatic triglyceride accumulation already described 
(Chapter 3). Inhibition of triglyceride accumulation in the present 
study was however, not statistically significant due to the wide 
individual variation in the animals studied.
The main question that is posed by these results, is whether the 
reversal of the fatty acid disposal alterations after ethanol 
administration by (+)-catechin is the direct result of correction of 
the redox-state (NADrNADH ratio), along with the implications of this 
for intermediary metabolism as already discussed (Section 1.2.3.). 
It is not clear whether other substances which prevent ethanol-induced 
hepatic triglyceride accumulation in the acute situation also affect
fatty acid utilisation in the same way as which (+)-catechin does, and
whether they also mediate these effects through modulation of the 
hepatic redox-state. It should be remembered that, in the present 
experiments, decreased fatty acid oxidation was found in liver tissue 
taken from ethanol-dosed animals, no ethanol being added to the 
incubation medium. Thus, this alteration in lipid disposal may not
be the consequence of direct, acute actions of ethanol (ie: 
redox-state changes) in the liver. In order to resolve these
problems, in the succeeding chapter, the effect of sorbitol
administration on hepatic lipid disposal has been studied, since this
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substance also induces a redox-state change. In addition, the effect 
of correcting the hepatic redox-state change after ethanol dosing with 
Naloxone, as reported by Badawy and Evans (1981) and Badawy and Aliyu 
(1984), on the various parameters studied here, has been determined 
(Chapter 6). These studies should clarify the true relationship
between redox-state changes and the triglyceride accumulation after 
ethanol dosing, and indicate the importance, or otherwise, of 
(+)-catechin's effects on the redox-state in the mechanism of action 
of this drug.
In view of the antioxidant properties of the (+)-catechin 
compounds described in Chapter 4, the influence of synthetic 
antioxidants on fatty liver production has been determined (Chapter 
7).
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Chapter 6
MODULATION OF TtC REDOX-STATE: INFLUENCE ON ACUTE AND CHRONIC
ETHANOL-INDUCED tePATIC LIPID ACCUMULATION
6.1 INTRODUCTION
Two approaches have been adopted here to attempt to answer the 
question posed at the end of the previous chapter, as to whether 
correction of the redox-state by the (+)-catechin compounds is 
responsible for the changes in hepatic lipid disposal after ethanol 
dosing. Firstly, the effect of acute sorbitol dosing on the hepatic 
redox-state and fatty acid utilisation has been determined, since this 
carbohydrate elicits a redox-state change, similar to that caused by 
ethanol, through its metabolism by sorbitol dehydrogenase. A dose of 
sorbitol, isocaloric to the ethanol dose employed in the previous 
experiments, was used and glucose-dosed animals served as controls.
Secondly, the influence of the opiate antagonist, Naloxone, on 
hepatic lipid utilisation after acute ethanol administration has been 
investigated. This drug is known to correct the ethanol-induced
redox-state change, without inhibiting ethanol metabolism (Badawy and 
Evans, 1981; Badawy and Aliyu, 1984). These experiments were 
designed to give information on the relationship between the 
redox-state changes and altered hepatic lipid disposal after acute 
ethanol administration. Since data obtained on fatty acid oxidation
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by liver slices taken after ethanol dosing may not be a true 
representation of events occurring in vivo, as sorbitol or Naloxone 
were not added to the incubation medium in these experiments, some in 
vitro studies were also carried out. These compared the effects of 
sorbitol and ethanol, added to liver slice incubations, on fatty acid 
oxidation and esterification, and related these parameters to 
redox-state changes in the in vitro assay system.
These acute studies should indicate the role of the (+)-catechin 
compounds' effects on the redox-state in preventing the acute 
ethanol-induced lipid accumulation, as already described. In order 
to establish whether these properties of (+)-catechin and 
3-palmitoyl-(+)-catechin might afford protection against fatty liver 
in the chronic ethanol-feeding model, an attempt has also been made to 
modify the redox-state under the latter experimental conditions. This 
was achieved by observing the influence that Methylene Blue has on the 
development of fatty liver after chronic ethanol feeding.
Methylene Blue is a hydrogen acceptor which carries out 
non-enzymatic oxidation of NADH and NADPH in vivo, so that some degree 
of correction of redox-state changes during ethanol ingestion can be 
achieved (Hrushesky et al, 1985). An attempt to access the influence 
of Methylene Blue, as well as another hydrogen acceptor, Menadione, on 
chronic alcoholic fatty liver was made by Lieber and DeCarli (1966) in 
their study on hepatoprotective agents. They found that neither 
compound had any protective effect against hepatic steatosis, although 
no redox-state measurements were made, and the effects of Methylene
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Blue alone on hepatic lipids were not fully reported. Thus, in the 
present experiments, the Lieber and DeCarli (1966) study has been 
repeated, using a similar level of supplementation of the 
alcohol-containing liquid diet with Methylene Blue, but, in addition, 
redox-state measurements have been made, and an appropriate, pair-fed, 
Methylene Blue-treated control group employed. One of the possible 
consequences of the mechanism of action of Methylene Blue, is that 
non-enzymatic oxidation of NADH and NADPH may cause a short-fall in 
ATP synthesis in the mitochondria, as well as possible affecting 
reduced glutathione concentrations, due to a decrease in NADPH to act 
as a cofactor for glutathione reductase. Thus, both ATP and reduced 
glutathione (GSH) concentrations have been measured in this study to 
determine whether any effects of Methylene Blue on these parameters 
might affect hepatic function, and the susceptibility of the animals 
to hepatic damage caused by ethanol.
6.2 METHODS
6.2.1. Acute in vivo studies:
Male Wistar Albino rats (University of Surrey strain, 180-220 g) 
were used. They were starved for 24 hours prior to receiving either 
ethanol (2 g/kg i.p. as a 20% (w/v) solution) or isocaloric sorbitol 
(3.5 g/kg i.p. as a 35% (w/v) solution). Saline served as the
control substance in the case of ethanol-dosed animals, whereas 
glucose was used as a control in the sorbitol experiments. Naloxone
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hydrochloride was dissolved fresh in sterile saline and given 1.0
hour, and, where appropriate 2.5 hrs., after ethanol administration (2
mg/kg i.p.). Ninety minutes after administration of either ethanol
or sorbitol, animals were injected with [U-^C] palmitic acid (1
pCi/100 g b.w.) and killed 10 mins. later for the determination of
radioactivity incorporated into hepatic lipids, as described
previously (Section 5.2). Alternatively, animals were sacrificed at
90 mins. for the preparation of liver slices which were then incubated
for 90 mins. in Krebs-Hanseleit buffer (pH = 7.4) containing 1 pCi 
_ 14 i
albumin-bound LI- C] palmitic acid, as described in Section 2.5.2. 
Freeze-clamped liver samples were obtained at sacrifice for the 
determination of the hepatic lactate, pyruvate, ^-glycerophosphate, 
3-hydroxybutyrate and acetoacetate cconcentrations as described 
previously. ATP was assayed using kits supplied by BCL Ltd.
Hepatic triglycerides were measured by the method of Fletcher (1968), 
as already described (Section 2.3.2.), at 1.5h and, in the Naloxone 
studies, also at 3.Oh after ethanol dosing.
6.2.2. In vitro studies:
Liver slices were prepared from male Wistar albino rats after 
an overnight fast, and incubated in Krebs-Hanseleit bicarbonate buffer 
(pH = 7.4) containing 1 pCi albumin-bound [l-^C] palmitate as 
described previously (Section 2.5.2.). Glucose, fructose, sorbitol 
or ethanol were added to the incubation medium at concentrations 
indicated on the Results tables. At one hour after the start of the 
incubation, 1.0 ml of incubation medium was removed through the septum
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cap of the incubation tube, using a disposable syringe, immediately 
mixed with 1.0 ml ice-cold IN perchloric acid, and centrifuged in the 
cold. Aliquots of the supernatent were used for the assay of lactate 
and pyruvate using kits supplied by BCL Ltd. (cat. no. 124842 and 
124982 respectively). The incubation was stopped with 1M citric
acid, and evolved determined as described previously (Section
2.3.2.). The incubation medium was homogenised, and a 1.0 ml portion 
of 'homogenate' was extracted with 3.0 mis chloroform:methanol (2:1) 
on a roller mixer for 20 mins., and the extract filtered through 
Whatman No.l filter paper. The residue was then extracted with 2.0 
mis chloroformrmethanol (2:1), filtered, and this second extract 
combined with the first one. The Folch washing step was then carried 
out (Section 2.3.1.), the extract dried down under nitrogen, and the 
lipid classes separated by thin-layer chromatography (Section 2.3.1.). 
Radioactivity incorporated into triglycerides during the incubation 
was then determined as described previously (Section 2.3.1.).
6.2.3. Effect of Methylene Blue on Chronic Alcoholic Fatty Liver: 
Male Wistar Albino rats (130-160g initially; University of
Surrey strain) were used. For the first four days of the study all 
animals received the control liquid diet containing no ethanol, that 
has been described in detail previously (Section 2.2). For the next 
six days of the study (days 5-11) ethanol was introduced into the diet 
as 20% of the total calories, and pair-feeding was commenced as 
described in Section 2.2. For the remainder of the study (days
12-30), ethanol was given as 36% of the total calories in the liquid
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diet, control animals being pair-fed diet in which the ethanol 
calories were replaced by glucose. One group each (n = 12 rats per 
group) of the ethanol-fed and the pair-fed control animals received 
liquid diet supplemented with Methylene Blue at the same concentration 
as that employed by Lieber and DeCarli (1966), namely 130 mg/1 diet. 
Methylene Blue supplementation was commenced on day 5 of the study, 
and the average daily intake using this method of administration was 
found to be 42 mg/kg/day. All diets were prepared fresh daily, and 
dietary intakes recorded daily throughout. Body weights were
recorded every two days.
Assessment of the hepatic redox-state: On days 12 and 27 of the
study, three animals from each treatment group were killed at midnight 
so as to assess the redox-state at a time when the animals were 
maximally intoxicated from ingestion of the ethanol-containing liquid 
diet. Portions of liver were freeze-clamped in situ within 10-12s of 
sacrifice and ATP, o£ -glycerophosphate, lactate, pyruvate,
3-hydroxybutyrate, and acetoacetate concentrations measured in the 
frozen tissue as described previously (Section 2.4). Remaining liver 
tissue was homogenised in 0.25M sucrose and assayed for triglycerides 
(Section 2.3). A blood sample was also collected from the necks of 
the animals for serum ethanol analysis by head-space gas 
chromatography (Section 2.6).
On day 30 of the experiment, the remaining animals in each group 
were anaesthetised with diethyl ether, blood collected by closed 
cardiac puncture snd serum prepared. After sacrifice, livers were
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excised, rinsed, blotted, weighed and a portion placed in
formal-saline for histological assessment using haematoxylin + eosin 
and Oil Red 'O’ staining methods. Remaining liver tissue was
homogenised in ice-cold 0.25M sucrose containing 3mM EDTA, and a
portion frozen immediately in liquid nitrogen for the determination of
reduced glutathione. Total hepatic lipid and triglycerides were
determined as described above. Serum was assayed for ethanol by 
head-space gas chromatography (Section 2.6) and GLDH activity was 
determined using kits supplied by BCL Ltd (Section 2.10). A 
modification of the method of Bernt and Bergmeyer (1974) was used to 
assay reduced glutathione (GSH) in liver homogenates (Section 2.9.3).
6.3 RESULTS
Results of the in vitro liver slice studies are shown in Table
6.1. The presence of ethanol in the incubation medium, at 20 and 40
mM concentrations, decreased the oxidation of [1-^C] palmitate to 
14
CO^ by 22% and 43% respectively. Addition of sorbitol to the
medium caused an increase in the lactate/pyruvate ratio slightly
greater than that caused by either 20 mM or 40 mM ethanol, but did not
r 14 timpair the oxidation of LI- C] palmitate. On the contrary, fructose 
and sorbitol enhanced this oxidation. Incorporation of palmitate 
into triglyceride was increased by sorbitol, although the most marked 
rise was seen after the addition of 40 mM ethanol to the incubation.
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In the in vivo studies, administration of Naloxone, one hour 
after ethanol, prevented the disturbances in the hepatic cytosolic and 
mitochondrial redox-states caused by ethanol, measured as the 
lactate/pyruvate and 3-hydroxybutyrate/acetoacetate ratios 
respectively. This correction of the ethanol-induced redox-state
changes by Naloxone was not associated with any significant decrease 
in the hepatic triglyceride accumulation measured either 1.5 hr or 3.0 
hr after ethanol (Table 6.2).
Naloxone had an effect on palmitate oxidation when liver slices 
taken from animals treated with this drug alone were studied in vitro. 
This resulted in an increased esterification of palmitate into 
triglycerides in vitro. While liver slices from ethanol-treated rats 
showed a lowered oxidation of palmitate, and increased incorporation 
of palmitate into triglycerides, these phenomena were not reversed by 
Naloxone pre-treatment (Table 6.3).
Experiments on the hepatic uptake of palmitate in vivo showed 
that ethanol administration caused increased incorporation of this 
fatty acid into total hepatic lipids and triglycerides. This effect 
was not influenced by Naloxone treatment, despite the correction of 
the redox-state changes by the latter compound.
Sorbitol administration produced a significant increase in the 
hepatic lactate/pyruvate ratio, similar to that observed after
ethanol, whilst also causing a 200?o increase in the hepatic 06-glycero 
phosphate concentration. Sorbitol also caused an increase in the
hepatic 3-hydroxybutyrate/acetoacetate ratio, although this was not
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TABLE 6.4. EFFECT OF SORBITOL ON THE HEPATIC REDOX-STATE AND LIPID
UTILISATION IN THE RAT
Treatment
Parameter Glucose Sorbitol
Liver
Lactate/Pyruvate 20.1+2.2 42.0+10.7*
3-Hydroxybutyrate/Acetoacetate 3.15 + 0.83 4.97 + 2.00
C)L -Glycerophosphate
(nmol/g liver) 98 + 11 294 + 22*
ATP (nmol/g liver) 3986 + 525 3102 + 193
% injected [U-^4C] 8.0 + 1.4 8.9 + 0.9
palmitate incorporated into 
liver lipids
[U-14C] Palmitate 67.3 + 11.6 103.9 + 45.5
incorporated into liver
triglycerides after
in vivo injection 
_2
(dpm x 10 /g liver)
[1-14C] palmitate 17.9 + 2.3 18.7 + 5.6
oxidised to ^^CO^ in liver 
slice incubations 
(dpm x 10 /g liver)
[1-14C] Palmitate 51.9 + 21.2 123.7 + 19.2*
incorporated into
triglycerides in liver
slice incubations
(dpm x 10 / liver)
Liver Triglyceride (mg/g) 8.8 + 1.6 9.7 + 2.2
90 mins after administration of glucose or sorbitol (3.5 g/kg i.p.), 
animals were sacrificed, freeze-clamped liver samples taken for metabolite 
determinations, and liver slices prepared for incubation with albumin-bound 
[1-14C] palmitic acid. In experiments where in vivo incorporation of 
[U- C] palmitate was measured, the label was injected (1 p.Ci/100 g b.w.)
90 mins after glucose or sorbitol dosing and animals sacrificed 10 minutes 
later. Values are means + 5.D. n = 5 rats per group. * = p < 0.001 
vs. glucose group
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statistically significant due to the wide individual variation in the 
extent of this effect. These changes in the hepatic redox-state 
observed after sorbitol were not associated with an increased 
incorporation of [U-^C] palmitate into liver lipids or triglycerides, 
or increased hepatic triglyceride concentrations. The oxidation of 
palmitate by liver slices from rats dosed with sorbitol was not 
different from that obtained with control animals which received 
glucose. Sorbitol did, however, cause increased esterification of
palmitate into triglycerides in these incubations (Table 6.4).
Various biochemical components associated with the hepatic 
redox-state were determined during the chronic Methylene Blue 
experiment, and the results are shown in Table 6.5. At the beginning 
of administration of 36% of the total calories as ethanol (day 12), 
ethanol-fed animals showed 154% and 249% increases in the 
lactate/pyruvate and 3-hydroxybutyrate/acetoacetate ratios 
respectively compared with their pair-fed controls. Ethanol caused a 
65% increase in the hepatic ^(-glycerophosphate concentration, but did 
not affect hepatic ATP concentrations at this time point. Methylene 
Blue alone did not affect any of these parameters in pair-fed controls 
at this stage of the experiment, but significantly reversed some of 
the redox-state changes observed in ethanol-fed animals. Partial 
correction of the lactate/pyruvate ratio was achieved by Methylene 
Blue, whilst the 3-hydroxybutyrate/acetoacetate ratio, and 
c/. -glycerophosphate concentrations were returned virtually to 
control values.
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After 16 days of ethanol feeding (ie: day 27 of the study), the 
redox-state changes observed in the ethanol-fed rats were less marked 
than at day 12, the increases in the lactate/pyruvate and 
3-hydroxybutyrate/acetoacetate ratios being 59% and 38% when 
ethanol-fed rats were compared with their pair-fed controls. The
hepatic o(-glycerophosphate concentration was increased by 37% in 
ethanol-treated rats. The ethanol-induced increase in the
3-hydroxybutyrate/acetoacetate ratio was not statistically significant 
at this time point, possibly as a result of the small number of 
animals studied. Once again, Methylene Blue corrected these
redox-state changes in ethanol-fed animals, although the effect on the 
lactate/pyruvate ratio was not statistically significant. Ethanol
alone did not affect ATP concentrations at day 27, whereas Methylene 
Blue caused a slight decrease in this parameter in both controls and 
ethanol-fed animals. Serum ethanol concentrations were unaffected by 
Methylene Blue on both day 12 and day 27 of the study.
Hepatic concentrations of individual redox-pair metabolites 
during the study are shown in Table 6.6. Methylene Blue alone
increased lactate and acetoacetate concentrations on day 12 of the
study, although no effect was observed on day 27. Hepatic lactate 
and pyruvate concentrations were consistently lower in the ethanol-fed 
animals. Methylene Blue corrected the lactate/pyruvate and
3-hydroxybutyrate/acetoacetate ratios in ethanol-fed animals on day 12 
through increases in hepatic pyruvate and acetoacetate concentrations, 
and by decreasing the 3-hydroxybutyrate concentration. Ethanol
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feeding caused significant increases in hepatic 3-hydroxybutyrate 
concentrations at both time points studied.
Hepatic triglyceride content at these time points in the study 
are shown in Table 6.7. On day 12 there was no significant
difference in triglyceride contents between any of the groups, whereas 
on day 27, there was a significant increase in the ethanol-fed rats, 
irrespective of whether they had received Methylene Blue supplements.
Hepatic lipid, body weight, ethanol intake and other 
determinations made at the end of the study are shown in Table 6.8. 
There was no difference in body weight gain between any of the groups 
and Methylene Blue did not affect ethanol intake. Ethanol feeding 
caused slight enlargement of the livers, which was not prevented by 
Methylene Blue supplementation. Ethanol feeding caused 89% and 196% 
increases respectively in the total hepatic lipid and hepatic 
triglyceride concentrations, which were not significantly influenced 
by Methylene Blue. Ethanol caused a slight decrease in the reduced 
glutathione content of the liver but, again, this was not affected by 
Methylene Blue. Serum ethanol concentrations and the elevated serum 
glutamate dehydrogenase activities observed in ethanol-fed animals 
were also not affected by Methylene Blue. Histological examination 
of liver tissue revealed the presence of the characteristic 
centrilobular fatty infiltration of alcoholic steatosis in all the 
ethanol-fed animals, the extent or intralobular distribution of the 
accumulated fat not being affected by Methylene Blue supplementation.
TA
BL
E 
6.
5 
EF
FE
CT
 
OF 
ME
TH
YL
EN
E 
BL
UE
 
SU
PP
LE
ME
NT
AT
IO
N 
OF 
ET
HA
NO
L-
CO
NT
AI
NI
NG
 
LI
QU
ID
 
DI
ET
S 
ON 
TH
E 
HE
PA
TO
CE
LL
UL
AR
 
RE
DO
X-
ST
AT
E 
DU
RI
NG
 
CH
RO
NI
C 
ET
HA
NO
L 
FE
ED
IN
G
CO
Oc
CO
JZ
4-3
LxJ
+
+ CD
rH-f- 00 COCN Os • • O
Csl IA  rA  CD On
t
a
i a +  a  vo
O  O  • • On
IA  Csl IA  CD IA
+ 1 +1 +1 +1 +1 +1 +1 +1 +1 +1
f s  lA  CO fA  N
VO CD • O  CO
On csj i—i • i—I
CSJ csj rA
< t  CD <J- rH  CSJ
VO O  • >—I O
VO CSl rH  • CSl
CSJ CSJ CSl
CJ
*
*  o
O  *  CD VO 
lA |s . . <J-
rA  csj <t csj rA
=r-
*  UA
LA *
a  • • csj
LA rH (A CD la
+ I+ I+ I+ I+ I  +1 +1+1 +1+1
A  H  lA  M A
lA  r— I • r—)
CO IA  rH  • <H
csj (A  CO
ON O  CO CD CD
CD On • IA  O n
LA CSJ VO • <H
rA  csj rA
Cl
X CO
o X
DC
CD +
H
o
f-l
4-3
c
o
C_J
*
CO
v_'
CSJ * ON
rH 00 a A <r
CD rH • • ON A « •
O n rA <D CD rH <H CSJ o
+  1 +11 + l+l « + l+l +  1 +
CSJ A iH CO ON rA <J- ON
VO CD • ON O n . A
CD CSJ A . CO <H LA .
IA •H rH CSJ <H rH
O O
rH A  ON rH rH -e A
O CO rH • • rH CO • •
f-i rH Csj KV »— ! CSJ CSJ CSJ O
4-3
c
Q +  1 +1 + +1 * +  1 +1 +1 +1
CJ ■— 1 On <t LA CSJ CO O n
ON CO • rA CD <H • rA
ON rH CSJ • <t csj VO •
c CSJ rH CSJ rA rH Csj
4J
c
CD
E
CD
f-iZJ
cn
CO
CD
0
4-3
CO
JZ
CL 0  
0  4-3
0 0 
JZ >
^  CL ZJ 
cn o  f-i\  H > 
rH 0  Q  
CD CJ \  
E  5s 0  
C  '— I 4-J
^  cr> 01 4-3 
CL O  I— 'sj 0 
<-r I i
0
4-3
0
4-3
0o ^
0 <H 
O  E
4-3
0 CD 
O  CD 
0 rH
w
0 CD 
4-3 E  0 ^  
f4
5s rH 
4-3 O  
ZJ CZ 
JD 0 
5s JZ
X  4-3
0 0 
f-l
XI E  
5s ZJ
ZC f-l1 0 
rA UD
0
4-3
0
JZ
CL 0  
W -P  O 0
JZ 
r-N Q .
cn o  A  uiH 0o o
E  5s 0 
4-3 
CD 0  
I 4-3
0
0
4-3
0
4-3
00 r'-'N 
0 »H 
O  E  
4-3
0 CD 
0 CD 0 iH
0 CD 
4-J E
0  s_x 
f-l
X  rH 
4-3 O  
ZJ C  
JD 0 
5S JZ 
X  4-3
0 0u
X  E
5s ZJ 
ZZ f41 0
rA cn
L—
O 5SX
Os ZJ CSJ A
0  4-3 «H CN
Q  cn
o
JZ
4-3
c
•H
C
O X
0
4-3 JD
• JZ *H
r-H CD t4
o •H O
c C 0 •
0 X 0 0
JZ •H X ZJ
4-3 E rH
0 0 CO
4-3 0
E 0 /-s 0
O 0 <z c
f4 X 0 v_/ 0
tl_ 0 4-3 <H
rH •H . 5s
X rH rH 0 JZ
0 •H O > 4-3
> V JD 0
•H 0 rH *'
f-i 0 4-3 CD
0 f-l 0 CD
X 0 E • CD
3 O L_
0 f-i
0 0 O V ..
E rH U- c0 CL o
5s E X •H
cn •H 0 II 4-3
f4 C 0 0
0 <r 5s * •H
c rH >
0 0 0
CZ f-i
<H . 0 • JD
0 5s N JD
4-3 cn 0 D - <
O f4 f-l ZJ
4-3 0 0 o
c E f-l
0 0 CD •
JZ 0 /^N
4-3 rH 0 f-i CJ
O rH 0 >_/
u~ c CL CL
o 0 E .
JZ 0 0 0
o° 4-3 0 4-> >
VO 0 0
IA f-i f-l rH
0 0 CD
JZ JZ > rA •
o 4-3 O
•H rH n
JZ X V
E 0 X c
O 0 v_/ CL
C 0 CL
•H r-H E II
CL 0
4-3 0 rH •-f-
0 f-l O  Q - i-
•H 1 •
X 0 0 cn
0 N
X O 0 +  1k~'
•H O 0 CJ
ZJ ZJ f-i cz — y
CT rH L_ 0
•H CD 0 •
rH X E on
JZ c >
0 o 0 0
•H 0 rH
t*_ JZ »v CD
O 2 5s C CD
X s •
4-3 C D c CD
f4 •H -P JZ
0 0 0 V
CL 4-3
0 0 0 CL
0 •H JZ f-l
0 X 4-3 0 II
<— 1 X U— 0+
o 0 o 4-3
cz > i—1
0 •H A ZJ
JZ 0 CSJ 0
4-3 O 0
0 0 5s CZ <
f-i 0
JZ X
4-3 0 •
•H rH f-i . 0
3 O o c >
f4 o
X 4-3 CSJ •H rH
0 c rH 4-3 CDL— o CJ .
CJ 5s 0 CD
0 0 0
fH X X V
0 0 0
2 L— f-i X CL
1 0 o
0 f-i JZ JZ II
4-3 •H 4-3 4-3
0 0 •H 0 *
OZ 0l 0 *
TA
BL
E 
6.
6. 
EF
FE
CT
 
OF 
ME
TH
YL
EN
E 
BL
UE
 
SU
PP
LE
ME
NT
AT
IO
N 
OF 
ET
HA
NO
L-
CO
NT
AI
NI
NG
 
LI
QU
ID
 
DI
ET
S 
ON 
TH
E 
HE
PA
TI
C
CO
NC
EN
TR
AT
IO
NS
 
OF 
RE
DO
X 
PA
IR
 
ME
TA
BO
LI
TE
S
CD
□Dr
CJ
CJ
CD
CO
0\ VO N  O
□  <r o- co
□  cst
*
CM *
CD * m  <j- 
r—( On On r—I
NO KN UN I 
KN CM COr- m
*<t *
o  h  o\Lf\ kn m <—I
O n r^ > co 
in NO <t ON 
CO rH rH 
CM
O H N O  
IA CM m  CM
<r m  o n  <h  
<f cm h  in 
m  <h  iH
P"
CD CM O n 1^ - 
rH t— | CM r-H
+ l + | + | + |  + |+ | + | + |
CO O n n o  m  
c m  m  co
CO <H
* * *
03 H  H  CM 
On iH  KN rH
+ I+I+1+I +I+I+I+I
cm m  m
NO CM O  NO 
NO CM
m
on on m
n  CM CM H
+I+I+I+I +I+I+I+I
< t  H  On ON 
i—i m  in co 
O  H  H  
CM
inN<t 0 <f 
m  rH CM H
+ I+I+I+I +I+I+I+I
on i—-mi—i
m  m  cm m
NO i— I rH 
CM
0 0
4-> 44
CO CO
u Ll
>> >,
4-) 0 44 0
J 44 ZJ 44
X 1 CO JD CO
4-> >■* 4-J 5^44
c 0 X 0 0 X 0
0 0 4-> o 0 0 44 O o
E 44 CO u CO 44 0 Li CO
0 0 > TJ o CO > TJ o
(H 4-) D 44 D X 4 4
J Ll O Li X 0 CJ u X 00 0 0 >> 1 CJ CO X 1 CJ
0 > _j CL m < CL m «c
0 •H
L_
O *D
>> D  CM 
CO 4-> rH
CD CO
CM
0
C0
rH>>
JZ
44
0
CD
•H
> c
0 V—/
H
JD •
JD 0
<Z >
rH
□
CD
m •
• CD
NO
0
rH
V
CL
JD
CO II
h -
o
44
TJ
*
C CL
0 DJ
cn O
0 Li
«H cn
0 Li
X 0
44 CL
c 0
•H 44
c
0
Li
0
> m
•H
cn n
0 c
CO '—
0
u
CD
0
0
D
44 0
•H 0
D ■H
0 44
0
U •
U—
44
3
o
c
44
0
o 3
•H
0 cn
0  \
0 «H
Lt o
CL E
X C
0
TJ in
C
CO 0 .
Li
0 0 CJ
rH
•H 0
0 0 .
44 D 0
0 rH >
TJ 0
> rH
rH □
CO rH CD
44 iH .
c c CD
0
E V
•H
Ll . CL
0 0
CL Z3 II
X rH
Ld C 0+
TA
BL
E 
6.
7.
 
EF
FE
CT
 
OF 
ME
TH
YL
EN
E 
BL
UE
 
SU
PP
LE
ME
NT
AT
IO
N 
OF 
ET
HA
NO
L-
CO
NT
AI
NI
NG
 
LI
QU
ID
 
DI
ET
S 
ON
 
HE
PA
TI
C 
TR
IG
LY
CE
RI
DE
 
CO
NT
EN
T 
DU
RI
NG
 
CH
RO
NI
C 
ET
HA
NO
L 
FE
ED
IN
G
- 187 -
C7
CD
XI*H
f-l
0
CDi—
C7 •H
f-l
O
•H
44
CD
o|
CDzc
Ci
CD
CQ
Q.
0O
f4
CD
LT\
CO
+ 1
CJ\
o
CM
m
IA
+ 1
m
•
in
o
CM
+ 1 
O 
m<—i
m 
+ 1
CDc
*r"
CO
+1
O n
VO
+ 1
m
•
o
m
o
+ 1
CO
VO
o
+1
m
m
C"*
CM
COc
c
f-i o
o JC
li­ (!)
en 0
CD U
i— i 0
CL
E (!)
CO 44
CO f—1
X
o
(!)
0 0
Q-tr
E 
CD 
>— 1
CD . 0
1 m 0
0 . rH
N VO CD
0
0 0 0
f-i r—1 C
ii- X 0
0 i— l
co f— X
ra JZ
o 44
0 44 0
E
•H X .
44 c ~ CL
0 CD 0
0 cnsz o
E 0 f-i
0 i— i
CO c
c O  00 •H •H E
JC 44 0
4-3 X 0 (!)
0 •H
4-> X >  f-i0 •H 0 O
U f-i fi-
c o JO0 (!) JO 0
Jar 0 <  0
0 X r—1
44 0
(!) >
0 0 •
0 CM
CO X Q. •—1
(!) 0 0
•H f4 O
44 0 f-i 0
Cl cn x
£-1 0
0 (4 f-i (!)
> CL0 0
•H CL (!)
i—1 0 f4
f-i (!) 0
C 0 44 >
o 2 0
0 (!)
t-i X
c
X 44 m  0
0 C
E 0 ii ^
E <
0 0 c  ^
f4 f-i >._/
0 0 .
CO (!)
0 >
(!) 0 .
C E  O  1— 1
o • CD
•H 0 cn o
44 44 .
0 0 + |o
C 44
•H (!) C  V
E 1 0
U X 0 CL
0 o E
44 X II
0 0 (!)
o f-l 0 *
TA
BL
E 
6
.8
. 
EF
FE
CT
 
OF 
ME
TH
YL
EN
E 
BL
UE
 
SU
PP
LE
ME
NT
AT
IO
N 
OF 
ET
HA
NO
L-
CO
NT
AI
NI
NG
 
LI
QU
ID
 
DI
ET
S 
ON 
TH
E 
HE
PA
TI
C
LI
PI
D 
CO
NT
EN
T 
AF
TE
R 
CH
RO
NI
C 
ET
HA
NO
L 
FE
ED
IN
G
m5r
O
z
CO
SZ
44
LJ
Q
**
lA <f H  
• • •
On CM O
+ 1 +1 +1 
VO CO IA. . r-
fA .
CO '— I
** *
On * O  
. r- rH
*LfA
r—I VO <“ 1 VO LA
+ 1 +1 +1 +1 +1
H  lA CO CO fA 
* • LA LA .
O n CO • i— ) O n 
i a  < j-
o_
IDCO
VC
CD
O
z
COSI
44
Lul
CJ
CO
o
u4->
z
o
CJ
*
O  IA
• O n rACSJ . .CM IA □
+ 1 +1 +1
O H < r  . *VO
O  l a  •
CD H  n
<ro <t
IA O
+ 1 I +1
NO
□
ON IA
* ** * +
CO IA <— I *
• • CO CO
CD IA • IA • 
H  H  O  CO UN
+ 1 +1 +1 +l+|
A  H  H  CD <t 
. * Cvl VO •
O  VO * r-t O n 
O n <t
CO
< t  CM CVJ 
• • •
CO VO Q
+ 1 +1 +1 I
LA CO VO . • <t
CVJ ON •
LA rH LA
+1
CD
OU
z
o
CJ
44
z
CD
E
0
f-i
D
CO
CO
0
<—1
CO «—! .VO <f LA
. . o • • .
CO □ rH CO o <H
+ 1 1 +1 + 1 +1 + 1 + 1
<t On o vO i—i T"-
• CVJ . • f-l .
VO CO LA • CVJ
on rA «—| vO
/-s 0
44 \
0 V ? rH —s
z cn O 1—1
•H .y >> E EU \  -o dD >> o V,_-*C0
XJ CD JO o
*o *—•. CDrH
. \  01 0 0  C \
44 CD \ \  0 03 ^  □ 0 01 *H E - V
a E E JZV_/rH
>> 0 .H '—^ 44 \
*D JC \ COrH ZD
O CO CD CD 0 44 o v_r
JO 44 *o *0 0 z
Z •H •H rH CODZ
Z " ' *H • CL f4 0JZ O
•H 0 4-> •H 0 44 _J
v' r—1 2 r—■!a *0 0 CJ
0 o >N 0
cm >> Z H U rH rH O E E
c *0 0 0 0 TO 0 0 0 0
a I £ > > 4->•H *0 t-i Hsi 44 44 -H •H O f-i 0 0 0
CJ CD LJ _1 H- 1— VC CO CO
0
0
rH
CO U-
O
0
Z
0 0
c H O r—1
E 0 0 rA
O rHClJZ
f4 44U-JZ 0 0 0
44 E *D r~
•0 0
0 s: CVJ ..> 0 m
•H •H v
f4 C - '-V
0 . o ..
*0 rH Z
0 0 o o
0 f-l c •HCO 0 0 0 44
2 z 44 SZ 0
0 c 44 •H
>N •H 0 >
0 rH 0 .
f4 o CD f4
0 z rH 0 JO<c
c 0 •H JO'— ^
0 JZ 0 >^ <c
44 *o 0 .
rH 0 f-l to
0 0 0 >
44 0 0 C .
osz0 0 /—\ LA
44 44 f4 0 . 0
0 f-i D O
0 *0 > •H o .
JZ 0 0 0 f-lo
44 a JZ 0
0 c 44 VC*_i—i0 f4
oCLU- 0Cl
0 0 oCl
f-t > I
vO •H to
rA 0 0 VO 44+torA 0sz O o f-ia U 44 0
•H 0 z VO .SZ i—1 •H ✓—s
s 0 1—1> I <\ •H
z SZ 0 0 Z
•H a
•H
E U
0 CO
44 JZ O f4 >
0 3 rA
•H rH U- .rH
*0 C o o O
•Hc_ .o
*0 oto CO .
•H 44 > s o
0 c 0 + 1
0 •H o *D V
•H *0 •H z
rH 44 O 0Cl
*0 0 CSJ 0
0 0
>
f4
44 f4
E I
C- •H c 0 to*
O 0a 0a 44U- 0 *
44 0 c 0 z
f4 f4 o s
0 o *D o .CL to 0 r~ r-\
rH 0 rH CO <
to O rH v_x
0 Ch 44 •H 0
44 0 f-i .
rH c 0 to
O o to 0 >
z o 44 f4 to
0 0 0 44 LAJZ *o •H 2 rH CVJ
44 0 *o ZJO
0 u- to to .
1 0 rH 0 O
c f4JZ 0VC
0 •H 44 E V> 0 •H
•H Cl. O Z Q.
0 44c
I
0 *o
f-i * 0 *D *
0 rH *0 . D
2 O *D 0 4 4c 0 V/to.to0 0
44 JZto>x 0D0 44 0 0 r~rHVC 0 3 *D 4 4 CO
6.4 DISCUSSION
The results of these experiments cast some doubts on the role of 
the altered hepatic redox-state as a mechanism of the acute and 
chronic ethanol-induced hepatic triglyceride accumulation. Data 
obtained from the studies in vitro (Table 6.1) suggest that there is 
no apparent association between the increased lactate/pyruvate ratio, 
and the decrease in palmitate oxidation in the presence of ethanol. 
Under these conditions, in vitro elevation of the cytosolic NADH:NAD 
ratio by either ethanol or sorbitol occurred in parallel with 
increased incorporation of palmitate into triglycerides. However, 
the fact that the higher concentration of ethanol (40 mM) was much 
more effective at increasing palmitate esterification, without further 
raising the lactate/pyruvate ratio above that found in the presence of 
20 mM ethanol, suggested that factors other than the redox-state 
alteration might be implicated. Experiments in vivo, with Naloxone, 
also support these conclusions drawn from the in vitro findings. 
Correction of the redox-state in ethanol-treated rats by Naloxone did 
not prevent the hepatic triglyceride accumulation, measured 1.5 hr 
after acute ethanol administration (Table 6.2). This may have been 
the consequence of administration of the drug 1.0 hr after ethanol, so 
that the redox-state disturbance in ethanol-treated animals prior to 
Naloxone administration could have contributed to the triglyceride 
deposition. Prolonging the period of study to 3.0 hr after ethanol, 
however, with a further Naloxone dose given at 2.5 hr, since the drug
- 190 -
has a short half-life in the rat (Weinstein et al 1974), still 
revealed that the drug did not prevent completely the increase in 
hepatic triglycerides caused by ethanol, although a non-significant, 
downward trend was observed.
The experiments on the in vivo incorporation of radio-labelled 
palmitate into hepatic lipids also indicate that the redox-state 
change following ethanol was not responsible for the observed increase 
in triglyceride synthesis (Tables 6.3 and 6.4). This probably cannot 
be attributed to any difference between the ethanol-treated and 
control animals in the specific activity of ^C-palmitate, since a 
dose of ethanol, identical to that used here, has been shown to have
no influence on the hepatic free fatty acid pool, serum free fatty
acid concentration, or the flux of fatty acids from the peripheral 
tissues (Abrams and Cooper, 1976a; Abrams and Cooper, 1976b). 
Naloxone treatment failed to reverse these ethanol-mediated chances in 
the in vivo incorporation of palmitate into liver triglycerides, 
whilst sorbitol only caused a small, non-significant increase.
Sorbitol also increased the -glycerophosphate concentration in
vivo, as was expected from the observed effects of this substance on 
the redox-state. However, this did not have much bearing on
triglyceride formation in vivo (Table 6.4).
The data obtained from experiments with liver slices taken from 
animals dosed with either ethanol or sorbitol, suggest that the 
redox-state does not influence the hepatic fatty acid oxidising
capacity. Sorbitol administration did not affect the ability of
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liver tissue to oxidise palmitate to CC^, when values were compared 
with those found with control animals which were given glucose. 
Interpretation of the results from Naloxone-dosed rats, on the other 
hand, presented a problem, since the drug alone tended to impair 
palmitate oxidation. This effect of the drug was also associated
with increased esterification of this fatty acid into triglyceride by 
the liver slices. This action of Naloxone did not appear, however, 
to influence incorporation of injected palmitate into liver lipids in 
vivo (Table 4). This observation raises the question as to whether 
the decreased fatty acid oxidation rate after ethanol reported here 
and previously (Lieber and Schmid, 1961; Ontko, 1973; Blomstrand et_ 
al, 1973) has any role in the hepatic triglyceride accumulation. 
However, in a recent study it was reported that administration of
4-pentenoic acid, a specific inhibitor of ^-oxidation, to rats 
increased hepatic triglyceride concentrations, the increases being 
quantitatively related to the degree of inhibition of fatty acid 
oxidation (Thayer, 1984).
The mechanism by which Naloxone corrects the ethanol-induced 
hepatic redox-state changes is not clear from this study, but in view 
of the lack of effect of the drug on ATP concentrations, non-enzymatic 
oxidation of NADH or simple uncoupling of oxidative phosphorylation do 
not seem to be involved. The apparent inhibition of oxidation by 
the drug could be a contributory factor, since this may cause sparing 
of hepatic NAD. However, no effect of the drug alone on the
redox-state was observed in control animals. It is clear from the
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blood ethanol data reported later (Chapter 8), that inhibtion of 
ethanol metabolism is not concerned with the action of Naloxone on the 
redox-state.
With regard to the decrease in palmitate oxidation by liver 
slices from ethanol-treated animals, the underlying mechanism may 
involve mitochondrial injury, rather than direct acute effects of 
ethanol, including changes in the redox-state, being implicated.
Such mitochondrial damage, as discussed earlier, could arise from
covalent binding of ethanol-derived acetladehyde with mitochondrial 
protein (Tuma and Sorrell, 1985), or peroxidative injury to the 
organelle (Rouach et al, 1983).
Some evidence for the latter mechanism being of importance comes
from the work described in the next chapter, in which antioxidants
have been found to counteract many of the altered patterns of fatty 
acid disposal and increased hepatic triglyceride levels after ethanol 
dosing. Furthermore, antioxidants achieved this without reversing
the ethanol-induced hepatic redox-state changes, adding more weight to 
the argument that ethanol-induced hepatic triglyceride accumulation
may not be related to the hepatocellular NADH:NAD ratio.
One possible consequence of the redox-state change that might 
contribute to the triglyceride deposition is increased fatty acid
synthesis resulting from increased NADPH levels (Lieber and Schmid,
1961). Although this has not been directly studied here, one recent 
study in which rates of lipogenesis were measured using tritrated 
water, showed that liver slices from ethanol-fed animals in fact
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showed lower rates of lipogenesis than those from control, pair-fed 
rats (Venkatesan et al, 1985).
The conclusions from these acute studies are similar to those to 
be drawn from the chronic Methylene Blue study. The results of the 
latter show that supplementation of ethanol-containing liquid diets 
with Methylene Blue can largely prevent the hepatocellular redox-state 
changes induced by chronic ethanol feeding in the rat. These 
redox-state changes are however, less marked than those that are often 
observed after acute ethanol administration to naive rats, and they 
become attenuated after long-term feeding, confirming previous reports 
(Domschke et al, 1974; Saluspuro et al, 1981). In this study, this 
attenuation of ethanol-induced redox-state changes between day 12 and 
day 27 occurred in spite of an increase in ethanol consumption by the 
animals in the intervening period, and the fact that serum ethanol 
concentrations were slightly higher at the later time point.
The mechanism by which Methylene Blue corrects the 
ethanol-induced redox-state changes is thought to be through 
non-enzymatic oxidation of NADH. This may, in turn, affect
availability of NADH for mitochondrial NADH oxidation and oxidative 
phosphorylation. This is indicated to some extent by the slightly
lower ATP concentrations found on day 27 in the Methylene Blue treated 
animals. This decrease was not sufficient, however, to cause any
evidence of deranged hepatocyte function, for example in the form of 
increased liver lipid contents or serum glutamate dehydrogenase 
activities, in control animals. Another possible consequence of the
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action of Methylene Blue might be decreased reduced glutathione 
concentrations as a result of lower NADPH concentrations to act as a 
cofactor for glutathione reductase. This, in turn, could possibly
affect the susceptibility of hepatocytes to injury from toxins such as 
ethanol. Acute injections of Methylene Blue can cause hepatic
glutathione depletion in mice (Hrushesky et al, 1985). However, in 
the present study there was no evidence of Methylene Blue 
supplementation of the diet affecting hepatic reduced glutathione 
concentrations in either controls or ethanol-fed animals.
The concentrations of the individual redox-pair metabolites 
(Table 6.6) show that the lower carbohydrate content of the
ethanol-containing diet causes decreases in the hepatic lactate and 
pyruvate concentrations when compared to the values obtained in 
pair-fed controls. Under these circumstances, there may be more
dependence on fatty acid oxidation for hepatic energy production, 
hence ketone body concentrations may increase simultaneously, 
providing that -oxidation of fatty acids to two-carbon fragments is 
not inhibited by ethanol. In this study, 3-hydroxybutyrate
concentrations were higher in ethanol-fed animals, but probably only 
as a consequence of the increased mitochondrial NADH:NAD ratio. 
Overall, taking this into account, the ketone body concentrations were 
comparable between the control and ethanol-fed rats, indicating that 
P -oxidation itself may not be affected by ethanol feeding. 
However, the complete oxidation of fatty acids to CO^ may be impaired 
at the tricarboxylic acid cycle stage, and thus be an important factor
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in the production of steatosis, as previously proposed by Lieber and 
Schmid (1961). This may arise after chronic ethanol intake through 
irreversible injury to the mitochondria (Cederbaum and Rubin, 1975), 
this being indicated in the present study by the elevated serum 
glutamate dehydrogenase activities in ethanol-fed animals, this enzyme 
being localized in the mitochondrial matrix.
The fact that Methylene Blue only caused partial correction of 
the cytosolic NADH:NAD ratio in ethanol-fed animals might indicate 
that the decrease in this ratio was a contributory factor in the 
production of steatosis. However, probably the most important
consequence of the decrease in this ratio, that in turn might 
influence triglyceride synthesis, is the increase in (^-glycero­
phosphate concentrations during ethanol feeding. In this respect,
concentrations of this metabolite were restored almost to control 
values by Methylene Blue without hepatic lipid content being 
decreased. The investigation of hepatic lipid concentrations clearly 
show that despite amelioration of the ethanol-induced redox-state 
changes, Methylene Blue does not prevent the fatty infiltration of the 
liver after chronic ethanol intake.
This experiment therefore suggests, as for the acute studies, 
that the increased NADH:NAD ratio resulting from ethanol oxidation is 
not the primary mechanism by which fatty liver is induced after 
long-term intake, and that the metabolic disturbances resulting from 
the redox-state change, including increased (^.-glycerophosphate
concentrations, may not be implicated in ethanol-induced steatosis.
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This view is supported by the finding in the present study that there 
was no significant increase in hepatic triglycerides on the day when 
the ethanol-induced redox-state changes were most marked (ie: day 12), 
whereas triglyceride accumulation was observed on day 27 when the 
ethanol-induced redox-state changes were attenuated.
In conclusion, these results confirm what was suspected from the 
acute experiments, namely that (+)-catechin and 3-palmitoyl-(+)- 
catechin do not protect against ethanol hepatotoxicity, either acute 
or chronic, through their ability to correct the ethanol-induced 
redox-state changes. It now seems likely that their mechanism of
action involves counteraction of some other ethanol-induced event, the 
most probable explanation in view of the cumulative findings, being 
inhibition of lipid peroxidation due to these drug's free 
radical-scavenging properties. In order to test this hypothesis, in 
the next chapter the influence of standard synthetic antioxidants on 
the redox-state, and hepatic lipid disposal after acute ethanol 
dosing, and the effect of antioxidant administration on the chronic 
ethanol-induced fatty liver has been studied, using identical methods 
to those employed here.
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Chapter 7
THE INFLUENCE OF ANTIOXIDANTS ON THE ^PATIC CHANGES AFTER ACUTE 
AND CHRONIC ETHANOL ADMINISTRATION
7.1 INTRODUCTION:
The work in this chapter aims to assess the possible role of the
antioxidant properties of the (+)-catechin compounds, as opposed to
their redox-state modulating properties, in preventing acute and
chronic ethanol-induced fat accumulation. This has been investigated
by examining the effects of synthetic antioxidants on the parameters
measured after acute ethanol administration in the experiments with
the (+)-catechin compounds (Chapters 3 and 3), namely, the
redox-state, triglyceride levels, and palmitate oxidation by liver
slices taken after ethanol dosing. Hepatic uptake and incorporation 
14of [U- CJ palmitic acid was not studied in these experiments, due to 
some uncertainty about the effect of injecting antioxidants as 
emulsions intraperitoneally on the hepatic uptake of fatty acids 
injected by the same route, as this has been shown to be an 
interfering factor in some studies (Abrams and Cooper, 1976b).
In addition to these experiments on the effect of antioxidants on 
the redox-state changes and lipid metabolism, the possible protective 
effect of these substances against the acute and chronic forms of
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fatty liver, has been assessed. This will allow direct comparison 
with the effects of the (+)-catechin compounds in these experimental 
situations, as described in Chapter 3. In the acute studies, the two 
antioxidants employed were Butylated Hydroxytoluene (BHT) and 
N,N'-Diphenyl-p-phenylenediamine (DPPD).
In the chronic fatty liver experiment, only DPPD was 
investigated, since long-term administration of BHT is known to be 
associated with hepatomegaly, enzyme induction and other effects which 
may complicate interpretation of the results in ethanol-fed animals 
(Babich, 1982).
7.2 METHODS
(i) Acute studies: BHT and DPPD were prepared as emulsions in 0.5%
(w/v) acacia gum containing 0.1?o (w/v) Tween 80, and given at doses 
of 400 mg/kg (i.p.) at 24 and 1 hours before ethanol administration (2 
g/kg i.p.). Fasted rats were used as described previously, and
appropriate controls were sham-dosed with vehicle substances at the 
same time-points at which ethanol and/or antioxidants were 
administered. Animals were sacrificed 90 mins. after ethanol, a
portion of liver freeze-clamped for metabolite determinations, liver 
slices prepared for incubation with [l-^C] palmitic acid, and the 
remaining liver tissue homogenised for determination of triglyceride 
concentrations. Some animals were sacrificed 3 hours after ethanol
dosing for triglyceride measurements, so as to assess the effect of
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antioxidants on ethanol-induced lipid accumulation over a slightly 
longer time period. All analytical methods and measurement of
production from [l-^C] palmitate were performed as described 
previously (Chapter 5).
The effects of BHT and DPPD on the fatty liver produced by a 
large oral dose of ethanol were also investigated in fasted rats. 
DPPD or BHT were given (400 mg/kg i.p.), as described above, at 24 and 
1 hours before ethanol (6 g/kg orally as a 50?o (v/v) solution). 
Glucose-dosed controls were employed, and animals were sacrificed 16 
hours after ethanol dosing for the measurement of liver triglycerides 
(see Chapter 3).
(.ii) Chronic studies: The effect of DPPD on chronic alcoholic fatty
liver production was studied using the 'Complan' liquid diet regime 
already desxribed in detail (section 2.2.). Groups of eight male 
Wistar albino rats (University of Surrey strain) were given ethanol as
36?o of the total calories for a period of 21 days following an initial
/
introductory period to the liquid diet, appropriate controls being 
pair-fed diet in which the ethanol calories were replaced by glucose. 
DPPD was given once weekly (400 mg/kg i.p.) in fresh corn oil, this 
dosing regime being sufficient to maintain effective levels of the 
substance in the body between doses, since the compound forms depots 
in the body fat, and does not undergo any significant hepatic 
metabolism. Dietary intakes and body weights were recorded
throughout. On the last day of the study, animals were bled by
closed cardiac puncture under ether anaesthesia, serum prepared, and
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the animals sacrificed. Livers were removed, weighed and homogenised
in 0.25M sucrose. Serum ethanol, glutamate dehydrogenase activity
(GLDH), total hepatic lipid, and liver triglycerides were determined
as described previously. Microsomes were prepared from the livers of
the animals as described in section 2.8. Susceptibility to in vitro
lipid peroxidation was determined by incubating microsomes in the
presence of the hydroxyl radical generating system (NADPH/Fe^+/ADP),
exactly as described for the testing of antioxidant activity of
various scavengers, as described in Chapter 4 and section 2.8.
Microsomal lipid peroxidation was expressed as absorbance at 535 nm/mg
microsomal protein, the production of thiobarbituric acid reactive
material being determined after a 15 minute incubation of microsomes 
2+
with NADPH/Fe /ADP. Microsomal protein was determined by the method 
of Lowry et al (1951) using bovine serum albumin as the reference.
7.3 RESULTS
(i) Acute studies: The effect of BHT on the parameters studied after
acute ethanol administration is shown in Table 7.1. Neither ethanol 
or BHT, alone or in combination, had any effect on liver ATP 
concentrations. As found previously, ethanol caused an increase in 
the lactate/pyruvate and 3-hydroxybutyrate/acetoacetate ratios, these 
changes being unaffected by BHT administration. However, ethanol 
caused 96% and 128% increases in the hepatic triglyceride 
concentrations measured at 90 and 180 mins. after dosing respectively,
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this accumulation being completely prevented by BHT. BHT alone had 
no effect on hepatic triglyceride concentrations. Ethanol caused a
40% decrease in the ability of liver slices taken at sacrifice to
14 14oxidise [1- CJ palmitate to CO^, the extent of this inhibition
being reduced to 15% when BHT was given with ethanol.
An almost identical pattern of results was seen when DPPD was 
given to ethanol-dosed rats (Table 7.2). This antioxidant also 
failed to reverse the ethanol-induced increases in the hepatic 
lactate/pyruvate and 3-hydroxybutyrate/acetoacetate ratios, yet 
prevented the hepatic triglyceride accumulation, and partially 
restored the ability of liver tissue to oxidise palmitate to CO2, 
after ethanol administration.
The results from the acute alcoholic fatty liver study are shown 
in Table 7.3. Ethanol administration (6 g/kg p.o.) caused a 128% 
increase in the hepatic triglyceride content measured 16 hours after 
dosing, the extent of this accumulation being reduced to 35% and 38% 
if ethanol-dosed animals were pre-treated with BHT or DPPD 
respectively.
(ii) Chronic study: The results from the chronic ethanol feeding
study are shown in Table 7.4. DPPD dosing did not affect body weight 
gain, ethanol intake, liver weights or serum ethanol concentrations at 
sacrifice in ethanol-treated rats. Ethanol feeding caused 100% and 
250% increases in the total hepatic lipid and triglycerides 
respectively, DPPD administration reducing the extent of these 
increases to 25% and 76% in ethanol-fed animals. There were some
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TABLE 7.3 EFFECTS OF BHT AND DPPD ON THE HEPATIC TRIGLYCERIDE 
ACCUMULATION FOLLOWING A LARGE ACUTE ORAL ETHANOL DOSE
Hepatic Triglyceride I6h after Ethanol (mq/q liver)
10.4 + 2.1 
12.1 + 2.0 
9.8 + 1.3
Ethanol only 23.7 + 0.4*
Ethanol + BHT 14.1 + 3.8**
Ethanol + DPPD 14.4 + 3.7**
BHT and DPPD were given (400 mg/kg i.p.) at 24 and 1 hours before ethanol 
(6 g/kg orally). Results are shown as mean + S.D. (n = 6 rats per 
treatment group). * = p < 0.001 vs. glucose group. ** = p < 0.001 vs. 
ethanol only group
Treatment 
Glucose 
Glucose + BHT 
Glucose + DPPD
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trends evident in the serum GLDH data, ethanol feeding causing an 
increase, and DPPD slightly counteracting this in ethanol-fed rats, 
although none of these changes were statistically significant due to 
the wide individual variation in the values obtained. Ethanol 
feeding caused only a small, non-significant increase in the
susceptibility of liver microsomes to peroxidation by NADPH/ADP/Fe^+ 
in vitro, but microsomes isolated from DPPD-treated animals, both 
pair-fed controls and ethanol-fed rats, were substantially protected 
against in vitro peroxidation.
7.4 DISCUSSION
The experiments described here have shown that standard 
antioxidant substances can prevent the hepatic triglyceride 
accumulation following acute doses of ethanol, and partly prevent the 
depressed fatty acid oxidation capability of liver tissue after 
ethanol dosing, without reversing the increase in the cytosolic or 
mitochondrial NADH:NAD ratio caused by ethanol metabolism. 
Subsequent experiments, described later (Chapter 8), will show that 
these effects are not related to any inhibition of ethanol metabolism 
by antioxidants. These results confirm the earlier findings of
Rossiter and Slater (1973), who showed that antioxidants failed to 
reverse the increased NADH:NAD ratio in the liver after a large acute 
dose of ethanol (6 g/kg p.o.), yet prevented the hepatic triglyceride 
accumulation. Thus, the ability of (+)-catechin and 3-palmitoyl-
(+)-catechin to prevent hepatic lipid accumulation after acute or
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chronic ethanol administration are probably not related to these 
drugs' capacity to prevent the ethanol-induced redox-state changes, 
but rather to their antioxidant properties described earlier. The
results thus cast some doubt on the popular 'redox-state theory' of 
fatty liver production discussed in detail in Chapter 1. Further 
experiments described here, confirm the potent ability of antioxidants 
to prevent fatty liver formation after large acute oral ethanol doses, 
and after chronic ethanol feeding.
The precise mechanism by which antioxidant substances might
prevent fat accumulation is not clear from these experiments. 
However, one common factor between the findings with (+)-catechin, BHT 
and DPPD is reversal of the decreased ability of liver tissue to 
oxidise fatty acids after acute ethanol dosing. The studies reported 
in the previous chapter showed a good correlation between inhibition 
of fatty acid oxidation and increased fatty acid esterification into 
triglyceride in vitro, so the same mechanism may contribute to the 
process of ethanol-induced triglyceride accumulation in vivo. The
protective effect of antioxidants against decreased lipid oxidation 
suggests that some peroxidative damage may occur to mitochondria in 
vivo, that affects fatty acid oxidation. This is possible, since 
lipid hydroperoxides have been observed to inhibit fatty acid
oxidation in vitro (Imagawa et al, 1984).
An additional possibility is that some peroxidative event after 
ethanol dosing may limit hepatic triglyceride secretion, although the 
role of this mechanism in acute hepatic steatosis is disputed (Wallin 
et al, 1984). It seems unlikely that other effects of antioxidant
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administration, such as impaired hepatic fatty acid uptake or 
decreased lipolysis are involved in the prevention of hepatic 
triglyceride disposal described here, since BHT and DPPD alone did not 
affect hepatic triglyceride levels, and previous studies have shown 
that administration of large doses of a variety of antioxidants, 
including DPPD, fails to influence peripheral lipolysis (Ugazio et al, 
1973).
One of the major findings here is that standard synthetic 
antioxidants protect against ethanol hepatotoxicity under identical 
experimental conditions to those under which (+)-catechin and 
3-palmitoyl-(+)-catechin have been shown to exert their protective 
effects. The lipid peroxidation measures in the chronic DPPD study 
showed that this substance did considerably improve the antioxidant 
status of the liver cell membranes, although ethanol feeding only 
caused a small, non-significant increase in this parameter. 
Previous studies have demonstrated an enhanced susceptibility of 
hepatic lipids to peroxidation after chronic ethanol feeding 
(MacDonald, 1973; Shaw et al, 1981; Roauch et al, 1983), using the 
more sensitive diene conjugation method.
Redox-state measurements were not made in the chronic experiment, 
but the findings described earlier, and the data obtained by Rossiter 
and Slater (1973) on the effect of antioxidants on the hepatic 
NADH:NAD ratio after acute ethanol dosing, indicate that the 
protective action of antioxidants observed in chronic ethanol feeding 
or after large acute oral doses of ethanol, is probably not due to
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these substances affecting the ethanol-induced redox-state change. 
Work which has been reported in Chapter 6 indicates that hepatic lipid 
accumulation resulting from both acute and chronic ethanol feeding is 
probably independent of the increase in the NADH:NAD ratio caused by 
ethanol metabolism. Serum ethanol levels and ethanol intake data
from the chronic DPPD experiment indicate that the protective effect 
of the antioxidant is not related to alterations in ethanol preference 
or metabolism. All of these considerations point to the antioxidant 
properties of BHT and DPPD being responsible for their protective 
effect on alcoholic fatty liver, and further suggests that it is 
similar properties of (+)-catechin and 3-palmitoyl-(+)-catechin that 
confer protective capabilities on the latter compounds, rather than 
redox-state correction being their mechanism of action.
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Chapter 8
THE EFFECTS OF 3-PALMIT0YL-(+)-CATECHIN. NALOXONE AND ANTIOXIDANTS 
ON ETHANOL AND ACETALDEHYDE METABOLISM AFTER ACUTE ETHANOL
ADMINISTRATION
8.1 INTRODUCTION
In Chapter 1 (section 1.2.2), the role of ethanol metabolism in 
the production of alcoholic fatty liver was discussed in detail. To 
summarise that discussion briefly, uninterrupted ethanol metabolism 
appears to be a requirement, certainly for the production of acute 
ethanol-induced fatty liver, and possibly also for the steatosis 
resulting from chronic ethanol administration. Thus, one mechanism 
by which drugs can reduce the extent of hepatic triglyceride 
accumulation is through interference with ethanol metabolism, as has 
been described for pyrazole (Morgan and DiLuzio, 1970). Thus, in 
this chapter, the effect of the agents investigated in the previous 
chapters on blood ethanol levels after an acute ethanol dose, under 
conditions identical to those used to study the redox-state changes 
and lipid utilisation, has been investigated to determine whether any 
of the effects of the compounds could have been due to alteration of 
ethanol metabolism.
It i;as also discussed in Chapter 1 (section 1.2.3) that there are 
probably two major primary metabolic consequences of ethanol
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metabolism that could initiate the sequence of events that causes fat 
accumulation, one of these being the redox-state change, the other 
being production of acetaldehyde. The latter may cause triglyceride 
deposition through direct inhibitory effects on mitochondrial function 
(including fatty acid oxidation), impairment of lipoprotein secretion 
and/or initiation of peroxidative damage. Thus, the effects of 
3-palmitoyl-(+)-catechin, Naloxone and antioxidants on hepatic 
acetaldehyde concentrations after acute ethanol dosing have been 
studied here, again, to determine whether any protective effects of 
these compounds (or lack of protection in the case of Naloxone) is due 
to alteration of hepatic steady-state levels of this ethanol 
metabolite.
t
8.2 METHODS
Male Wistar rats were used, and were fasted for 24 hours prior to 
ethanol administration. Ethanol was given (2 g/kg i.p. as a 20%
(w/v) solution in saline) and 90 mins. later, animals were sacrificed 
by cervical dislocation and a portion of liver rapidly isolated by 
freeze-clamping. Hepatic acetaldehyde concentrations were determined 
in these frozen liver samples as described in section 2.6. Blood was 
collected from the necks of the animals and assayed for ethanol by 
head-space gas chromatography as described in section 2.6. Some 
animals were also sacrificed at three hours, or other time points 
after ethanol administration, in order to assess the effect of drug
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treatments on blood ethanol and/or hepatic acetaldehyde concentrations 
at these various time points.
Drug treatments: Naloxone (2 mg/kg i.p.) was given at 1.0 h, and 
where appropriate, 2.5 h and 4.0 h after ethanol administration. The 
drug was given as pure Naloxone hydrochloride dissolved fresh in 
sterile saline, appropriate controls being sham-dosed with saline at 
the same time points. 3-Palmitoyl-(+)-catechin was suspended in 5% 
(w/v) Arabic Gum and given (100 mg/kg orally) at one hour before 
ethanol dosing. DPPD and BHT were given as emulsions in 0.5% (w/v) 
Gum Acacia containing 0.1% (w/v) Tween 80 at doses of 400 mg/kg (i.p.) 
at 24 and 1 hours before ethanol administration. Appropriate control 
animals were sham-dosed with vehicle substances at the same time 
points in all the experiments.
8.3 RESULTS
Hepatic acetaldehyde and blood ethanol concentrations after 
administration of ethanol in 3-palmitoyl-(+)-catechin-treated rats 
were determined at various time points after ethanol dosing. The 
drug had no influence on either parameter at all of the time points 
studied (Figs. 8.1 and 8.2). Since hepatic acetaldehyde
concentrations appeared to reach an approximate steady-state value 90 
mins. after ethanol administration in this experiment, in subsequent 
studies on Naloxone and antioxidants, acetaldehyde levels were studied 
at this time point only.
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Naloxone administration also failed to affect either hepatic 
acetaldehyde or blood ethanol levels after acute ethanol 
administration (Table 8.1). Experiments with the antioxidants BHT 
and DPPD revealed that neither compound affected liver acetaldehyde 
levels, and DPPD also failed to influence the blood ethanol 
concentrations after this ethanol dose. BHT, on the other hand, 
appeared to cause a slight stimulation of ethanol elimination, as the 
blood ethanol concentration was significantly lower in animals treated 
with this antioxidant at three hours after ethanol administration 
(Table 8.2).
8.4 DISCUSSION
These experiments have shown that 3-palmitoyl-(+)-catechin does 
not affect hepatic acetaldehyde concentrations or the ethanol 
elimination rate after acute ethanol administration. Thus, the 
protective actions of the compound against the altered hepatic lipid 
disposal after ethanol dosing already described, cannot be attributed 
to either inhibition of ethanol metabolism (in a manner similar to 
pyrazole) or to ’trapping1 of ethanol-derived acetaldehyde. The 
latter process has been proposed as the mechanism by which certain 
thiol compounds, such as cysteine, protect against ethanol 
hepatotoxicity (Hirayama et al,'1983).
Naloxone treatment also failed to affect ethanol elimination or 
acetaldehyde concentrations, indicating that correction of the
TA
BL
E 
8.
1
- 216 -
CD
C
o
X
o r H CO
CD 1— I CM CD • .
CD . » rH CD
< z VO A '—1 r H
x
i— + +1 +  1 +  1 +  |
Ld
- H CO LT\ VO CO
CD O o . • • •
O i— I c r-' o in Ov
CD f— CD CM CM m VO
_! JZ CM i-H
CD oz -D
i— Ld
O CO
H-l
< 2
IH
Ld
CD CD
>- < >N
x t—H m
Ld C i-1 CD • VO
CD O o . • r H .
_1 z: <r LA pH A
<C <c I— 1
t— x o +  1 +  1 +  1 +  1
Ld i— c
CD Ld CO LT\ CO Cv A
< JZ . . • .
Ld 4-> CM ON ON CM
CD V— Ld CM •H A
H— 1 ZD CM rH
L— CD
< C
Q_
Ld cz
~7~ Ld f-l1— 0
2: Li_ j_)
o < L-0
Ld LO
Z z CO
o □ c
X HH ■H
o 1— E /-N
< r— t
< cz O E1— CT\
z CD
b- Ld 0 CD
o CD TD > H
z >> \
L— o r~ CO
CD CD o  ^ E
Ld TD cn — s JZ r~ JZ
b_ f-i 1—1 \
Ll_ 0 0  r—1 i—1 A O □
Ld 4J 44 O O « . •0 0  E c <—i a VO
Ld E o c 0
DI CO JZ1— f-l 44
CO O  rH Ld
0_ •H O
44 c TD
0  0 CD
CL JZ O
0  44 rH
X  0 CD
VO
TD
C II
0
cz
JZ
A
•
CM
•
CD
0 •
44 CO
0
•H +1
U
Q. c
O 0
U 0
CL E
Cl
0 0
0
0
f-i cz
0 5 44
JZ O c
2 r~ 0
0 o
TD •H
C 0 L—
0 U •H
0 C
»N CO
f-l 0 •H
D 44 0
O rH 1
JZ D c
CO o
CD 0 c
. CZ
rH 0
f-l
44 0
0 .
X— V 0
cz . 0
0 CL o
> . c
•H •H 0
CO f-l
CO 0
CO U-
0  \  L_
2 co •HTD
/—>.o
. . i— 1
CL CM rH
•v_✓ <c
• H
r H
CO o
JhC c «
\ 0 Z' >
CO r~ Cl
E 44 D
0 O
CM f-i
v~' U0
CO
0 44 f-l
C lH 0
o 0 C l
X
o r~ 0
r H O 44
0 > 0
z f-i
TH
E 
EF
FE
CT
 
OF 
N
,
N
1 -
DI
PH
EN
YL
-p
-P
HE
NY
LE
NE
DI
AM
IN
E 
(D
PP
D)
 
AN
D 
BU
TY
LA
TE
D
- 217 -
X
CD
+
o
o c
2: CD
< X
~T~ 4->
(— Ld
Ld X
o
o l-H
O 1—
□ <
DC C
CD 1— CL
LO CL
Cl C
z: X<z i—i +
Ldc fH
C O
>- c
X _J CD
Ld o X
C X 4-1
_J < Ld
< X
1—
LdLd
<_>
< Ld >»
L- rH
o X C
l-HCd CD
1—
< rH
CL DC O
Ld Ld C
X 1— CD
Li­ X
X ce 44
o Ld
UD
—\X
f— o
X HH
COI—
V-✓<c
DC
Ld1—
X X
LdLd
X CJ
_JX
o o
h— CJ
>-
X
o U
DC 0c 44
>- 0
X E
0
Li
CD
CL
VO
KN
+ 1
On
CNI
VO 
CM 
+ 1
•
CM
CM
ON
+1
in
CM
CM
r H
O E
O n
O
0 o
X I—1
X  r H
X o X
0 c E
X 0
1— 1 X
0 4 4 r H
4 4 0 o
0 c
o u 0
0 0 X
4 4 /-s 4 4
u L— X Ld
• H 0
4 4 i—1 X
0 0 o o
0 . c E o
0 • H C i-H
_ L E CO
0
44
0
On * fH
• I""
O • VO
CM m
I
+ 1 + 1
•H C
i-H m o
• • c
On r-' 0
r-~ i-H X •
iH i-H 44 CD
0 •
to
0
L< + 1
oh- c
O rH 0 0
• • X 0
m CM E
rH CM f-i
ZD 0
+ 1 + 1 O 0
X
o CD SZ
• • iH 3
m VO O CLCD m X X D
CM i-H c 0 O
0 fH
0 X
<t Li
CM 0 >N
1-1
X m 44 0 c
• • 0 44 oCD i—i rH
rH rH /-sD iH» 0 O
+ 1 + 1 CL 0 c•DC 0
O ON •H X
• • 44
CM ON X 0
ON m V •
i—l rH \ /-N •
X 0
E Cl >
O •Hm
O o
<r X O'—rX •
\ CDc X
0 V
> CD
•H • CL
X CM
\_y I
CO
0 C *
B5 o
X X •H
1— 44
in CD X 0 •
• » CO fH □_
i-H m 44 ZD
fH 0 O
o •H fH
C XCD •H
Q_ E Li
CL X 0
CD 0 CL
- 218 -
redox-state after ethanol both by this drug and 
3-palmitoyl-(+)-catechin is not due to inhibition of alcohol 
dehydrogenase (ADH) activity. This being the case, it is thus
possibly surprising that correction of the ethanol-induced redox-state 
change by either compound is not associatd with any acceleration of 
ethanol metabolism. It has been proposed that the reoxidation of
NADH, either to release ADH from inhibition, or to provide more NAD 
for the dehydrogenase, is a rate-limiting factor in ethanol oxidation 
(Badawy, 1978). However, the findings here do not support this
hypothesis, and suggest that other factors, such as the hepatic 
acetaldehyde concentration during ethanol metabolism (Dawson, 1983), 
or the total hepatic ADH activity, may be of more importance in this 
respect.
The present data on the effect of Naloxone on blood ethanol 
concentrations does not agree with the findings of Badawy and Evans 
(1981) and Badawy and Aliyu (1984), both of these studies reporting 
lowering of blood ethanol concentrations by the drug in association 
with correction of the hepatic NADH:NAD ratio. These authors 
proposed that correction of the redox-state by Naloxone was the 
mechanism by which the blood ethanol concentration was decreased, 
assuming that the NADH:NAD ratio is important in regulating ethanol 
oxidation (Badawy, 1978). There has been much interest in the
possible use of Naloxone as a treatment for acute alcohol-induced 
narcosis, some clinical studies demonstrating a 'sobering-up' effect 
of this opiate antagonist (Jeffcoate et al, 1979; Jeffreys et al,
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1980). These clinical studies suggested that opoid receptors might 
be involved in the mechanism of ethanol intoxication, but Badawy and 
Evans (1981) subsequently presented a metabolic basis for the reversal 
of alcohol-induced narcosis as described above. Other clinical 
studies have failed to show any effects of Naloxone in alcohol
intoxication (Nuotto et al, 1984) and the present results agree with 
those of Khanna et al (1982), who had to give Naloxone at doses of 
greater than 50 mg/kg i.p. before any effect on blood ethanol
concentrations in mice could be observed. The discrepancy between 
the present data and that of Badawy and Evans (1981) and Badawy and 
Aliyu (1984) is difficult to account for, since identical ethanol
doses, and a slightly higher Naloxone dose were employed.
Differences in feeding status (the animals here were fasted, whereas 
those in Badawy’s laboratory were fed) or strain differences in 
response to Naloxone are possible explanations.
The data obtained with the antioxidants BHT and DPPD also show 
that these compounds do not interfere with ethanol or acetaldehyde 
metabolism. Thus, it is feasible that the mechanism underlying the 
protective effects of these compounds described in earlier chapters, 
is scavenging of free radicals. BHT appeared to cause a slight 
increase in the rate of ethanol disappearance from blood, from the 
limited data presented here. This could be due to either an increase 
in microsomal ethanol-oxidising system (MEOS) activity resulting from 
induction of cytochrome P450 by the compound, or an increase in total 
liver ADH activity, since BHT is known to cause liver enlargement and 
stimulate hepatic mitotic activity (Lane and Lieber, 1967), in 
addition to being a microsomal enzyme inducer (Babich, 1982).
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Chapter 9
EFFECTS OF 3-PALMIT0YL-(+)-CATECHIN (3-PC) AND N,N'-DIPHENYL-P- 
PHENYLENEDIAMINE (DPPD) ON ICPATIC LIPID PEROXIDATION AND 
TRIGLYCERIDE CONTENT AFTER ACUTE ETHANOL DOSING
9.1 INTRODUCTION
The results of the experiments reported in the previous chapters 
are all consistent with free radical scavenging being the mechanism of 
action of the (+)-catechin compounds against ethanol-induced liver 
injury. In an attempt to provide some direct experimental evidence 
that the drugs may prevent steatosis at the same time as inhibiting 
ethanol-induced lipid peroxidation, the present set of experiments was 
carried out.
Some of the difficulties of determining hepatic lipid 
peroxidation after ethanol dosing, particularly in rats, have already 
been discussed in Chapter 1. Although, ideally, it would have been 
most appropriate to carry out studies on the effect of (+)-catechin on 
lipid peroxidation in the chronic ethanol feeding model, examination 
of some of the more recent studies on ethanol-induced lipid 
peroxidation (Macdonald, 1973; Torelli et al, 1978; Shaw et al,
1981) suggested that more consistent and reproducible results might be 
obtained using a moderately high (but not too high) acute oral dose of 
ethanol. Thus, in the current experiments, the effects of
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3-palmitoyl-(+)-catechin, and one reference antioxidant compound 
(DPPD), on two parameters of lipid peroxidation (diene conjugation and 
malonaldehyde levels) have been determined at various time points 
after an acute oral dose of ethanol (5 g/kg), and these parameters 
related to the liver triglyceride and blood ethanol concentrations in 
the same experiments. It was hoped that this approach would indicate 
whether there is a causal link between ethanol-induced lipid 
peroxidation and triglyceride accumulation in the liver, and whether 
antioxidant compounds (including 3-palmitoyl-(+)-catechin) may prevent 
steatosis by inhibiting any lipid peroxidation observed under these 
conditions.
9.2 METHODS
Male Wistar albino rats (250-300 g) were used. They were 
maintained on a standard 41B cube diet and water, and were fasted for
24 hours prior to ethanol administration (5 g/kg p.o. as a 20% (w/v) 
solution in saline), control animals receiving an equivalent volume of 
saline by the same route. 3-Palmitoyl-(+)catechin was given as a 
suspension in PEG 300 at 24 and 0 hours before ethanol, at a dose of
25 mg/kg (i.p.) on each occasion. DPPD was given in an identical 
manner at the same time points, but at a dose of 400 mg/kg i.p.
Animals Were sacrificed at either 1.0, 3.0, 5.0. or 8.0 h after 
ethanol, and blood samples collected from the necks of the animals. 
Livers were rapidly excised, rinsed in ice-cold 0.25M sucrose buffered
- 222 -
with 10 mM potassium phosphate (pH = 7.4) containing 3 mM EDTA,
blotted, weighed, and homogenised in the same medium to produce a 50% 
(w/v) homogenate. Portions of this freshly-prepared homogenate were 
immediately frozen in liquid nitrogen, and stored at -70°C for the 
analysis of reduced glutathione (G5H) and malonaldehyde (MDA) 
concentrations. Further portions of homogenate were diluted to 10%
(w/v) with buffered sucrose-EDTA and centrifuged at 400 g for 10 mins 
to sediment thev nuclei. The supernatent fraction was then
centrifuged at 4000 g for 12 mins to produce a mitochondrial pellet. 
The supernatent from this last centrifugation step was then further 
centrifuged to produce a microsomal pellet as described previously. 
These subcellular fractions were assayed for diene conjugates, and 
malonaldehyde was measured in liver homogenates, using methodology 
described in Chapter 2 (section 2.9). Reduced glutathione (G5H) was 
measured in liver homogenates by the methyglyoxal method given in 
section 2.9.3. Blood ethanol was determined by head-space gas
chromatography, and liver triglycerides measured by the method of 
Fletcher (1968), all experimental details for these assays being as 
given in Chapter 2.
9.3 RESULTS
Liver mitochondria and microsomes were examined for evidence of 
lipid peroxidation (as diene conjugate formation) at 1.0, 3.0 and 5.0 
hours after ethanol dosing. At 3.0 h and 5.0 h after ethanol, there
- 223 -
was no evidence of increased diene conjugates in either subcellular 
fraction. At 1.0 h after ethanol, there was a significant increase 
in the absorbance at 233 nm of the mitochondrial lipids from 
ethanol-dosed animals, when values were compared with those found in 
saline-treated controls (Fig. 9.1), indicating the presence of diene 
conjugates. Repetition of this experiment confirmed the presence of 
this marker of lipid peroxidation in the liver mitochondria one hour 
after ethanol dosing, and also showed that pre-treatment with either 
3-palmitoyl-(+)-catechin or DPPD largely prevented this peroxidative 
change caused by ethanol (Fig. 9.2). There was, however, no evidence 
of diene conjugate formation in the liver microsomes at 1.0 hour after 
ethanol dosing (Fig. 9.3). Treatment of animals with
3-palmitoyl-(+)-catechin or DPPD alone had no effect on the U.V. 
absorption spectra of the mitochondrial or microsomal lipids in 
control animals (results not shown).
Ethanol dosing caused significant increases in the liver 
malonaldehyde concentrations at 5.0 and 8.0 h after administration, 
both antioxidant compounds maintaining levels below control values in 
both ethanol-dosed (Fig. 9.4) and control animals (data not shown) 
throughout the period of study. The ethanol-induced decrease in 
liver G5H content was statistically significant by 5.0 h after dosing, 
this phenomenon not being reversed by treatment with either 
3-palmitoyl-(+)-catechin or DPPD (Fig. 9.5). These compounds alone 
did not affect liver GSH concentrations in control animals (data not 
shown).
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Hepatic triglycerides were significantly increased, by 83?o and 
73?o over control values, at 5.0 hours and 8.0 hours after ethanol 
dosing respectively. Treatment with either 3-palmitoyl-(+)-catechin
or DPPD significantly reduced liver triglycerides in ethanol-dosed 
animals, both substances maintaining levels close to those found in 
control animals throughout the intoxication period (Fig. 9.6). 
3-Palmitoyl-(+)-catechin and DPPD did not influence liver triglyceride 
concentrations in control animals (data not shown). Neither compound 
had any effect on blood ethanol concentration or the disappearance 
rate of ethanol from blood in ethanol-dosed animals (Fig. 9.7). 
Standard deviations have been omitted from the figures for clarity of 
presentation.
9.4 DISCUSSION
The experiments reported here have produced some limited evidence 
that acute ethanol dosing produces hepatic lipid peroxidation in the 
rat, in contrast to some earlier reports (Hashimoto and Recknagel, 
1968). It is clear, however, that ethanol is a much weaker proxidant 
than, for example, carbon tetrachloride. The diene conjugate changes 
in the mitochondria are in agreement with those reported by DiLuzio
(1968) and MacDonald (1973), although it is interesting that the 
evidence of peroxidation here is rather transient, and is not 
detectable at any time in the microsomal fraction. It is difficult 
to assess the importance of this early peroxidative event in the
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mitochondria to the hepatic triglyceride accumulation after ethanol, 
although it is interesting that this change precedes the peak in the 
liver triglyceride levels. The fact that 3-palmitoyl-(+)-catechin 
and DPPD inhibit the mitochondrial lipid peroxidation as well as 
preventing the increase in liver triglycerides after ethanol, suggests 
a causal link between these two phenomena. In addition, since 
3-palmitoyl-(+)-catechin appears to exert almost identical effects in 
these experiments as DPPD, this further suggests that free radical 
scavenging is the mechanism of action of the (+)-catechin compounds.
The time-course of the changes in the liver malonaldehyde levels 
(or to be more precise, thiobarbituric acid (TBA)-reactive compounds), 
is rather different from the time-course of the changes in the 
mitochondrial diene conjugates. This may reflect the fact that these 
two factors occur at different stages in the peroxidative chain, or 
that the production of TBA-reactive material occurs as a result of 
ethanol-induced changes in the tissue (eg: triglyceride accumulation), 
rather than being a precursor lesion to any such effects of ethanol. 
Another possibility is that the increase in TBA-reactive material 
content of the liver increases after ethanol due to a decrease in the 
glutathione content of the tissue (Fig. 9.5). Interestingly, DPPD 
and 3-palmitoyl-(+)-catechin do not prevent the ethanol-induced 
decrease in G5H concentrations, suggesting that the latter probably 
does not occur as a consequence of ethanol-induced lipid peroxidation.
It is clear from the blood ethanol data (Fig. 9.7), that DPPD and 
3-palmitoyl-(+)-catechin do not prevent peroxidation or triglyceride
- 233 -
accumulation after ethanol dosing through inhibiting ethanol 
metabolism in these experiments.
To conclude, the studies reported in this chapter have shown that 
there may be a causal link between lipid peroxidation and the hepatic 
triglyceride accumulation after acute ethanol dosing in rats, and 
further indicate that free radical scavenging could be the mechanism 
of action of the (+)-catechin compounds against ethanol 
hepatotoxicity, certainly in the acute situation. The results do not 
shed any further light, however, on the precise mechanism by which 
lipid peroxidation occurs after ethanol intake, or on the mechanism 
linking peroxidation to the observed triglyceride accumulation. Some 
of the possible , mechanisms here have been discussed in detail in 
Chapter 1.
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Chapter 10 
CONCLUSIONS AND DISCUSSION
The aims of the work in this thesis were:
(i) To confirm and assess the potential protective properties
of (+)-catechin and 3-palmitoyl-(+)-catechin against 
ethanol hepatotoxicity (fatty liver) in the rat.
(ii) To investigate the mechanisms underlying any such observed
protective effects of these compounds.
The second of these aims is fairly difficult to achieve in the 
case of protective agents for alcoholic liver injury, since, as will 
be clear from the discussion in Chapter 1, there is much controversy 
as to what the important mechanisms causing the process are. For 
(+)-catechin, however, there were two possible candidates as potential 
mechanisms of action of the drug. Firstly, the correction of
elevated NADH:NAD ratio (redox-state) in the liver after ethanol 
administration, and secondly, free-radical scavenging and the ability 
to inhibit lipid peroxidation, seemed feasible explanations for any 
protection of (+)-catechin against ethanol-induced steatosis in the 
rat.
In the first experiments, it was confirmed that (+)-catechin and 
also 3-palmitoyl-(+)-catechin, protected against both acute and 
chronic ethanol-induced fatty liver, possibly indicating that common 
mechanisms of action were operating in both experimental situations.
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It has also been assumed that a common mechanism of action exists for 
both compounds studied, as discussed in earlier chapters. 
3-Palmitoyl-(+)-catechin was more potent in the chronic 
ethanol-feeding model than the parent compound, probably as a result 
of its greater lipid solubility and more favourable pharmacokinetic 
characteristics. This work is the first demonstration of a
protective action of the (+)-catechin compounds in a proper, 
controlled model of long-term alcohol feeding in the rat, previous 
studies employing a rather inadequate repeated ethanol-dosing regime 
to induce steatosis (Gajdos et al, 1972).
The first series of studies on the mechanism of action of the 
drugs, investigated the effect of the (+)-catechin compounds on the 
hepatic redox-state changes, and possible related components of fatty 
acid metabolism, so as to test the hypothesis of Gajdos et al (1972) 
that (+)-catechin acted through reversing the elevated NADH:NAD ratio 
after ethanol. Both (+)-catechir» compounds were, in fact, found to 
correct the redox-state change in ethanol-dosed animals, at the same 
time as reversing the depressed fatty acid oxidation, and increased 
incorporation of fatty acids into triglycerides in the liver tissue, 
under these conditions of acute intoxication. This provided a fairly 
neat explanation for the way in which (-j-)-catechin might act, as well 
as apparently indicating that ethanol caused fat accumulation in the 
first place through a redox-state type of mechanism, suggesting a link
I
between the NADH:NAD ratio change and the alterations in lipid 
metabolism.
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To gain further evidence in favour of these proposed mechanisms, 
a series of experiments was carried out in which the hepatic 
redox-state was changed by means other than ethanol administration, 
namely, by giving sorbitol. This caused changes in the redox-state 
similar to those seen after ethanol, yet failed to affect the liver 
triglyceride content or lipid metabolism parameters, as studied above 
in the (+)-catechin experiments. furthermore, amelioration of the 
ethanol-induced redox-state changes, either by Naloxone (in the acute 
study) or Methylene Blue (chronic study), failed to prevent the 
altered lipid metabolism or hepatic triglyceride accumulation. These 
findings obviously cast some doubt on the redox-state change as an 
important mechanism of fatty liver production, as well as showing that 
modulation of the NADH:NAD ratio by the (+)-catechin compounds has 
little part to play in the mechanism of protection of the drugs. For 
this reason, the possible mechanism by which (+)-catechin and 
3-palmitoyl-(+)-catechin affects the NADHrNAD ratio was not pursued 
further, although it was evident that the compounds did not act 
through simply inhibiting ethanol metabolism.
Therefore, the remainder of the work investigated the possibility 
that the (+)-catechin compounds prevented fatty liver through acting 
as antioxidants, and preventing ethanol-induced lipid peroxidation. 
This was an opportunity to test the hypothesis of DiLuzio (1973) that 
lipid peroxidation was an important event in the pathogenesis of 
alcoholic fatty liver. Reference synthetic antioxidants (BHT and 
DPPD) were found to prevent the acute fatty liver, and DPPD prevented
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the chronic ethanol-induced steatosis, under the same conditions as 
which the (+)-catechin compounds were found to be protective. In the 
acute experiments, antioxidants prevented fat accumulation and 
decreased fatty acid oxidation after ethanol without affecting the 
redox-state change, supporting the conclusions drawn from the earlier 
experiments that the increased NADH:NAD ratio is not reponsible for 
the altered hepatic lipid disposal after ethanol. The ability of 
antioxidants to cause partial reversal of the reduced fatty acid 
oxidation in liver tissue after ethanol, suggests that peroxidative 
damage to the mitochondria may play a part in this phenomenon. This 
view is supported by data in the penultimate chapter showing that 
mitochondrial lipid peroxidation is an early event after acute ethanol 
dosing. These findings do not conclusively prove, however, that
depressed lipid oxidation is the link between lipid peroxidation and 
triglyceride accumulation after ethanol.
Once it had been established that the (+)-catechin compounds and 
antioxidants did not prevent steatosis through interfering with 
ethanol metabolism or by altering steady-state acetaldehyde 
concentrations, an attempt was made to test the hypothesis that there 
was a causal link between lipid peroxidation and hepatic triglyceride 
accumulation after acute ethanol dosing, and that 
3-palmitoyl-(+)-catechin prevented the latter process through 
inhibiting lipid peroxidation. It was found that the (+)-catechin 
compound, as well as DPPD, prevented the changes in lipid peroxidation 
parameters (mitochondrial diene conjugation and liver malonaldehyde)
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at the same time as inhibiting triglyceride accumulation after acute 
ethanol administration. These findings support the DiLuzio (1973) 
hypothesis of alcoholic liver injury, as well as adding further 
evidence in favour of free radical scavenging being the mechanism of 
action of the (+)-catechin compounds.
In order to confirm that free radical scavening is indeed the 
mechanism of action for (+)-catechin and 3-palmitoyl-(-f-)-catechin, 
further studies on the influence of these compounds on lipid 
peroxidation after chronic ethanol feeding could be performed. These 
would not be easy experiments to carry out, since ethanol is a fairly 
weak pro-oxidant and the changes in lipid peroxidation after chronic 
ethanol feeding in the rat are fairly subtle. It is unfortunate in 
this respect that ethanol is thought to interfere with one of the most 
sensitive methods for measuring in vivo lipid peroxidation, namely the 
measurement of exhaled hydrocarbons (ethane and pentane). Further 
experiments on the influence of a wider range of antioxidants (eg: 
propyl gallate or ethoxyquin) on chronic ethanol-induced fatty liver 
might clarify the role of lipid peroxidation in this situation. It 
is of interest, however, that throughout these studies, agents that 
have been found to protect against the acute triglyceride accumulation 
after ethanol also prevent the chronic fatty liver, suggesting similar 
mechanisms are at work in both experimental situations. The precise 
link between lipid peroxidation and fat accumulation after ethanol is 
still a matter for some speculation, however.
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The findings presented here are certainly interesting in terms of 
re-evaluating the basic biochemical mechanisms of ethanol-induced 
liver injury. There is fairly good evidence that the elevated
NADH:NAD ratio resulting from ethanol metabolism has little part to 
play in either the acute or chronic alcoholic fatty liver, which goes 
against a lot of conventional thinking in this area, this 
'redox-state' mechanism being quite widely-quoted as the underlying 
cause of fat accumulation. Furthermore, these studies provide
evidence in favour of the lipid peroxidation hypothesis of fatty liver 
production, so that future studies on ethanol hepatotoxicity should 
concentrate on this, and the possible role of acetladehyde in the 
process, as discussed earlier. A simplified, diagrammatic
representation of how ethanol metabolism may lead to hepatic lipid 
accumulation, and how the (+)-catechin compounds may interfere with 
the process on the basis of the work presented in this thesis, is 
shown in Fig. 10.1.
Finally, to put some of these findings into a clinical context, 
it has to be asked what the value, if any, of agents that prevent 
fatty liver is to patients with alcoholic liver disease. The 
arguments for and against fatty liver, a benign and reversible lesion 
though it is, being a precursor of the more severe forms of alcoholic 
liver disease (hepatitis and cirrhosis) have already been given in 
Chapter 1. If fat accumulation is important as a precursor event of 
cirrhosis, and it should be remembered that there is often a 
substantial degree of cell necrosis associated with fatty liver as
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well as haemodynamic alterations in the liver, preventing it may not 
be a bad thing, and could significantly afffect the prognosis in those 
patients 'at risk' of proceeding to the full-blown cirrhotic lesion. 
Against this arugment, however, there are a number of practical and 
ethical difficulties. Firstly, these protective agents are generally 
only effective prophylactically, and it would be very diffficult to
administer the substances to patients during ongoing alcohol
consumption. Many patients do not present, of course, until they
already have severe fatty liver or hepatitis. Secondly, there is the 
ethical problem of whether administering an agent that may limit liver 
damage to patients may, in fact, encourage them to drink more. If
this was found to be the case, then, even though the liver may be
protected, damage to other organs (pancreas or brain) may continue 
unabated and, of course, the drugs cannot overcome the sociological 
difficulties that arise out of frequent intoxication. Only
closely-monitored clinical trials of these 'hepatoprotective1 agents 
will provide answers to these questions.
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